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2-OG 2-oxoglutarate
Ang2 angiopoietin-2
AKT Synonym for protein kinase B
APC antigen-presenting cell
ARD1 arrest-defective-1
ARNT aryl hydrocarbon receptor nuclear translocator
ATF-4 activating transcription factor-4
bHLH basic helix-loop-helix
BSA bovine serum albumin
C-TAD carboxy-terminal transactivation domain
Cdr cerebellar degeneration-related protein
ChIP chromatin immunoprecipitation
CITED2 cAMP-responsive element-binding protein (CBP)/p300-
interacting transactivators with glutamic acid (E) and aspartic
acid (D)-rich tail
CODDD c-terminal oxygen-dependent degradation domain
CTL cytotoxic T lymphocyte
DC dendritic cell
DFX desferrioxamine
EGL egg-laying abnormal
EPO erythropoietin
ERK extracellular signal-regulated protein kinase
ER endoplasmatic reticulum
FIH factor inhibiting HIF
FKBP38 FK506-binding protein 38
GSE genetic supressor element
GST glutathione-S-transferase
HDM2 human ortholog of mouse Mdm2
HIF hypoxia-inducible factor
HLZ helix-leucine zipper
HPH HIF prolyl hydroxylase
HRE hypoxia response element
ICAM-1 intercellular adhesion molecule 1
IGF1/2 insulin-like growth factor 1/2
ING4 inhibitor of growth family member 4
Km Michaelis Menten constant
NGF nerve growth factor
NF-B nuclear factor kappa B
NLS nuclear localization signal
NODDD N-terminal oxygen-dependent degradation domain
NO nitric oxide
NOS nitric oxide synthase
N-TAD amino-terminal transactivation domain
MAPK mitogen-activated protein kinase
MDM2 mouse double minute 2
MEF mouse embryonic fibroblast
MHC major histocompatibility complex
mTOR mammalian target of rapamycin
MCS multiple cloning site
OD optical density
ODDD oxygen-dependent degradation domain
p300 300 kDa protein, histone acetyl transferase
PAS PER/ARNT/SIM
PCD paraneoplastic cerebellar degeneration
PER Drosophila periodic protein
PDFG-B platelet-derived growth factor B
PHD prolyl-4-hydroxylase domain protein
PI3-K phosphatidylinositol 3-kinase
4PKC protein kinase C
PKB protein kinase B
PND paraneoplastic neurological disease
PTEN phosphatase and tensin homolog deleted on chromosome ten
Siah seven in absentia homolog
SIM Drosophila single-minded protein
SLE systemic lupus erythematosus
SUMO small ubiquitin-related modifier
TAD transactivation domain
TAP transporter associated with antigen processing
TCA tricarboxylic acid
TCR T cell receptor
TNF- tumor necrosis factor alpha
VCAM-1 vascular cell adhesion molecule 1
VEGF vascular endothelial growth factor
pVHL von Hippel-Lindau tumor suppressor protein
wt wild-type
5Zusammenfassung
Bis 1995 war der molekulare Mechanismus, wie Organismen sich an eine
veränderte Sauerstoffverfügbarkeit anpassen, noch wenig verstanden. Ein
wesentlicher Durchbruch gelang mit der Entdeckung des heterodimeren
Transkriptionsfaktors Hypoxie-induzierbarer Faktor (HIF). Unter normoxischen
Bedingungen ist die HIF- Untereinheit aufgrund einer Prolylhydroxylierung
durch HIF Prolyl-4-hydroxylasen (PHDs) instabil. Diese HIF-
Prolylhydroxylierung führt zur Erkennung und zur Bindung des von Hippel-
Lindau Tumor-Suppressor Proteins (pVHL), einer Komponente eines E3-
Ubiquitin-Ligase Komplexes. HIF- wird polyubiquitinyliert und im Proteasom
abgebaut. Unter Hypoxie fehlt den PHDs molekularer Sauerstoff als Kosubstrat
für die Hydroxylierung, wodurch ihre Aktivität reduziert ist und dadurch die HIF-
Untereinheit stabilisiert wird. HIF- transloziert in den Nukleus, heterodimerisiert
dort mit HIF-, rekrutiert zusätzliche Koaktivatoren und induziert schliesslich die
Transkription von Zielgenen wie zum Beispiel Erythropoietin.
Die Hydroxylierungskapazität der PHDs ist im wesentlichen bestimmt durch die
Sauerstoffverfügbarkeit, d.h. sie agieren als molekulare Sauerstoffsensoren
innerhalb der Zelle. Bis heute sind drei verschiedene HIF PHDs bekannt.
Obwohl alle drei fähig sind, HIF- in vitro zu hydroxylieren, unterscheiden sie
sich in der Gewebsverteilung, ihrer Induzierbarkeit unter Hypoxie und ihrer
subzellulären Lokalisation. PHD1 wird überwiegend im Hoden, im Gehirn und in
der Leber exprimiert. Im Gegensatz zur PHD2 und PHD3 ist die mRNA von
PHD1 nicht durch Hypoxie induzierbar.
Ziel dieser Doktorarbeit war es, neue Interaktoren der PHD1 zu identifizieren.
Hierfür haben wir zwei unabhängige Hefe Zwei-Hybrid Screenings durchgeführt.
Wir wählten für das Screening eine Humane und eine Maus Hoden cDNA Bank
und fanden unter anderem das onkoneurale Antigen Cerebellar degeneration-
related protein 2 (Cdr2) als neuen Interaktor der PHD1. Cdr2 wurde benannt
nach der Detektion seiner Antikörper in einer Krankheit namens
paraneoplastische Kleinhirndegeneration (PCD). Dabei handelt es sich um eine
seltene Autoimmunerkrankung, die auftritt, wenn Brust- oder Ovarialtumore das
Cdr2 Protein exprimieren. Dieses Protein ist unter physiologischen Bedingungen
nur im Kleinhirn und im Hoden vorzufinden. Die Folge ist eine durch
6zytotoxische T-Killerzellen vermittelte Immunantwort, welche zu Tumorimmunität
und zu einer Degeneration des Kleinhirns führt. Es wird angenommen, dass
Cdr2-spezifische zytotoxische T-Killerzellen und Antikörper die
Kleinhirndegeneration auslösen, indem sie die Bluthirnschranke überschreiten
und im Kleinhirn exprimiertes Cdr2 als Antigen erkennen. PCD ist eine der
wenige Fälle in der eine natürlich vorkommende Tumorimmunität sichtbar wird.
Aufgrundessen stellt dieses Krankheitsbild ein interessantes Model zur
Untersuchung und zum Verständnis von Tumorimmunität im Menschen dar.
In der vorliegenden Dissertation zeigte ich, dass Cdr2 in der Hefe und auch in
vitro mit PHD1 interagiert. Während Cdr2 mRNA nicht sauerstoffabhängig
reguliert ist, waren Cdr2 Proteinmengen in transienten Transfektionen unter
Hypoxie und unter Hemmung der PHDs und des Proteasoms erhöht.
Aufgrund dieser Resultate nahmen wir an, dass Cdr2 ein neues Substrat der
PHD1 ist und unter Normoxie hydroxyliert wird. Das Gehirn und der Hoden sind
Organe mit relativ niedrigen Sauerstoffpartialdrücken. Desweiteren ist bekannt,
dass solide Tumore, verglichen zu ihren gesunden Ursprungsgeweben, gering
oxygeniert sind. Sollten also Cdr2 Proteinmengen hauptsächlich über die
sauerstoffabhängige Hydroxylierung durch PHD1 reguliert sein, würde sich die
Cdr2 Protein Stabilisierung in Ovarial- und Brusttumoren durch die Hemmung
der PHD1 aufgrund geringer Oxygenierung des Gewebes erklären lassen.
Um die Regulation von endogenem Cdr2 Protein in Ovarial- und Brustkrebs
Zellinien zu untersuchen, stellten wir poly- und monoklonale Antikörper gegen
Cdr2 her. Entgegen unseren Erwartungen konnten wir die Stabilisierung von
endogenem Cdr2 unter Hypoxie und PHD Hemmung nicht bestätigen.
7Summary
Until 1995, the molecular mechanism by which organisms are able to adapt to
low oxygen conditions was poorly understood. The discovery of the
heterodimeric transcription factor hypoxia-inducible factor (HIF) represented a
breakthrough in the understanding of transcriptional adaptation of the cell to
changes in oxygen availability. Under normoxic conditions, the HIF- subunit is
unstable due to hydroxylation of prolyl residues catalyzed by HIF prolyl-4-
hydroxylases (PHDs). Hydroxylated HIF- prolyl residues are recognized and
bound by the von Hippel-Lindau tumor suppressor protein (pVHL), a component
of an E3 ubiquitin ligase complex. HIF- becomes polyubiquitinated and is
degraded via the proteasome. In contrast, under hypoxia, the PHDs are inhibited
because the co-substrate oxygen is limiting and HIF- is stabilized, translocates
into the nucleus, recruits additional co-activators and finally induces the
transcription of target genes such as erythropoietin.
The hydroxylation capacity of the PHDs is mainly determined by the oxygen
availability, and thereby PHDs act as molecular oxygen sensors within the cell.
So far, three different PHDs are known and even though all three are able to
hydroxylate HIF- in vitro, they differ in their tissue distribution, their response to
hypoxia and their subcellular localization. PHD1 is mainly found in testis, brain
and liver. In contrast to PHD2 and PHD3, PHD1 mRNA is not induced under
hypoxic conditions.
We carried out two independent yeast two-hybrid screenings to identify novel
interactors of PHD1. We screened a human and a mouse testis cDNA library
and identified among others the onconeural antigen cerebellar degeneration-
related protein 2 (Cdr2) as a novel PHD1 interactor. The physiological function
of Cdr2 is unknown, but anti-Cdr2 antibodies are found in a disease called
paraneoplastic cerebellar degeneration (PCD). This uncommon autoimmune
disease develops when breast or ovarian tumors start to express Cdr2 protein,
which is under physiological conditions limited to the cerebellum and the testis.
The consequence is a CD8+ cytotoxic T cells-mediated immune response which
leads to tumor immunity and cerebellar degeneration. It is believed that Cdr2
specific CD8+ cytotoxic T cells and antibodies elicit the cerebellar degeneration.
They seem to be able to pass the blood-brain-barrier and to recognize Cdr2 as
8an antigen expressed in the cerebellum. PCD is one of the rare cases where
naturally occurring tumor immunity becomes visible and thereby it represents an
interesting model for studying tumor immunity in human beings.
I showed in my thesis that Cdr2 interacts in yeast and in vitro with PHD1.
Whereas Cdr2 transcription is not regulated in an oxygen-dependent manner,
Cdr2 protein levels were increased under hypoxic conditions as well as after
inhibition of the PHD enzymes and the proteasome in transient transfection
assays. Therefore, we hypothesized that Cdr2 might be a novel substrate of
PHD1 which could hydroxylate Cdr2 under normoxic conditions. Brain and testis
are organs with relatively low oxygen partial pressure and it is well established
that also solid tumors are poorly oxygenated in comparison to their tissue of
origin. If Cdr2 protein levels are mainly regulated by oxygen-dependent
hydroxylation by PHD1, Cdr2 protein stabilization in ovarian and breast tumors
might be due to inhibition of PHD1 by reduced tissue oxygenation.
We then generated polyclonal and monoclonal antibodies against Cdr2 to
investigate the protein regulation of endogenous Cdr2 in ovary and breast
cancer cell lines. Unfortunately, oxygen- and PHD-dependent regulation of
endogenous Cdr2 protein levels could not be confirmed.
9Introduction
1 The hypoxia-inducible factor (HIF)
1.1 Discovery and function of HIF
Oxygen is the final electron acceptor in the respiratory electron transport chain
and thereby its abundance is crucial for the aerobic generation of energy in form
of ATP within the cell. The oxygen homeostasis itself is tightly controlled to
maintain intracellular oxygen levels necessary for metabolic processes and to
avoid oxygen-mediated toxicity. Although specific oxygen-sensing mechanisms
were defined in bacteria and yeast, until 1995 it was barely understood how
higher organisms are able to adapt to a decrease in oxygen.
The discovery of the heterodimeric transcription factor hypoxia-inducible factor
(HIF) more than one decade ago represented a breakthrough in the
understanding how organisms respond and adapt to low oxygen conditions
(hypoxia) (Wang and Semenza 1995). HIF was initially identified as transcription
factor that upregulates erythropoietin gene expression in kidney tissues when
oxygen availability is decreased. Over the last years more than 70 HIF target
genes involved in oxygen-homeostasis, glucose-energy-metabolism, apoptosis
and growth have been identified (Wenger et al. 2005). HIF binds to the
conserved sequence 5’-RCGTG-3’ in hypoxia-response elements (HREs) of
these genes and thereby upregulates gene expression (Wenger et al. 2005).
Table 1 shows few examples of HIF target genes.
HIF target genes
Glucose metabolism HK1, HK2, AMF/GPI, ENO1, GLUT1, GADPH, LDHA, PFKBF3, PFKL, PGK1, PKM, TPI
Angiogenesis EG-VEGF, ENG, LEP, LRP1, TGF-3, VEGF
Erythropoesis EPO
Iron metabolism Ceruloplasmin, Transferrin, Transferrin receptor
pH regulation Carbonic anhydrase 9
Cell proliferation Cyclin G2, IGF2, IGF-BP1, IGF-BP2, IGF-BP3, WAF1, TGF-, TGF-
Cell survival ADM, EPO, IGF2, IGF-BP1, IGF-BP2, IGF-BP3, NOS2, TGF-, VEGF
Apoptosis NIP3, NIX, RTP801
Vascular tone 1B-adrenergic receptor, ADM, ET1, Haem oxygenase-1, NOS2
Cell adhesion MIC2
Cytoskeletal structure KRT14, KRT18, KRT19, VIM
Motility AMF/GPI, c-MET, LRP1, TGF-
Transcriptional regulation DEC1, DEC2, ETS-1, NUR77
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Regulation of HIF-1 activity p35srj
Epithelial homeostasis Intestinal trefoil factor
Drug resistance MDR1
Nucleotide metabolism Adenylate kinase 3
Extracellular-matrix
metabolism
CATHD, Collagen type V (1), FN1, MMP2, PAI1, Collagen prolyl-4-hydroxylase  (I),
UPAR
Energy metabolism LEP
Amino-acid metabolism Transglutaminase 2
Table 1: HIF target genes (Semenza 2003). ADM, adrenomedullin; ALDA, aldolase A; ALDC, aldolase C;
AMF, autocrine motility factor; CATHD, cathepsin D; EG-VEGF, endocrine-gland-derived VEGF; ENG, endoglin; ET1,
endothelin-1; ENO1, enolase 1; EPO, erythropoietin; FN1, fibronectin 1; GLUT1, glucose transporter 1; GLUT3, glucose
transporter 3; GAPDH, glyceraldehyde-3-P-dehydrogenase; HK1, hexokinase 1; HK2, hexokinase 2; IGF2, insulin-like
growth-factor 2; IGF-BP1, IGF-factor-binding-protein 1; IGF-BP2, IGF-factor-binding-protein 2; IGF-BP3, IGF-factor-
binding-protein 3; KRT14, keratin 14; KRT18, keratin 18; KRT19, keratin 19; LDHA, lactate dehydrogenase A; LEP,
leptin; LRP1, LDL-receptor-related protein 1; MDR1, multidrug resistance 1; MMP2, matrix metalloproteinase 2; NOS2,
nitric oxide synthase 2; PFKBF3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-3; PFKL, phosphofructokinase L;
PGK 1, phosphoglycerate kinase 1; PAI1, plasminogen-activator inhibitor 1; PKM, pyruvate kinase M; TGF-,
transforming growth factor-; TGF-3, transforming growth factor-3; TPI, triosephosphate isomerase; VEGF, vascular
endothelial growth factor; UPAR, urokinase plasminogen activator receptor; VEGFR2, VEGF receptor-2; VIM, Vimentin
1.2 Composition of the HIF complex
HIF is a heterodimeric protein complex, which consists of oxygen sensitive HIF-
 subunits (HIF-1, HIF-2 or HIF-3) and a constitutively expressed HIF-1
subunit, also known as ARNT (aryl hydrocarbon receptor nuclear translocator).
Both  and  subunits are members of the basic helix-loop-helix Per/Arnt/Sim
(bHLH-PAS) transcription factor family (Wang and Semenza 1995).
HIF- consists of an N-terminal basic helix-loop-helix domain (bHLH), which is
necessary for DNA binding, followed by the PAS domain that is essential for
dimerization with ARNT (Jiang et al. 1996). HIF- undergoes oxygen-regulated
degradation which is dependent on the presence of two independently
functioning domains, called NODDD and CODDD, standing for N-terminal and
C-terminal oxygen-dependent degradation domain, respectively (ODDD). The
ODDD contains two proline residues (P402 and P564) (numbering according to
human HIF-1). Two transactivation domains (TAD), an N-terminal and a C-
terminal, complete the domain structure in the C-terminal part of HIF-1 and
HIF-2 whereas HIF-3 lacks a C-terminal TAD. In addition, a nuclear
localization signal (NLS) is also found within the C-terminal part of HIF-1 and
HIF-2. Figure 1 indicates the domain structure of the three HIF- isoforms.
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Figure 1: Domain structure of HIF- isoforms. HIF- isoforms share bHLH, PAS domain and
the ODDD which contains the N-terminal TAD. Two proline residues within the ODDD are
hydroxylated in normoxia. HIF-1 and HIF-2 possess additionally the C-terminal transactivation
domain, whereas HIF-3 contains a leucine zipper in the C-terminus. In addition the nuclear
localization sequence is shown (NLS).
1.3 Regulation of HIF-1 by oxygen
1.3.1 Oxygen-dependent regulation of HIF-1 protein stability
HIF-1 and HIF-1 mRNAs are both constitutively and oxygen-independently
expressed. In contrast, HIF-1 protein undergoes oxygen-regulated
degradation. In normoxia, PHDs hydroxylate two conserved proline residues,
proline 402 and 564 within the HIF-1 ODDD which mediate the binding of von
Hippel-Lindau tumor suppressor protein (pVHL), the substrate recognition
component of an E3 ubiquitin ligase complex. Polyubiquitination of HIF-1 takes
place and the subunit is targeted for proteasomal degradation (Maxwell et al.
1999). In patients, suffering from the von Hippel-Lindau disease, a rare
hereditary cancer syndrome, one allele of the VHL gene is mutated. In case of
loss or somatic inactivation of the wild-type allele, these patients loose VHL
function and hence develop sporadic renal cell carcinomas (Gnarra et al. 1994).
Constant HIF upregulation in the absence of pVHL in these carcinomas
suggested that pVHL-dependent proteolysis is the prime oxygen-dependent
degradation pathway (Maxwell et al. 1999). Under hypoxic conditions, PHD
activity is reduced because molecular dioxygen is limited and  subunits
become stabilized.
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1.3.2 Oxygen-dependent regulation of the HIF-1 transactivation activity
In addition to prolyl hydroxylation under normoxia, hydroxylation of an
asparagine residue (Asn803) in the C-terminal transactivation domain by factor
inhibiting HIF (FIH) takes place. Asn803 hydroxylation blocks the recruitment of
coactivators such as p300 and CREB-binding protein and thereby inhibits
transactivation activity (Lando et al. 2002). Like PHDs, FIH is also inhibited
under hypoxia due to limited molecular oxygen, and the C-terminal TAD
undergoes no modification and stays active. HIF-1 translocates into the
nucleus and heterodimerizes with its HIF-1 subunit. A functional transcriptional
complex is formed, which binds to the consensus sequence in the HREs of its
target genes and induces their expression (Metzen and Ratcliffe 2004). Figure 2
shows the oxygen-dependent regulation of HIF by PHDs and FIH.
Figure 2: Oxygen-dependent regulation of HIF-1 (Metzen and Ratcliffe 2004)
Under normoxia, HIF-1 is unstable and inactive due to hydroxylation of proline and asparagine
residues by PHDs and FIH. HIF-1 undergoes VHL-mediated ubiquitination and proteolysis.
Under hypoxia, the hydroxylases are inhibited and HIF-1 becomes stabilized, translocates to
the nucleus and recruits coactivators for transactivation of its target genes.
1.4 Additional positive and negative regulators of HIF
HIF-1 is induced by a variety of growth factors and cytokines such as insulin,
insulin-like growth factors (IGF1/2), endothelial growth factor (EGF) or tumor
necrosis factor alpha (TNF-). Most of these stimuli act through PI3-K/Akt/PKB
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and MAPK signaling cascades and are oxygen independent (Semenza 2002).
Within the PI3-K/Akt signaling pathway, HIF-1 is upregulated through PI3-K
itself, PTEN, Akt and also through some insulin signaling downstream targets
like HDM2 and mTOR (Zundel et al. 2000; Stiehl et al. 2002). The second
pathway known to be involved in oxygen-independent upregulation of HIF-1 is
the MAPK pathway. Inhibition of MAP kinase results in downregulation of HIF-1
transcriptional activity. Although ERK1/2 MAP kinases have been suggested to
be able to phosphorylate HIF-1, no specific phosphorylation sites had been
identified (Richard et al. 1999). Treatment of cells with the unselective tyrosine
kinase inhibitor genistein led to lower HIF-1 DNA-binding activity and reduced
HIF-1 stabilization under hypoxia. Likewise, treatment with the unspecific
phosphatase inhibitor sodium orthovanadate increased HIF-1 phosphorylation
and thereby enhanced DNA-binding activity. These results suggest that HIF-1
phosphorylation might be a potential way of modulating HIF-dependent signaling
pathways (Wang et al. 1995).
In 2004, Bae et al. reported a novel post-translational modification that
influences HIF-1 stability as well as transcriptional activity. Small ubiquitin-
related modifier-1 (SUMO) modifies its target proteins similar to the
ubiquitination process. Although the underlying mechanism is not clear,
sumoylation of the lysines 391, 477 and 532 upregulates HIF-1 protein level as
well transcriptional activity, resulting in higher expression of VEGF (Bae et al.
2004).
The influence of the immune regulator and inflammatory molecule nitric oxide
(NO) on HIF-1 is controversially discussed. Some studies report that NO
inhibits HIF in hypoxia, others observe HIF-1 upregulation in response to NO in
normoxia (Huang et al. 1999; Sandau et al. 2001). HIF-1 cysteine 300 S-
nitrosylation has been shown in vitro and in cell culture experiments, but the
biological role and function of this modification remains unclear (Sumbayev et al.
2003).
The function of the tumor suppressor protein p53 in the regulation of HIF-1 is
widely discussed. HIF-1 dependent p53 degradation as well as HIF-dependent
p53 induction have been reported (An et al. 1998; Ravi et al. 2000). However,
our group provided evidence that hypoxic upregulation of HIF-1 is not sufficient
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for oxygen-regulated p53 induction (Wenger et al. 1998). Only near anoxic
conditions, mimicked through treatment of cells with the iron chelator and PHD
inhibitor desferrioxamine (DFX), induced p53. Furthermore, p53 upregulation
was observed even in HIF-1-deficient cells, suggesting that oxygen-dependent
p53 induction is HIF-1 independent.
The N-acetyltransferase arrest-defective-1 (ARD1) was reported to acetylate
HIF and it has been suggested that inhibition of ARD1 is sufficient to stabilize
HIF-1 protein (Jeong et al. 2002). In contrast, Fisher et al. recently showed that
inhibition of ARD1 did neither increase HIF protein levels nor expression of HIF
target genes (Fisher et al. 2005). In addition, other research groups were unable
to reproduce ARD1-dependent HIF-1 regulation (Arnesen et al. 2005; Bilton et
al. 2005).
Another negative regulator of HIF-1 is a p300-binding protein called CITED2
(cAMP-responsive element-binding protein (CBP)/p300-interacting
transactivators with glutamic acid (E) and aspartic acid (D)-rich tail 2). CITED2
protein is bound within the cell by p300 and therefore competes with HIF-1 for
p300 binding. This means that the interaction of CITED2 with p300 blocks the
HIF-1-p300 interaction and thereby the transactivation of HIF-1. The fact that
CITED2 expression is upregulated by hypoxia led to the assumption that a
negative feedback loop may exist which downregulates HIF-1-mediated
transactivation under hypoxia (Bhattacharya et al. 1999).
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2 The HIF prolyl-4-hydroxylases function as oxygen sensors
2.1 The HIF prolyl-4-hydroxylases (PHDs)
In 2001, Epstein and colleagues described a family of three human and mouse
HIF prolyl-4-hydroxylases which showed high homology to the egg-laying
abnormal-9 (EGL9) family in Caenorhabditis elegans (C. elegans) (Epstein et al.
2001). They termed the three isoforms of HIF prolyl-4-hydroxylases PHD1,
PHD2 and PHD3, standing for prolyl-4-hydroxylase domain-containing protein.
These enzymes have alternatively been termed HIF prolyl hydroxylase (HPH3,
HPH2 and HPH1) or egg laying abnormal nine homolog (EGLN2, EGLN1 and
EGLN3) (Bruick and McKnight 2001; Ivan et al. 2002). Each of the three PHD
isoforms contains a conserved gene structure, suggesting duplication in the
lineage leading to vertebrates (Taylor 2001). The three HIF prolyl hydroxylases
show 42 to 59% sequence identity to each other but no distinct sequence
similarity to the well known collagen prolyl-4-hydroxylases (Hirsilä et al. 2003).
Only one HIF prolyl hydroxylase orthologue has been identified in Drosophila
melanogaster (D. melanogaster) (Bruick and McKnight 2001).
PHD1, also known and discovered as the mouse orthologue Falkor (Erez et al.
2002), is located on chromosome 19q13.2 and encodes a predicted open
reading frame of 407 amino acids (Bruick and McKnight 2001). PHD1 is able to
hydroxylate both Pro402 and Pro564 of human HIF-1 in vitro (Epstein et al.
2001). When fused to green fluorescent protein (GFP), PHD1 is found
exclusively in the nucleus of the cell (Metzen et al. 2003). In contrast, a recent
publication of Soilleux et al. used novel monoclonal antibodies against PHD1
and observed predominantly cytoplasmic staining in normal tissue. Furthermore
bronchogenic and breast carcinoma showed similar staining for PHD1 (Soilleux
et al. 2005).
PHD2 is located on chromosome 1q42-43 (Dupuy et al. 2000) and GFP-PHD2 is
found predominantly in the cytoplasm of the cell (Metzen et al. 2003). Berra et
al. showed that regulation of HIF-1 protein stability seems to be mainly
dependent on PHD2 (Berra et al. 2003). Soilleux et al. detected endogenous
PHD2 mainly in the cytoplasm (Soilleux et al. 2005).
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PHD3 was originally termed SM-20 and found to be upregulated in rat smooth
muscle cells after stimulation with platelet-derived growth factor (Wax et al.
1994). With 239 amino acids, PHD3 represents the shortest of the three PHDs.
Overexpressed GFP-PHD3 was found both in the nucleus and the cytoplasm
(Metzen et al. 2003). Endogenous PHD3 was as well observed in the nucleus
and the cytoplasm (Soilleux et al. 2005).
Recently a fourth prolyl hydroxylase termed PH-4 was found through a database
search approach. Despite a high similarity to the other three PHDs and
suppression of HIF-2 accumulation as well as HIF-dependent reporter gene
activation in PH-4 overexpressing cells, this isoform did not show any activity in
a HIF-1-pVHL in vitro interaction assay (Oehme et al. 2002).
2.2 PHD mRNA expression pattern
PHD1, PHD2 and PHD3 mRNA was found to be expressed in all tissues albeit
at different levels (Cioffi et al. 2003). PHD1 mRNA is mostly detected in testis
and PHD2 and PHD3 mRNA in heart and liver (Lieb et al. 2002). Recently,
Hirsilä et al. identified alternatively spliced isoforms of PHD2 and PHD3, which
showed no enzymatic activity. The levels of expression of these splice variants
were, in comparison to the mRNAs containing all exons, lower in all tissues
examined (Hirsilä et al. 2003).
2.3 Enzymatic activity and catalytic mechanism of the PHDs
PHDs are iron- and 2-oxoglutarate (2-OG) dependent dioxygenases and
catalyze the hydroxylation of specific prolyl residues within the ODDD of HIF-
subunits. They need oxygen as co-substrate and ascorbate as co-factor. The
requirement of molecular oxygen for the hydroxylation of proline residues
presents their O2-sensing function. Figure 3 shows the proposed mechanism of
prolyl hydroxylation by PHDs.
During the enzymatic reaction, one oxygen atom is added to a peptidyl proline to
form hydroxyproline. In a coupled decarboxylation reaction that converts 2-
oxoglutarate to succinate the second oxygen atom is incoporated into succinate
(Welford et al. 2005). Within the enzyme Fe(II) is bound through a triad of two
histidinyl residues and one aspartyl residue. Three remaining coordination sites
are occupied by two to three labile water molecules. The detailed mechanism of
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the catalysis by HIF prolyl hydroxylases is still not clear. One common
suggested mechanism is that an enzyme-Fe(II) complex first binds 2-
oxoglutarate. As a next step 2-OG substitutes a water molecule that is co-
ordinated to the Fe(II) and thereby triggers the reaction with molecular oxygen.
The next step is thought to be the oxidative decarboxylation of 2-oxoglutarate,
which produces succinate and a ferryl species at the iron centre. The generated
highly reactive intermediate is then able to oxidize the prime substrate (RH), a
peptidyl proline (Costas et al. 2004; Hausinger 2004).
Figure 3: Proposed mechanism of prolyl hydroxylation by PHDs (McNeill et al. 2005)
It is suggested that an enzyme-Fe(II) complex binds co-substrate 2-OG. Binding of 2-OG
releases a water molecule and thereby triggers the reaction with O2. After binding of oxygen an
oxidative decarboxylation of 2-oxoglutarate to succinate releases CO2 and generates a ferryl
species (FeIV=O) at the iron centre. The generated highly reactive intermediate is then able to
oxidize the prime substrate RH.
2.4 Substrate specificity
All three PHDs are able to hydroxylate proline residues in a conserved LXXLAP
(Leu-X-X-Leu-Ala-Pro) sequence motif in vitro, but their relative activity seems to
be different. Whereas PHD2 and PHD3 show similar specific activity, PHD1 has
a lower activity (Tuckerman et al. 2004). Concerning proline specificity, all three
PHDs can hydroxylate HIF-1 Pro564, but PHD1 and PHD2 preferentially
hydroxylate HIF-1 Pro402 (Chan et al. 2005). Although all PHDs seem to
contribute to HIF-1 regulation, the extent of the contribution of each PHD
enzyme might be dependent on its relative abundance (Appelhoff et al. 2004).
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Li et al. recently showed that amino acid substitutions in a HIF-1 peptide
caused only minor changes in PHD hydroxylation activity. The hydroxylation
activity was measured by an in vitro method based on the hydroxylation-coupled
decarboxylation of 2-oxoglutarate and mass spectrometry to analyse peptide
hydroxylation (Hirsilä et al. 2003; Li et al. 2004). They reported that the two
leucines in the LXXLAP motif of a 20-residue peptide can be replaced by many
other amino acids, resulting in no or only a slight decrease in hydroxylation
activity. Also the two amino acids glutamate and methionine (indicated here as
X-X residues) could be substituted by almost any residue with no change
compared to the wild-type peptide. Alanine showed the strictest requirement for
hydroxylation and no other amino acid was able to fully substitute for it in case of
PHD2, whereas in case of PHD1 and PHD3 it could be substituted by only
serine, isoleucine, valine or serine. Additionally, Huang et al. showed that
Leucine 574 in HIF-1 is required for VHL binding and VHL-mediated
degradation. When Leucine 574 was mutated the degradation process of HIF-1
was prevented (Huang et al. 2002).
2.5 Regulation of PHD expression and degradation
PHD2 and PHD3 are oxygen-dependently regulated by HIF (Epstein et al. 2001;
Metzen et al. 2005; Pescador et al. 2005). Whereas the induction of PHD3 is
HIF-1 and HIF-2 dependent, PHD2 is not affected by overexpression or
downregulation of HIF-2 (Aprelikova et al. 2004). In contrast, PHD1 shows no
upregulation under hypoxia and is not a HIF target gene (Appelhoff et al. 2004).
PHD1 and PHD3 are proteasomally degraded by Siah1a/2 (Nakayama et al.
2004). Siah are specific ring finger E3-ubiquitin ligases catalyzing
polyubiquitination. Nakayama et al. showed that overexpression of Siah2 and
Siah1a resulted in decreased levels of PHD1 and PHD3 in human embryonic
kidney (HEK293T) cells and that PHD3 is stabilized under normoxic (20% O2) as
well as hypoxic (1% O2) conditions in Siah2-/- and Siah1a-/- mouse embryonic
fibroblasts (MEFs). They also observed an increase of Siah1 and Siah2 mRNA
by hypoxia and impaired hypoxic HIF-1 induction in Siah2-/- cells (Nakayama et
al. 2004).
In addition, several other stimuli are known to regulate PHD expression. PHD1
mRNA was shown to be upregulated by estrogen in the breast cancer cell line
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ZR75-1 (Seth et al. 2002) and the rat orthologue of human PHD3, SM20, was
induced in response to p53 activation (Madden et al. 1996) as well as nerve
growth factor withdrawal in PC-12 cells (Lipscomb et al. 2001).
2.6 Regulation of prolyl-4-hydroxylation activity
2.6.1 Molecular oxygen
In 2003, Hirsilä et al. determined Km values for oxygen of the PHDs using insect
cell lysates overexpressing PHDs and a synthetic 19-residue peptide with a
sequence identical to the C-terminal hydroxylation site of HIF-1. The in vitro
hydroxylation activity assay was based on the determination of [14C]CO2 formed
during the hydroxylation-coupled decarboxylation of [1-14C]2-oxoglutarate
(Kivirikko and Myllyla 1982). The measured Km values for oxygen were between
230 - 250 M close to the oxygen partial pressure (pO2) in air (Hirsilä et al.
2003). These data confirmed already existing data from 2001 showing that PHD
enzyme activity was indeed highly sensitive to hypoxia (Epstein et al. 2001).
Epstein et al. in vitro hydroxylated HIF-1-derived peptides and used a VHL
capture assay and showed a progressive reduction of hydroxylation activity by
decreasing pO2 levels. However, these in vitro values are of somewhat limited
relevance, since the length of peptide substrates showed a marked effect on the
Km values for oxygen (Koivunen et al. 2006). When determined with
recombinant HIF-1 ODDD (amino acid 356-603) as substrate, Km values of 100
M were obtained, corresponding to 40% of the values determined with 19-
residue peptides. Nevertheless, the Km values for oxygen are clearly above
physiological pO2 values in the body (Hirsilä et al. 2003). This suggests that
PHDs work with maximal sensitivity in the range of physiological tissue pO2 and
therefore act as cellular oxygen sensors. An important aspect is the mechanism
by which PHDs are able to adapt to different physiological oxygen
concentrations. Whereas Schofield and Ratcliffe assumed that oxygen is the
limited factor for PHD hydroxylation capacity (Schofield and Ratcliffe 2005),
Stiehl et al. recently showed that increased PHD protein abundance can
compensate for a decrease in oxygen levels (Stiehl et al. 2006). Upregulation of
PHD2 and PHD3 mRNA levels under 2% oxygen in cell culture reached a
transient maximum after 64 to 112 hours and remaining upregulated for more
than 10 days. Co-transfection of Hif-1-/- MEFs with a one-hybrid reporter gene
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containing the HIF-1 ODDD and PHD expression plasmids showed that
increased PHDs levels are able to compensate for reduced oxygen availability
(Stiehl et al. 2006).
2.6.2 Iron and divalent metal ions
PHDs are non-heme Fe-binding dioxygenases and able to bind divalent iron
directly. Inhibition of the PHD activity by iron chelators induces HIF target genes
(Epstein et al. 2001). Other divalent ions such as Co2+, Ni2+ and Mn2+ were able
to mimic hypoxia and induce HIF target genes in vivo (Goldberg et al. 1988).
Interestingly, Hirsilä et al. recently showed that recombinant PHDs purified from
insect cells exert considerable in vitro hydroxylation activity without addition of
iron. It was shown that Fe2+ is tightly bound to the PHDs with a remarkably low
Km value, 0.03 M for PHD1 and 2 and 0.1 M for PHD3 (Hirsilä et al. 2005).
These data were confirmed by the fact that the enzyme preparations were only
partially inhibited by various divalent metal ions, such as Co2+, Ni2+ and Mn2+ as
well as up to 1 mM DFX. Recently, Martin et al. found that Cu2+ can increase
HIF-1-dependent reporter gene induction and CuCl2 is able to inhibit HIF-1
prolyl-4-hydroxylation independent of the Fe2+ concentration (Martin et al. 2005).
Based on spectroscopic and structural studies, it was assumed that metals
would be effective competitive inhibitors of the PHDs. However, this could not be
confirmed by in vitro assays (Schofield and Ratcliffe 2004). Therefore, other
mechanisms might exist by which metals inhibit the PHD enzymes or stabilize
HIF-1 in vivo. Salnikow et al. reported that intracellular ascorbate, previously
shown to be necessary for PHD activity, might be depleted by Co2+ and Ni2+
(Salnikow et al. 2004).
2.6.3 Ascorbate
Ascorbate oxidation is known to be necessary for the reduction of oxidized FeIV
(Myllyla et al. 1984) and it is thought to be necessary for the protection of the
PHDs from uncoupled reactions by which no substrate hydroxylation takes place
but damaging ROS are generated (Myllyharju and Kivirikko 1997). Two
independent studies showed that ascorbate promotes PHD activity and HIF
hydroxylation, one in rapidly growing tissue culture cells and another one in
junD-deficient cells which contain reduced anti-oxidant defense systems. These
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studies suggest that ascorbate might act as a mediator between antioxidant and
hypoxia pathways (Knowles et al. 2003; Gerald et al. 2004).
2.6.4 2-oxoglutarate
2-oxoglutarate is a tricarboxylic acid (TCA) cycle intermediate and necessary as
co-substrate for PHDs, thereby linking oxygen sensing and glucose metabolism.
Hereditary cancer syndromes, associated with mutations in the succinate
dehydrogenase gene, lead to succinate accumulation which inhibits the HIF
prolyl hydroxylases and thereby increases stabilization of HIF (Selak et al.
2005). Another study additionally showed that endogenous 2-oxoacids, such as
pyruvate and oxaloacetate, are both able to act as competitive inhibitors of the
2-OG-dependent PHDs (Dalgard et al. 2004).
Fumarate hydratase catalyzes the conversion of fumarate to malate in the TCA
cycle. Individuals with hemizygous germline mutations in the fumarate hydratase
gene have elevated intracellular fumarate levels and are predisposed to renal
cancer. Isaacs and co-workers recently demonstrated that fumarate hydratase
inhibition leads to elevated HIF levels by PHD inhibition. They demonstrated that
fumarate inhibits PHD activity by competing with its co-substrate 2-OG (Isaacs
et al. 2005).
2.6.5 Nitric oxide (NO)
NO is an in vitro inhibitor of the 2-oxoglutarate-dependent dioxygenases.
Several studies showed inhibition of hydroxylation of HIF-1 by different NO
donors (Sogawa et al. 1998; Metzen et al. 2003). The mechanism believed to
influence PHD hydroxylation activity might be competition of NO with O2 for
binding to the iron in the active site (Zhang et al. 2002). This competition might
explain activation of HIF by NO donors under normoxia (Metzen et al. 2003). In
contrast another study suggested that NO inhibits complex IV of the
mitochondrial electron transport chain in hypoxia and thereby oxygen is
redistributed towards the PHDs (Hagen et al. 2003).
2.6.6 Reactive oxygen species (ROS)
The role of ROS on HIF and PHD activity is discussed controversially. It has
been suggested that PHDs are highly susceptible to oxidative damage, either
via active site oxidation (Hausinger 2004) or inactivation via conversion of Fe2+
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to Fe3+. Evidence for oxidative damage of PHDs by ROS could be recently
demonstrated using junD-deficient cells. JunD is responsible for the reduction of
ROS levels as part of a defence against oxidative stress. Gerald et al. observed
that junD-/- cells show reduced PHD2 activity and elevated HIF-1 stabilization
which could be rescued by ascorbate. In addition, electron paramagnetic
resonance (EPR) measurements showed an increase of oxidized iron (Fe3+) in
the catalytic site of PHD2 (Gerald et al. 2004). This observation of oxidative
inactivation of PHDs might also represent an explanation why HIF-1 can be
stabilized by substances such as hydrogen peroxide (Guzy et al. 2005). Another
postulation is that ROS species produced by mitochondria might be involved in
hypoxia signaling (Chandel et al. 1998). Chandel et al. suggested that ROS
production at complex III of the respiratory chain is elevated in hypoxia and that
this signal is linked to HIF stabilization. Inhibitors of the respiratory chain which
reduced ROS production also reduced hypoxic stabilization of HIF-1. However,
this hypothesis is controversial and it is not even clear whether ROS levels are
elevated or reduced in hypoxia.
2.7 Known interactors of the PHDs
Ring finger E3-ubiquitin ligases Siah1 and Siah2 were described in 2004 as
PHD1 and PHD3 interactors (Nakayama et al. 2004). They catalyze the
polyubiquitination of PHD1 and PHD3 and thereby mediate proteasomal
degradation. Overexpression of these E3-ubiquitin ligases resulted in decreased
levels of PHD1 and PHD3 in human 293T cells. Nakayama et al. also reported
an increase of Siah1 and Siah2 mRNA by hypoxia, and that Siah2-/- cells exhibit
impaired induction of HIF-1 under hypoxia (Nakayama et al. 2004).
Several yeast two-hybrid screenings were performed and revealed novel
interactors of the PHD isoforms. A protein termed human amplified in
osteosarcoma nine (OS-9) was identified as HIF-1, PHD2 and PHD3
interacting protein (Baek et al. 2005). Several experiments suggested the
formation of a complex consisting of HIF-1, OS-9 and PHD2 or PHD3. OS-9
and PHD2 were binding independently of HIF-1 at non-overlapping sites.
Whereas HIF-1 was promoting the interaction between OS-9 and PHD2, OS-9
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overexpression enhanced HIF-1 and PHD2 or PHD3 interaction and thereby
promoted HIF-1 hydroxylation, VHL binding and proteasomal degradation.
The tumor suppressor inhibitor of growth family member 4 (ING4) was identified
in a yeast two-hybrid screening as PHD2 interacting protein (Ozer et al. 2005).
No evidence was found that ING4 is a substrate for PHD2 or that it influences
PHD2 activity. Surprisingly, ING4 suppresses HIF transcriptional activity.
Suppression of ING4 via siRNA increased the expression of a stably transfected
HIF-dependent luciferase reporter gene in HeLa cells. ING family members have
been shown to promote chromatin remodeling through the recruitment of factors
that promote or suppress transcriptional activation. Ozer et al. suggested that
under normoxic conditions, ING4 might be responsible for recruitment of
chromatin-remodeling factors to the promoter regions of HIF target genes and
thereby suppress their transcription. It has been proposed that ING4 retains
PHD2 in the nucleus in order to degrade HIF upon reoxygenation. However,
recent data showed predominant cytoplasmic localization of PHD2 (Soilleux et
al. 2005).
PHD3 was identified to interact specifically with the cytosolic chaperonin TCP-1
Ring Complex (TRiC), when co-purified in extracts from several cell types
(Masson et al. 2004). The function of this interaction is still not clear, but
additionally it has also been shown that TriC interacts with VHL in mammalian
cells. Feldman et al. further showed that TriC is required to assemble VHL into
the VHL-Elongin B-Elongin C (VBC) complex. When Feldman and co-workers
used in vitro translated VHL in a lysate of immune-depleted TRiC they failed to
produce correctly folded VBC complex (Feldman et al. 1999).
Hopfer et al. identified the WD-repeat protein MAPK organizer 1 (Morg1) as an
in vitro and in vivo interactor of PHD3 (Hopfer et al. 2006). The two proteins
displayed similar tissue expression patterns and co-localized in the cytoplasm as
well as in the nucleus. Additionally, Hopfer and co-workers showed that HIF-
mediated reporter gene activity was decreased by Morg1 and even further
reduced to basal levels when Morg1 was co-expressed with PHD3. RNAi-
mediated downregulation of Morg1 or PHD3 resulted in strong upregulation of
HIF-1 activity. Morg1 was described as molecular scaffold for components of the
ERK signaling cascade (Vomastek et al. 2004) and the authors suggested that
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Morg1 might interact specifically with PHD3 by acting as a molecular scaffold,
thereby influencing HIF-1 activity (Hopfer et al. 2006).
We recently found that FKBP38, a peptidyl-prolyl cis/trans isomerase is an
interactor of PHD2. HeLa cells in which FKBP38 was stably downregulated via
siRNA showed an increase of PHD2 protein levels in comparison to the wild-
type cell line (Barth et al., under revision), suggesting that FKBP38 influences
PHD2 protein stability.
A novel PHD3 interactor, the activating transcription factor-4 (ATF-4) was as
well identified. ATF-4 is stabilized under hypoxia and seems to be a specific
hydroxylation target of PHD3 (Koeditz et al., under revision).
3 The HIF prolyl-4-hydroxylase 1 – PHD1
3.1 Cloning of PHD1
Bruick and McKnight searched the GenBank database for sequences related to
the catalytic  subunit of the collagen-modifying prolyl-4-hydroxylases and found
five human homologs (Bruick and McKnight 2001). All five homologs contained
conserved amino acid residues predicted to bind Fe2+ and 2-oxoglutarate. They
cloned each of these homologs into an expression vector and in vitro
transcribed/translated them in a rabbit reticulocyte lysate system. Subsequently,
the three HIF prolyl hydroxylases were identified in an in vitro hydroxylation
assay. In parallel, Epstein et al. cloned the three human Egl-9 gene homologs,
PHD1, PHD2 and PHD3 and amplified them from cDNA banks and a human
colonic cDNA library, respectively (Epstein et al. 2001).
In 2002, Seth et al. utilized Serial Analysis of Gene Expression (SAGE)
technology for the identification of estrogen- and tamoxifen-regulated genes in
the estrogen-dependent breast cancer cell line ZR75-1. They identified EIT-6 as
a direct transcriptional target of the estrogen receptor and showed that
constitutive expression of EIT-6 promoted colony growth in human breast cancer
cells. Analysis of the EIT-6 sequence revealed that EIT-6 is a human homolog of
the rat SM-20 and C. elegans Egl-9 gene and sequence alignment showed
highest similarity to PHD1 (Seth et al. 2002).
In 2002, a novel cell growth regulator, named Falkor, was identified (Erez et al.
2002). The Genetic Supressor Elements (GSE) method was used to screen
genes critical for cellular DNA-damage response in MEFs. Falkor is expressed
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at different levels in various tissues and seems to be localized in the nuclei of
cells. Further database blasts showed that Falkor is the mouse orthologue of
PHD1. Cobb et al. finally cloned the PHD1 rat homolog from a rat liver cDNA
library and showed that the PHD1 sequence is highly conserved in human,
mouse and rat (Fig. 4) (Cobb et al. 2005).
Figure 4: Alignment of human, mouse and rat PHD1 (Cobb et al. 2005)
3.2 Transcriptional regulation of PHD1
In contrast to PHD2 and PHD3, PHD1 mRNA is not upregulated under hypoxia
(Epstein et al. 2001; Appelhoff et al. 2004). Erez et al. showed a decrease of
PHD1 mRNA levels under hypoxic conditions and in response to DFX (Erez et
al. 2004). A study of the human PHD1 promoter revealed an ARNT binding site
and ChIP analysis showed indeed association of ARNT with the PHD1 promoter
in hypoxia and after DFX treatment. ARNT is known to form transcriptionally
26
active heterodimers with different bHLH-PAS proteins, such as HIF-1, aryl
hydrocarbon receptor or SIM and to regulate gene expression in response to
hypoxia and xenobiotics. Erez et al. suggested that ARNT may be involved in
induction and repression of genes under hypoxia, depending on its
heterodimerization partner (Erez et al. 2004).
The fact that PHD1 was found as an estrogen-induced gene, EIT-6, was
recently confirmed in a study, showing that PHD1 mRNA is induced by estrogen
in the breast cancer cell line ZR751 and BT474 (Appelhoff et al. 2004; Tian et al.
2006).
3.3 Alternative initiation of translation and proteolytic regulation of PHD1
In previous experiments, Tian et al. observed in a wide variety of cell lines two
species of PHD1, termed PHD1p43 and PHD1p40 due to their molecular weight
(Tian et al. 2006). Both species were present in cancer cells derived from a
variety of different tissues. When specific PHD1 siRNA oligonucleotides were
used, they observed a downregulation of expression of both forms, indicating
that both species were the product of PHD1 mRNA. Studies of the PHD1 mRNA
revealed an alternative initiation codon corresponding to methionine 34, also
found in rat and mouse PHD1 cDNA sequences. Initiation at this start codon
produced a 40.2 kDa protein in comparison to 43.7 kDa for a PHD1 species
generated by initiation at the upstream ATG codon. PHD1 is proteolyticaly
regulated by the specific ring finger E3-ubiquitin ligases Siah1/2 (Nakayama et
al. 2004). Tian et al. showed that both PHD1 species are subject to proteolytic
regulation, but that they differ significantly in their protein stability. PHD1p40 has
a shorter half-life than the longer species PHD1p43, approximately 50 versus
100 minutes. Overexpression of either Siah1 or Siah2 reduced protein levels of
the two species. However, PHD1 protein levels of both isoforms were identical in
wild-type and Siah1a-/- / Siah2-/- MEFs suggesting that other proteolytic
pathways might be responsible for the difference in protein stability of the two
isoforms (Tian et al. 2006). Both PHD1 isoforms showed similar hydroxylation
activity of HIF-1-derived peptides in a VHL capture assay, suggesting that
differential isoform regulation could influences activity on another, non-HIF-,
substrate. This would also explain the functional relevance of the two PHD1
species which are highly conserved in mammals (Tian et al. 2006).
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3.4 Possible function of PHD1
When Erez et al. isolated PHD1 mRNA from cisplatin-treated MEFs, they
showed that the C-terminal domain of PHD1 enhances cell growth under stress
conditions such as cisplatin treatment but also under normal conditions (Erez et
al. 2002). In contrast, co-expression of full length PHD1 or its C-terminal
fragment abolished the growth enhancing effect. EIT-6 was found to promote
colony growth in a human breast cancer cell line (Seth et al. 2002). To clarify
these contradictive data, Erez et al. further investigated the role of PHD1 in cell
and tumor growth and showed that PHD1 is able to inhibit HIF-1 accumulation
and transcriptional activity under normoxic conditions and DFX treatment (Erez
et al. 2003). To exclude p53 dependency of this effect, they performed the same
assay in wild-type p53 or p53-/- HCT116 colon cancer carcinoma cells. No
difference was observed in the PHD1-mediated transcriptional inhibition
between the wild-type and the knock-out cell line. Furthermore, they compared
survival of HCT116 cells stably transfected with PHD1, with a control cell line
after DFX treatment. Erez and co-worker observed reduced cell survival after
DFX treatment in HCT116 PHD1 transfected cells compared to the control cell
line. No difference in cell growth between the two cell lines was observed in the
absence of hypoxia-mimetic treatment. These results led to an in vivo
experiment in which HCT116 PHD1 transfected cells were injected into CD1-
nude mice. The result was a significantly reduced average tumor volume in
HCT116 PHD1 treated mice compared to the control group. Histological analysis
of the tumors indicated that tumors from HCT116 PHD1 mice showed more
necrosis than those derived from control mice. When capillary density analysis
of the tumors was examined, it was remarkable that PHD1 overexpressing cells
showed a 50% reduced microvessel density compared with control tumor cells.
Based on these data, Erez et al. proposed that PHD1 is able to inhibit tumor
growth in hypoxia via inhibition of HIF-1 accumulation and transactivation
activity. Resulting inhibition of HIF target gene activation, such as VEGF,
reduced tumor neovascularization (Erez et al. 2003). Recently, a PHD1-/- knock
out mouse strain was generated. These mice are viable and show no phenotype
except a reduced fertility of male mice (Takeda et al. 2006; Ratcliffe et al.
unpublished). These data would confirm a suggested PHD1 function in
spermatogenesis and is consistent to the high expression of PHD1 in testis.
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4 Working hypothesis
The fact that three different HIF prolyl-4-hydroxylases are known and that these
isoforms differ in their response to hypoxia, in their expression pattern and their
subcellular localization suggests that in addition to HIF, other substrates of each
specific PHD enzyme may exist.
The goal of my PhD thesis was to identify and characterize new interactors of
PHD1. Human and mouse testis cDNA libraries were independently screened by
yeast two-hybrid methodology and more than 300 potential interactors were
identified. Fourty of each screening were confirmed by re-testing in yeast and
eight interactors finally tested for in vitro interaction. Among others the cerebellar
degeneration-related protein 2 (Cdr2) was identified as an interactor of PHD1 in
both independent yeast two-hybrid screenings. Subsequently, I investigated the
interaction of PHD1 and Cdr2 in vitro, analyzed Cdr2 mRNA levels under
normoxic and hypoxic conditions as well as its expression pattern in tissues and
cell lines. Additionally, the degradation pathway of Cdr2 was examined, poly-
and monoclonal antibodies generated and ongoing studies include now the
analysis of a possible Cdr2 prolyl hydroxylation by PHD1.
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Material and Methods
The principle of a yeast two-hybrid system
The yeast two-hybrid system is an in vivo system that identifies the interaction
between two proteins. Therefore a bait (here PHD1) forms a fusion protein with
a Gal4 DNA Binding domain and the second protein, the prey (here a protein of
a testis cDNA library) is fused to a Gal4 Activation Domain.
In case of an interaction between PHD1 and a testis cDNA protein, a functional
transcription factor is build and is able to activate chromosomally-integrated
reporter genes in the yeast, such as his3, uracil and -galactosidase. This
interaction can be monitored by growth of cells on plates lacking histidine or
uracil, respectively. Furthermore the yeast cells stain blue in a -galactosidase
assay. The combination of three different reporter genes reduces the risk of
false positive interaction. Figure 5 shows the principle of a yeast two-hybrid
system.
Figure 5: The principle of a yeast two-hybrid system
In two different yeast expression vectors a bait protein is fused to a Gal4 DNA Binding domain
and a prey protein forms a fusion protein with a Gal4 Activation Domain. Interaction of bait and
prey reconstitutes a functional transcription factor which activates chromosomally-integrated
reporter genes.
Gateway Cloning System
The Gateway Cloning System (Invitrogen) is a lambda phage-based site-specific
recombination system, which facilitates the cloning and subcloning between
different vectors. This recombination system was found to be used by lambda
during the switch between the lytic and the lysogenic pathways. The
recombination sites termed att (attachment sites), incorporate the DNA
sequence of interest and thereby allow the switch between different vectors.
Most Gateway vectors contain the ccdB gene cassette flanked by two att sites.
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The CcdB protein interferes with E. coli DNA gyrase and thereby is able to
inhibit growth of most E. coli strains. In case of recombination, the ccdB gene is
replaced by the gene of interest and allows negative selection of the donor and
destination vectors in E. coli. Two different types of reactions can be
distinguished:
1. The BP Reaction, a recombination reaction between an expression
vector and a Donor vector to create an Entry Clone.
2. The LR Reaction, a recombination reaction between an Entry Clone and
a Destination Vector generates an expression clone through added
recombination proteins/enzymes.
Figure 6: BP and LR reaction of the Gateway Cloning System
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The following recombination reactions were used:
BP Recombination Reaction:
attB expression clone (150 ng/l) 1-2 l
pDONR vector (supercoiled, 150 ng/l) 1 l
5  BP Clonase reaction buffer 2 l
TE Buffer, pH 8.0 to 8 l
2 l BP Clonase enzyme is added to the components above and mixed well by vortexing briefly
twice and the reaction is incubated at 25°C overnight
LR Recombination Reaction:
Entry clone (supercoiled, 100 – 300 ng) 1-2 l
Destination vector (150 ng/l) 1 l
5  LR Clonase reaction buffer 2 l
TE Buffer, pH 8.0 to 8 l
2 l LR Clonase enzyme is added to the components above and mixed well by vortexing briefly
twice and the reaction is incubated at 25°C overnight
After overnight incubation 2 l of 2 g/l Proteinase K solution was added to the
mixture and incubated at 37°C for 10 minutes. 1 - 3 l of reaction mix was
transformed into competent E. coli Top10 and selected for the appropriate
antibiotic-resistant entry or expression clones.
The Invitrogen Gateway ProQuest Yeast-Two-Hybrid System
Vectors
The Gateway-based ProQuest Yeast Two-Hybrid System is an in vivo screening
method allowing a rapid switch of genes of interest found in the screening to
different expression vectors for analysis and expression. The mouse testis
cDNA library is provided in the pEXP-AD502 vector fusing the gene of interest to
a GAL4-activation domain (GAL4AD). The bait is fused to the GAL4-DNA-
binding domain (GAL4DB). Both proteins of interest are incorporated in the
specific recombination site att1 and att2.
33
Figure 7: Yeast expression vectors used in yeast two-hybrid screening
pEXP-AD502 contains a protein encoded by a cDNA in fusion library and pDEST32 contains a
protein of interest (bait).
Vector features
pEXP-AD502 generates a fusion of the GAL4AD and a protein of interest (or
protein encoded by a cDNA in fusion library) cloned into the MCS in the correct
orientation and reading frame.
GAL4AD GAL4 activation domain
ADH1 Truncated 410 bp S. cerevisiae ADH1 promoter
ADH TT S. cerevisiae ADH1 terminator
TRP1 S. cerevisiae TRP1 gene for auxotrophic selection in yeast
pUC origin Bacterial origin of replication which allows propagation of the plasmid in E. coli
at low copy numbers
Amp Ampicillin resistance gene
attB1 Recombination site
attB2 Recombination site
ARS4/CEN6 Yeast origin
pDEST32 generates a fusion of the GAL4BD and a protein of interest (bait)
cloned into the MCS in the correct orientation and reading frame.
GAL4 BD GAL4 DNA binding domain
ADH1 Truncated 410 bp S. cerevisiae ADH1 promoter
ADH TT S. cerevisiae ADH1 terminator
LEU2 S. cerevisiae LEU2 gene for auxotrophic selection in yeast
pUC origin Bacterial origin of replication which allows propagation of the plasmid in E. coli
at low copy numbers
Gen Gentamicin resistance gene
attR1 Recombination site
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attR2 Recombination site
ccdB ccdB gene for gateway-compatible selection
ARS4/CEN6 Yeast origin
Additional vectors used in ProQuest yeast two-hybrid screening
pDEST22 generates a fusion of the GAL4AD and a protein of interest cloned
into the MCS in the correct orientation and reading frame. pDEST22 represents
the pEXPAD502 analog used for confirmation of protein:protein interaction in
further yeast two-hybrid assays.
pDBLeu expresses GAL4BD and is used as control vector for bait dependent
self-activity.
Yeast strain
The Yeast strain MaV203 with the following genotype was used:
MaV203 (MAT, leu2-3,221, trp1-901, his3200, ade2-101, gal4, gal80,
SPAL10::URA3, GAL1::lacZ, HIS3UAS GAL1::HIS3@LYS2, can1R, cyh2R)
All used control strains were derived from MaV203 and have the same
genotype.
The strains used in this system contain:
 A set of non-reverting auxotrophic mutations: leu2 and trp1 to allow selection
for the DB-X and AD-Y fusion vectors, and his3 for growth dependent upon
induction of the reporter gene GAL1::HIS3
 Deletions of the GAL4 and GAL80 genes encoding GAL4 and its repressor
GAL80, respectively. In the absence of GAL80, galactose is not required for
activation of GAL4-inducible promoters.
 Three stably integrated single-copy GAL4-inducible reporter genes:
SPAL10::URA3 integrated at URA3; HIS3UAS GAL1::HIS3 integrate at LYS2;
and GAL1::lacZ integrated at unknown loci
 The recessive drug resistance marker cyh2R for curing the control vector
pDBLeu for plasmid shuffling
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Yeast Control Strain A – E
Reporter gene expression within the yeast two-hybrid screening can vary from
strong to weak, which might not reflect the affinity of protein:protein interaction in
the native environment. To facilitate the selection of potential interactors a set of
five control strains was used to compare found interactions in its strength to the
increasing strength of interaction of the control strains A-E. Table 2 summarizes
the control strain A – E and shows their interacting inserts.
Table 2: Control strains A-E of ProQuest yeast two-hybrid screening
Cloning of pENTR4PHD1, -PHD2 and -PHD3
Entry vectors were generated by cloning PCR fragments into BamHI and
EcoRV-digested pENTR4 or pENTR/D-TOPO vectors. Full-length PHD1 to 3
(accession numbers NM_053046, NM_022051 or NM_022073, respectively)
were amplified by PCR from plasmids pcDNA3.1/PHD1, pcDNA3.1/HA-PHD2
and pcDNA3.1/PHD3.
The Clontech Matchmaker/Dualsystems Biotech yeast two-hybrid system
The Clontech/Dualsystem Matchmaker yeast two-hybrid system represents a
combination of the Clontech Matchmaker system, which libraries are provided in
the pACT2 expression vector, and the Dualsystem Biotech system using the
pLexA bait vector.
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Figure 8: Yeast expression vectors used in yeast two-hybrid screening
pACT2 contains a protein encoded by a cDNA in fusion library and pLexA-dir contains a protein
of interest (bait).
Vector features
pACT2 generates a fusion protein between the GAL4AD, an HA epitope tag,
and a protein of interest (or protein encoded by a cDNA in fusion library) cloned
into the MCS in the correct orientation and reading frame.
GAL4AD GAL4-DNA activation domain
ADH1 Truncated 410 bp S. cerevisiae ADH1 promoter
LEU2 S. cerevisiae LEU2 gene for auxotrophic selection in yeast
pBR322 Bacterial origin of replication which allows propagation of the plasmid in E. coli
at low copy numbers
Amp Ampicillin resistance gene
2micron Origin of replication derived from the endogenous yeas 2 circle.
HA Hemagglutinin (HA) epitope
pLexA generates a fusion protein between the GAL4BD and a protein of
interest cloned into the MCS in the correct orientation and reading frame.
GAL4DB GAL4-DNA binding domain
LexA LexA amino acids 1-202
ADH1 Truncated 410 bp S. cerevisiae ADH1 promoter
ADHterm S. cerevisiae ADH1 terminator
TRP1 S. cerevisiae TRP1 gene for auxotrophic selection in yeast
colE1 Bacterial origin of replication which allows propagation of the plasmid in E. coli
at low copy numbers
KanR Kanamycin resistance gene
2micron Origin of replication derived from the endogenous yeast 2 circle
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Yeast strain
The yeast strain DSY-1 with the following genotype was used:
DSY-1 (MAT, his3200, trp1-901, leu2-3,221 ade2, LYS2::(lexAop)4-
HIS3,URA3::(lexAop)8-lacZ, GAL4)
The strains used in this system contain:
 Two integrated reporter genes, HIS3 for auxotrophic selection on minimal
medium lacking the amino acid histidine and the colorimetric reporter lacZ
endocing -galactosidase. The two genes are under the control of two
different minimal promoters which are fused to 4 or 8 copies of the lexA
operator sequence
Cloning of pLexAPHD1, -PHD2 and -PHD3
pLexAPHD1 was obtained by digesting pcDNA3.1PHD1 with BamHI and
EcoRV, Klenow fill-in and cloned into SmaI digested pLexA. pLexAPHD2 was
obtained by digesting pcDNA3.1PHD2 with SacI and 3’5’-exonuclease and
cloned into SmaI digested pLexA. pLexAPHD3 was obtained by digesting
pcDNA3.1PHD3 with KpnI and 3’5’-exonuclease and cloned into SmaI digested
pLexA.
Yeast (S. cerevisiae) cultivation
S. cerevisiae was cultivated at 30°C in liquid culture or on solid agar plates.
Yeast cells have different stages of growth divided into early-log phase, mid log-
phase, late log-phase and stationary phase. These phases are based on cell
density and how quickly the cells are able to grow and divide based on nutrient
use. Table 3 gives relation of the absorbance of the sample at 600 nm and its
corresponding cell density.
Phase of growth OD600 Cells/ml
Early log-phase < 0.4 < 107
Mid log-phase 0.4 – 1.7 1 – 5 x 107
Late log-phase 1.7 – 6.6 5 x 107 - 2 x 108
Stationary phase > 6.6 2 x 108
Table 3: Growth stages of yeast and corresponding OD600
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Yeast Transformation
Small scale transformation
For small scale yeast transformation, 25 ml culture in YPAD (Yeast extract -
Peptone - Dextrose plus Adenine medium) or selection medium were inoculated
with several yeast colonies from a fresh plate and grown overnight at 30°C on a
rotary shaker up to a density of OD600 > 1.3. Overnight culture was diluted to
receive a starting culture with an OD600 of 0.2. Cells were grown at 30°C up to
OD600 0.6. Afterwards the culture was pelleted at 2 500 rpm for 5 minutes and
washed with distilled water. Per small scale transformation 1.5 ml culture was
centrifuged at 2 500 rpm for 5 minutes and the supernatant was removed. 100
ng DNA was added to a fresh tube and mixed with 300 l of freshly prepared
PEG/LiAc mix. PEG/LiAc mix was prepared per transformation of 240 l 50%
PEG, 36 l of 1 M LiAc and 25 l of denaturated single stranded DNA (2 mg/ml
stock solution). To keep the DNA single strand it was boiled in advance for 5
minutes at 100°C and chilled on ice immediately. 300 l of the whole mixture
was then added to the yeast pellet, gently vortexed and incubated for 45
minutes on 42°C. Afterwards the cells were pelleted and resuspended in 100 l
0.9% NaCl, finally plated on selection medium and incubated at 30°C for 48 – 72
hours. This method should yield a transformation efficiency of approximately
104-105 cfu/g.
YPAD liquid (1 l)
10 g Bacto yeast extract
20 g Bacto peptone
100 mg Adenine sulfate
Dissolve in 950 ml H2O, adjusted pH with HCl to 6.0 and autoclave. Afterwards add 50 ml 40%
Glucose
YPAD plates (500 ml)
5 g Bacto yeast extract
10 g Bacto peptone
50 mg Adenine sulfate
Dissolve in 225 ml H2O, adjust pH with HCl to 6.0, autoclave and cool to 50°C. Afterwards add
50 ml 40% Glucose. Separately dissolve 10 g Agar in 250 ml H2O, autoclave and mix after cool
to 50°C with yeast extract, peptone and adenine sulfate solution.
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Synthetic complete drop-out media (Sc drop-out) liquid (1 l)
6.7 g Yeast nitrogen base w/o amino acids
0.65 g Drop-out (DO) Supplement
Dissolve in 950 ml H2O, adjusted pH with 10 M NaOH to 5.9 and autoclave. Afterwards add 50
ml 40% Glucose.
Sc plates (500 ml)
3.35 g Yeast nitrogen base w/o amino acids
0.32 g DO Supplement
Dissolve in 225 ml H2O, adjust pH with 10 M NaOH to 5.9 and autoclave. Afterwards add 25 ml
40% Glucose; Dissolve 10 g Agar in 250 ml H2O, autoclaved separately and add after cooling to
50°C to yeast nitrogen base and DO supplement mix.
Nutrients
Tryptophan stock conc.: 10 g/l add 2 ml/l medium (final conc.: 0.02 g/l)
Histidine stock conc.: 10 g/l add 2 ml/l medium (final conc.: 0.02 g/l)
Leucine stock conc.: 10 g/l add 10 ml/l medium (final conc.: 0.1 g/l)
Adenine stock conc.: 10 g/l add 2 ml/l medium (final conc.: 0.02 g/l)
Filter sterile solutions and store dark at 4°C.
PLATE transformation
The abbreviation PLATE stands for PEG, Lithium acetate, Tris and EDTA. A
single yeast colony was inoculated as starter culture in 2 – 3 ml media and
grown overnight at 30°C on a rotary shaker. Per transformation, 0.5 ml of the
culture was centrifuged at 12 200 rpm for 30 seconds. To the remaining yeast
pellet 50 l of denatured single stranded DNA (2 mg/ml stock solution) was
added. 1 – 2 g of plasmid DNA were added and mixed by pipetting. Finally, 0.5
ml of PLATE solution was mixed gently by pipetting with the yeast pellet and the
single stranded DNA. The PLATE solution consists of 40% PEG3350 (w/v), 100
mM Lithium acetate, 10 mM Tris, pH 7.5 and 1 mM EDTA. The cultures were
incubated at 30°C without shaking for 24 – 48 hours. After collecting by
centrifugation and resuspension in 200 l in 0.9% NaCl yeast culture was
spread on solid selection media and incubated at 30°C for 48 – 72 hours.
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Yeast plasmid DNA preparation
A single yeast colony was inoculated in appropriate medium and incubated on a
rotary shaker overnight at 30°C. 8 ml of yeast cultures were centrifuged at 2 500
rpm for 5 minutes and the pellet was resuspended in 500 l sorbitol buffer. The
resuspension was incubated gently shaking at 30°C for 30 minutes. After
centrifugation the remaining spheroblasts were resuspended in 300 l buffer 1,
afterwards 300 l buffer 2 was added and the gently mixed suspension was
incubated for 5 minutes at room temperature. Furthermore, 300 l buffer 3 were
added, the tubes mixed by inverting and again incubated 5 minutes at room
temperature. The cloudy suspension was centrifuged at 13 krpm for 10 minutes
and the supernatant was transfered to a fresh tube and precipitate with 600 l
isopropanol. After centrifugation at 13 krpm for 30 minutes the remaining DNA
pellet was washed with 70% ethanol and finally vacuum dried and resuspended
in 50 l H2O. For transformation of yeast plasmid into bacteria (E. coli) via
electroporation 5 l were used.
Sorbitol Buffer
5 ml 3 M Sorbitol
2.5 ml 0.5 M EDTA pH 8.0
15 l -Mercaptoethanol
10 mg Lyticase (733 units/mg)
Add H2O to 15 ml
Buffer 1 Buffer 2 Buffer 3
50 mM TrisCl, pH 8.0 200 mM NaOH 3 M KAc, pH 5.5
10 mM EDTA 1% SDS (w/v)
100 g/ml RNase A
X-gal Assay
The yeast culture was grown on two layers of filter paper on agar plates. The
filter paper was shortly deep frozen in liquid nitrogen for few seconds and added
to a new plate with 8 ml freshly prepared X-gal solution. Excess solution was
removed and the membrane soaked with the X-gal solution incubated at 37°C.
The incubation duration varied between few minutes and several hours
depending on the strength of interaction.
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Z-Buffer X-gal solution
60 mM Na2HPO4 100 l X-gal (100 mg/ml DMF)
40 mM NaH2PO4 60 l 2-Mercaptoethanol
10 mM KCl 10 ml Z-Buffer
1 mM MgSO4
50 mM 2-Mercaptoethanol
pH 7.0, sterile filtered
Coupled in vitro transcription/translation reaction (Promega)
The TNT quick coupled transcription/translation system enables in a single tube
coupled transcription/translation reaction for eukaryotic in vitro translation. The
system consists of a rabbit reticulocyte lysate, RNA polymerase, nucleotides
and recombinant RNase inhibitor. The system is available for either T7 or SP6
RNA polymerase promoters and can be used to synthesize proteins with or
without radioactive labeling. The following table represents the standard reaction
protocol used in radioactive GST pull-downs.
Standard Reaction using [35S] methionine Volume
TNT Quick Master Mix 20 l
[35S] methionine 1 l
Plasmid DNA template (0.5 g) 1 l
Nuclease-free water to final volume Σ 25 l x l
The reaction mix was incubated at 30°C for 90 minutes and used for protein
expression analysis or GST pull-down assay.
Bacterial expression of recombinant proteins
Recombinant proteins were fused to Glutathione-S-transferase (GST). The
plasmids were transformed into the BL-21-AI E. coli. An overnight culture
containing the corresponding antibiotic and 0.1% glucose for repression of
expression was inoculated with a single colony. On the next day, the overnight
culture was diluted 1:40 and grown at 37°C to an OD600 of 0.4. Expression was
induced by arabinose. The bacteria were induced for 3 - 4 hours at 37°C.
Afterwards, the bacterial culture was centrifuged at 8 000 rpm for 15 minutes at
4°C and pellets were stored at -20°C until purification.
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Lysis of bacteria
Bacterial pellets of a 2 l culture were resuspended in 8 ml PBS with EDTA-free
protease inhibitors (Roche). Bacterial lysis was carried out by disruption of
bacteria in a French press at 2.7 kbar. In case of FPLC purification, the lysate
was centrifuged at 40 000 rpm for 1 hour at 4°C.
Purification of recombinant proteins with Biologic Duo Flow fast
performance liquid chromatography (FPLC)
GST-fusion proteins
After centrifugation the supernatant of the lysate was loaded on a GSTrap FF
column (Amersham) with a flow rate of 0.2 ml/minute to bind the fusion protein
to the glutathione sepharose matrix. The 2-buffer system consisted of a buffer A
(1 PBS) as washing buffer and a buffer B (32.5 mM glutathione/50 mM Tris/Cl
pH 8.0) used as elution buffer.
Step Number Step
1 Isocratic flow with 100% buffer A at 1.00 ml/min for 10.0 ml
2 Dynamic loop: Inject x ml sample at 0.2 ml/min
3 Isocratic flow with 100% buffer A at 1.00 ml/min for 10.0 ml
4 Elution with 100% buffer B at 1.00 ml/min for 10.0 ml
5 Isocratic flow with 100% buffer A at 1.00 ml/min for 10.0 ml
GST-fusion protein pull-down with IVTT proteins
GST pull-down assays were used to test protein-protein interaction in vitro.
Glutathione sepharose beads were washed three times with bead binding buffer
and centrifuged at 1000 rpm for 30 seconds at 4°C. To bind the recombinant
protein to beads, 10 – 20 g protein were diluted in 500 l bead binding buffer
and 30 l glutathione sepharose beads were added. The beads were rotated
either overnight or for a minimum of 2 hours at 4°C. Afterwards the beads were
washed three times with 500 l Co-IP buffer and 20 l of the IVTT reaction were
added to the corresponding sample and rotated again for 2 hours at 4°C. Beads
were pellet at 1 000 rpm for 30 seconds at 4°C and washed 3 – 5 times with 1
ml Co-IP buffer. The supernatant was removed completely after centrifugation
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and the pellet was boiled for 5 minutes at 95°C with 20 l 2  SDS sample
buffer. 18 l of the supernatant were load to a SDS-PAGE, avoiding spill-over
across lanes. After run, the gel was stained with coomassie staining solution for
15 minutes and 30 minutes fixed in a fixation solution consisting of 50%
methanol and 10% acetic acid. Using a washing solution with 7% methanol, 7%
acetic acid and 1% glycerol the gel was destained completely and vacuum dried
at 80°C for 2 hours and exposed to an autoradiography screen overnight. To
reduce unspecific binding, beads were blocked with 1% BSA and up to 0.5%
Triton-X-100 was added to the Co-IP buffer to increase the stringency.
Bead Binding Buffer (GST-fusion protein) Co-IP Buffer
50 mM K-phosphate pH 7.5 50 mM Tris-Cl pH 7.6
150 mM KCl 100 mM NaCl
1 mM MgCl2 0.1% Triton X-100
10% Glycerol 2 mM EDTA
1% Triton X-100
Database search and analysis of identified interactors
The following databases were used to identify and characterize found interactors
of PHD1:
BLAST/Protein search
http://www.ncbi.nlm.nih.gov/BLAST/
http://au.expasy.org/
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Protein&itool=toolbar
http://www.ebi.ac.uk/interpro/databases.html
http://genome-www5.stanford.edu/cgi-bin/source/sourceSearch
Protein domain search:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=cdd
http://elm.eu.org/
http://www.sanger.ac.uk/Software/Pfam/search.shtml
http://scansite.mit.edu/motifscan_seq.phtml
Homology search
http://www.wormbase.org/
http://flybase.bio.indiana.edu/
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Results
ProQuest yeast two-hybrid screening
Figure 9 represents the process flow of both yeast two-hybrid screenings.
Process flow of yeast two-hybrid cDNA library screening
Screening preparations:
• Cloning of bait
• Library titration
• 3-AT titration
Transformation of cDNA library into
bait containing yeast strain
Retest of each clone on plates
containing determined 3-AT
screening concentration
Growth selection / LacZ selection
on plates containing increasing
3-AT concentrations
Isolation of plasmid DNA
from yeast
Transformation into E. coli
for selection of library plasmid
and amplification
Isolation of library plasmids
from bacteria Sequence analysis
Retransformation assay in yeast
Confirmation of phenotype in yeast
BLAST and analysis of interactors
Database research
Figure 9: Process flow of yeast two-hybrid screening
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Titration of mouse testis cDNA library (Invitrogen)
The mouse testis cDNA library (Invitrogen) (1.6 g/l) contained an expected
amount of 3.38  107 number of independent clones. To screen a total number
of clones in the 105 - 106 range several small scale transformations with different
amounts of cDNA library from 0.5 g up to 10 g were tested. The use of 5 g
cDNA library in a 10  transformation scale achieved only 3.2  104 clones. In
the corresponding yeast two-hybrid screening the number of independent clones
was increased by transformation of 50 g cDNA library using a 250 ml yeast
culture scale.
Self-activation and transformation control
The following combinations of plasmids were tested in a small scale
transformation to exclude self-activation of bait and mouse testis cDNA library
(Table 4). Additional pDBLeu was used as transformation control.
Plasmid 1 Plasmid 2 Selection Purpose
pDBLeu - SC -leu Transformation control
- - SC –leu -trp Transformation control
pDBLeu pEXP-AD502 SC –leu -trp Self activation control
pDEST32PHD1 pEXP-AD502 SC –leu -trp
Self activation control of
pDEST32PHD1
pDBLeu mtestis cDNA SC –leu -trp
Self activation control of
mouse testis cDNA
pDEST32PHD1 pEXP-AD502-HIF2 73-870 SC –leu -trp Positive interaction control
Table 4: Self activity and transformation controls
Titration of the 3-aminotriazol (3-AT) concentration
To determine the 3-AT concentration necessary to suppress basal levels of
HIS3 expression, four clones of Mav203 containing the following plasmids were
plated on selection plates with different 3-AT concentrations ranging from 5 mM
– 50 mM.
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1. Control strains A - E
2. pDBLeu
3. pDBLeu + pEXPAD502
4. pDEST32-PHD1 + pEXP-AD502
5. pDEST32-PHD1
The titration resulted in an optimal 3-AT concentration of 10 mM, where no
growth of yeast cells except the interaction controls B – E was observed. To
avoid false positive growth due to basal histidine expression, the screening was
carried out at 12.5 mM 3-AT.
ProQuest mouse testis cDNA library screening
Selection medium (250 ml Sc –trp) was inoculated with Mav203 pDEST32PHD1
overnight and diluted the next day in 500 ml YPDA to achieve a starting OD600 of
0.3. The culture was grown up to a density of 0.6 and then distributed over 10
tubes and centrifuged at 2 500 rpm for 5 minutes. Each pellet was washed with
30 ml sterile H2O and all pellets resuspended and pooled in 6 ml H2O. In total, 4
transformations were carried out in parallel as follows:
32 l mouse testis cDNA library (= 50 g)
+ 400 l ssDNA (herring sperm DNA)
+ 1.5 ml yeast suspension Mav203 transformed with pDEST32PHD1
+ 6 ml 40% PEG/1  TE/1  LiAc
Yeast cells were incubated for 45 minutes at 30°C in a water bath, then 700 l
DMSO were added. Cells were heat shocked for 20 minutes at 42°C, the culture
was regularly gently mixed in between and immediately after the heat shock
cells were put on ice for exactly 2 minutes and centrifuged for 5 minutes at 2 500
rpm. All 4 pellets were resuspended in 24 ml 0.9% NaCl and 200 l culture was
plated per 15-cm Sc –leu-trp-his 12.5 mM 3-AT plate. In addition dilutions of
1:10, 1:100, 1:1000 and 1:10000 were plated on Sc–leu-trp plates to determine
the transformation efficiency. As positive interaction control, the pellet of 10 ml
Mav203 culture transformed with pDEST32PHD1 was resuspended in 120 l
H2O and transformed with 1 g pEXP-AD502HIF-273-870 and plated on
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screening plates. After incubation of 48 – 72 h clones were picked and retested
on 12.5 mM 3-AT plates and glycerol stocks were generated from potential
interactors. In total, 3  106 independent clones were screened.
Determination of phenotype
To further characterize positive interactions, clones were plated in triplicates on
plates with an increasing concentration of 3-AT ranging from 12.5 mM up to 50
mM 3-AT. In addition, control strains A – E as well as a positive control
(pDEST32PHD1 + pEXPAD502HIF-273-870) and a negative control
(pDEST32PHD1 + pEXPAD502) were added. Figure 10 shows the
determination of phenotype on different concentration of 3-AT as well as an X-
gal assay of the first 70 potential interactors.
Figure 10: Determination of phenotype. Clones were plated on different concentrations of 3-
AT to determine the strength of interaction and a X-gal assay was carried out.
All growth differences on 3-AT plates as well as the intensity of the blue staining
in the X-gal assay were reported. Plasmid DNA was isolated from 40 interactors
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that formed the first clones. Isolated yeast plasmid DNA was transferred by
electroporation in XL-1-Blue E. coli bacteria, plasmids were isolated and
sequenced. The sequencing results are summarized in table 12 and table 13.
Retransformation assay
All sequenced interactors were retested by transformation of the isolated
plasmids into Mav203 pDEST32PHD1. The phenotype was assessed by plating
on plates with increasing concentrations of 3-AT and in X-gal assays.
In the following tables 5 – 11 the phenotype of potential interactors of PHD1 are
shown.
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+ 3-AT - ura b-Gal + 3-AT - ura b-Gal
1  25 mM   P P 300 ng /μl P 25 mM  ─ P
2  ─ ─  P P 300 ng /μl P ─ ─  ─ P
3  25 mM ─  P P 300 ng /μl P 25 mM ─  ─ P
4  10 mM ─  P P 300 ng /μl P 10 mM ─  ─ P
5  50 mM   P P 300 ng /μl P 10 mM ─  ─ P
6  10 mM ─  P P 300 ng /μl P 25 mM ─  ─ P
7  50 mM ─  P P 300 ng /μl no growth ─ ─ ─ ─ P
8  25 mM ─  P P 300 ng /μl P 50 mM ─  ─ P
9  25 mM ─  P P 300 ng /μl P 25 mM ─  ─ P
10  10 mM ─  P P 300 ng /μl P 10 mM ─  ─ P
11  50 mM   P P 300 ng /μl P 25 mM   ─ P
12  25 mM ─  P P 300 ng /μl P 10 mM ─  ─ P
13  50 mM   P P 300 ng /μl P 25 mM   ─ P
14  50 mM   P P 300 ng /μl P 25 mM ─  ─ P
15  25 mM   P P 300 ng /μl P 10 mM   ─ P
16  50 mM   P P 300 ng /μl P 50 mM   ─ P
17  50 mM   P P 300 ng /μl P 50 mM   ─ P
18  25 mM ─ ─ P P 300 ng /μl P 25 mM ─  ─ P
19  25 mM   P P 300 ng /μl no growth ─ ─ ─ ─ P
20  25 mM ─  P P 300 ng /μl P 25 mM ─  ─ P
21  50 mM   P P 300 ng /μl P 50 mM   ─ P
22  25 mM ─  P P 300 ng /μl P 25 mM ─  ─ P
23  10 mM ─ ─ P P 300 ng /μl P 25 mM ─  ─ P
24  10 mM ─  P P 300 ng /μl P 25 mM ─  ─ P
25  50 mM   P P 300 ng /μl P 25 mM   ─ P
26  50 mM ─  P P 300 ng /μl P 25 mM ─  ─ P
27  25 mM   P P 300 ng /μl P ─ ─ ─ ─ P
28  25 mM ─  P P 300 ng /μl P 25 mM ─  ─ P
29  50 mM   P P 300 ng /μl P 25 mM ─  ─ P
30  50 mM ─  P P 300 ng /μl P 50 mM ─  ─ P
31  50 mM   P P 300 ng /μl P 50 mM   ─ P
32  50 mM   P P 300 ng /μl P 50 mM   ─ P
33  50 mM   P P 300 ng /μl P 50 mM   ─ P
34  50 mM ─  P P 300 ng /μl no growth ─ ─ ─ ─ P
35  25 mM ─  P P 300 ng /μl P 50 mM ─  ─ P
36  25 mM  ─ P P 300 ng /μl no growth ─ ─ ─ ─ P
37  50 mM   P P 300 ng /μl P 50 mM ─  ─ P
38  50 mM   P P 300 ng /μl P 50 mM   ─ P
39  10 mM ─ ─ P P 300 ng /μl P 10 mM ─ ─ ─ P
40  25 mM ─  P P 300 ng /μl P 25 mM ─  ─ P
# Glycerolstock
DNA isolated from
yeast
E.coli
transformation
activates
itself Sequencing
Phenotype retransformationPhenotype
Yeast re-
transformation
DNA conc.
approx. ng/ml
Table 5: Phenotype of the first 40 potential interactors of PHD1 in yeast two-hybrid
screening
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+ 3-AT - ura b-Gal
41  25 mM ─ 
42  25 mM ─ 
43  50 mM ─ 
44  50 mM  ─
45  25 mM ─ 
46  25 mM  ─
47  50 mM ─ 
48  50 mM ─ 
49  10 mM ─ 
50  50 mM  
51  50 mM  
52  50 mM  
53  50 mM  
54  50 mM  
55  25 mM ─ 
56  25 mM ─ 
57  50 mM ─ 
58  10 mM ─ ─
59  10 mM ─ ─
60  10 mM ─ 
61  ─ ─ 
62  10 mM ─ 
63  50 mM ─ 
64  50 mM ─ 
65  50 mM  
66  25 mM ─ 
67  10 mM ─ 
68  50 mM  
69  25 mM ─ 
70  25 mM ─ 
71  10 mM ─ 
72  25 mM  
73  10 mM ─ 
74  25 mM ─ 
75  25 mM ─ 
76  25 mM ─ 
77  25 mM  
78  50 mM  
79  50 mM ─ 
80  25 mM ─ 
# Glycerol stock
Phenotype
Table 6: Phenotype of potential PHD1 interactors in yeast two-hybrid assay I
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+ 3-AT - ura b-Gal
81  25 mM ─ 
82  50 mM  
83  50 mM  
84  50 mM  
85  25 mM  
86  50 mM  
87  50 mM  
88  25 mM  
89  50 mM ─ 
90  50 mM ─ 
91  50 mM  
92  50 mM ─ 
93  50 mM  
94  50 mM  
95  25 mM  
96  10 mM ─ 
97  10 mM ─ ─
98  50 mM  
99  25 mM ─ 
100  10 mM ─ ─
101  25 mM ─ 
102  50 mM  
103  50 mM ─ 
104  50 mM  
105  50 mM  
106  50 mM  
107  25 mM ─ 
108  50 mM ─ 
109  50 mM  
110  50 mM  
111  25 mM  
112  25 mM ─ 
113  50 mM  
114  25 mM ─ 
115  ─ ─ 
116  50 mM  
117  25 mM ─ 
118  25 mM ─ 
119  50 mM ─ 
120  50 mM ─ 
# Glycerol stock
Phenotype
Table 7: Phenotype of potential PHD1 interactors in yeast two-hybrid assay II
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121  25 mM ─ 
122  25 mM ─ 
123  50 mM ─ 
124  50 mM ─ 
125  50 mM  
126  10 mM ─ 
127  25 mM ─ 
128  25 mM  
129  50 mM  
130  50 mM ─ 
131  50 mM ─ 
132  25 mM ─ 
133  25 mM ─ ─
134  25 mM  
135  50 mM ─ 
136  50 mM  
137  50 mM ─ 
138  50 mM  
139  25 mM ─ 
140  25 mM ─ 
141  10 mM ─ 
142  10 mM ─ 
143  10 mM ─ 
144  10 mM  
145  25 mM ─ 
146  10 mM ─ 
147  50 mM  
148  50 mM  
149  10 mM ─ 
150  50 mM  
151  25 mM  
152  10 mM ─ ─
153  10 mM ─ 
154  50 mM  
155  50 mM ─ 
156  50 mM  
157  50 mM ─ 
158  10 mM ─ ─
159  25 mM  
160  10 mM ─ ─
# Glycerol stock
Phenotype
Table 8: Phenotype of potential PHD1 interactors in yeast two-hybrid assay III
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201  50 mM  
202  10 mM ─ ─
203  25 mM ─ 
204  25 mM  
205  50 mM  
206  25 mM  
207  25 mM ─ 
208  10 mM  
209  25 mM ─ 
210  10 mM ─ 
211  25 mM ─ 
212  50 mM ─ 
213  25 mM ─ 
214  50 mM ─ 
215  10 mM ─ 
216  50 mM  
217  10 mM ─ 
218  10 mM ─ 
219  10 mM  
220  50 mM ─ 
221  ─ ─ ─
222  25 mM ─ 
223  10 mM ─ 
224  25 mM ─ 
225  10 mM ─ ─
226  50 mM ─ 
227  25 mM  
228  50 mM  
229  50 mM ─ 
230  10 mM ─ ─
231  25 mM  
232  25 mM  ─
233  25 mM ─ ─
234  10 mM ─ ─
235  25 mM ─ 
236  10 mM ─ ─
237  25 mM  
238  25 mM ─ 
239  10 mM ─ ─
240  50 mM ─ 
# Glycerol stock
Phenotype
Table 9: Phenotype of potential PHD1 interactors in yeast two-hybrid assay IV
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241  50 mM ─ 
242  25 mM ─ 
243  25 mM ─ 
244  25 mM  
245  25 mM  
246  50 mM  
247  50 mM ─ 
248  25 mM ─ 
249  25 mM ─ 
250  50 mM ─ 
251  50 mM ─ 
252  25 mM ─ ─
253  10 mM ─ 
254  10 mM ─ ─
255  25 mM ─ ─
256  50 mM  ─
257  50 mM  
258  25 mM  
259  25 mM ─ 
260  50 mM  
261  50 mM  
262  25 mM  
263  50 mM  
264  25 mM ─ 
265  50 mM ─ ─
266  50 mM  ─
267  50 mM ─ 
268  25 mM ─ ─
269  25 mM ─ ─
270  25 mM ─ 
271  ─ ─ ─
272  50 mM ─ 
273  50 mM ─ ─
274  ─ ─ ─
275  10 mM ─ ─
276  50 mM ─ 
277  ─ ─ ─
278  25 mM ─ 
279  50 mM  
280  50 mM ─ 
# Glycerol stock
Phenotype
Table 10: Phenotype of potential PHD1 interactors in yeast two-hybrid assay V
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281  10 mM ─ 
282  25 mM  
283  10 mM ─ 
284  10 mM ─ 
285  10 mM  
286  50 mM  
287  50 mM ─ 
288  25 mM  
289  50 mM ─ 
290  10 mM ─ 
291  10 mM ─ 
292  50 mM  
293  10 mM ─ 
294  25 mM ─ 
295  ─ ─ 
296  ─ ─ ─
297  50 mM  
298  10 mM ─ 
299  25 mM ─ 
300  25 mM ─ 
301  10 mM ─ 
302  10 mM ─ 
303  ─ ─ ─
304  50 mM  
305  25 mM ─ 
306  25 mM ─ 
307  10 mM ─ ─
308  25 mM  
309  50 mM  
310  50 mM ─ 
311  10 mM ─ 
312  25 mM ─ 
313  10 mM ─ 
314  50 mM  
315  10 mM ─ 
316  ─ ─ ─
317  10 mM ─ 
318  10 mM ─ 
319  25 mM ─ ─
320  10 mM ─ 
# Glycerol stock
Phenotype
Table 11: Phenotype of potential PHD1 interactors in yeast two-hybrid assay VI
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Yeast two-hybrid assay with PHD 2, 3 and PH-4
The sequenced interactors were additionally tested in interaction assays with
PHD2, PHD3, and PH-4 (amino acid 83-502). 27 interactors showed also a
positive phenotype for PHD3, which was mainly weaker compared to the PHD1
phenotype. No interaction was observed with PHD2 and PH-4. Tables 12 and 13
represent the observed phenotypes of interaction showing the maximum
concentration of 3-AT on which the clones were still growing, growth on uracil
lacking plates and the strength of X-gal-Blue staining ranging from + (weak blue
staining) to +++ (strong blue staining).
1 (A1) Laminin, beta 2 BC026051 25 mM _ 
2 (A2) Adult male testis cDNA,
hypothetical protein
AK005628 25 mM _  50 mM  
3 (A3)
Adult male hypothalamus
cDNA, hypothetical C2
domain (Calcium / lipid-
binding domain, CalB)
structure containing protein
AK038916 50 mM  
6 (B1)
Similar to hypothetical protein
MGC24975 XM_148801 25 mM _
 25 mM _ 
8 (B2)
Mouse DNA sequence from
clone RP23-184G6 AL645861 50 mM _
 25 mM _ 
10 (B3) RIKEN cDNA
4930404K22 gene
XM_136025 25 mM _  25 mM _ _
12 (B4) Cerebellar degeneration-
related 2 (Cdr2)
NM_007672 50 mM   10 mM _ _
14 (B5) LIM-only protein ACT AF083394 25 mM _ 
15 (C1) Spr mRNA for speriolin AB032199 25 mM   10 mM _ _
16 (C2)
Similar to nuclear protein with
a coiled coil-4 domain of
bilateral origin like
XM_196054 10 mM   25 mM _ 
18 (C4) Tripartite motif-containing 45(Trim45) BC057358 25 mM _
 25 mM _ 
19 (C5) Mus musculus RIKEN cDNA4930404K22 gene XM_136025 50 mM _
 50 mM _ _
22 (D1) Similar to hypothetical proteinMGC5356 BC051628 25 mM _

23 (D2)
Rattus norvegicus
similar to RelA-
associated inhibitor
XM 2380882 50 mM   25 mM _ 
25 (D4) Zinc finger protein 212
(Zfp212)
BC006693 50 mM   10 mM _ _
26 (D5) Mouse DNA sequence fromclone RP23-422L16 AL603707 50 mM
  25 mM _ 
28 (E2)
RIKEN cDNA clone
4921524L21: hypothetical
protein
AK014961 25 mM _  10 mM _ 
29 (E3)
Mouse adult male testis
cDNA: hypothetical Retroviral-
type aspartic protease
containing protein
AK005882 10 mM _ 
31 (E4) TPA: Adam38 gene fortestase-8 BN000119 25 mM _

32 (E5)
Tankyrase, TRF-1interacting
ankyrin-related ADP-ribose
polymerase
BC057370 50 mM  
33 (F1)
RIKEN cDNA clone
1700010L19: Weakly similar
to Tektin A1
AK005842 10 mM _ 
ß-Gal 3-AT
Accession
Nucleotide Phenotype PHD3Phenotype PHD1
Uracil ß-Gal
PHD1-
Interactor No. Protein
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interactionNo interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
Phenotype PH-4 (83-502)
No interaction
Interaction of HIF prolyl hydroxylases with potential PHD1-Interactors in a Yeast Two Hybrid Assay
Phenotype PHD2
3-AT Uracil β-Gal3-AT Uracil β-Gal Uracil3-AT
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
Table 12: Interaction of HIF prolyl hydroxylases with potential PHD1 interactors in yeast
two-hybrid assay I
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34 (F2) Latent transforming growthfactor beta binding protein 4 BC032073 10 mM _ _
35 (F3) Procollagen, type VIII,
alpha 1
BC011061 10 mM _ 
37 (F5) / (C1)
RFX2 regulatory factor X, 2
(Regulatory factor trans
acting) 2)
BX648130 50 mM _  50 mM _ _
39 (G2) Similar to hypothetical protein
(LOC385766)
XM_358937 10 mM _  25 mM _ 
40 (G3) Arsenate resistance
protein 2
BC066831 10 mM   50 mM _ 
41 (G4) Nidogen 2 ( Entactin BC057016 25 mM _  10 mM _ _
44 (H1) / A4
Testis specific serine
kinase substrate /
Serine / Threonine
kinase 22 substrate
(Stk22s1)
AF025310 10 mM _ 
45 (H2)
Hypothetical Laminin-type
EGF-like domain /
Cytochrome c family heme-
binding site / G-protein beta
WD-40 repeats containing
protein
AK040807 50 mM   10 mM _ _
A6 RIKEN cDNA 2310038K02gene BC057041 25 mM _
 50 mM _ 
A7 RIKEN clone 4932411P22similar to PROXI (fragment) AK029978 50 mM _
 50 mM  
B3 Clone IMAGE:5036118 BC025923 10 mM _  10 mM _ _
B4 / D6
Eukaryotic translation
initiation factor 4E nuclear
import factor 1 (Eif4enif1)
BC033410 25 mM   50 mM  
B7 / C4 Mouse DNA sequence fromclone RP23-193K14 AC091548 50 mM
  10 mM _ _
B8 / C3 / E2 Mouse DNA sequence fromclone RP23-49C8 AL805980 50 mM   50 mM _ 
C2 Tubby super-family protein(Tusp) / tubby like protein 4 AF219945 25 mM _
 10 mM _ 
C5/E4 Granulin (Grn) / Progranulin,
Acrogranulin
NM_008175 25 mM _ 
D3
Similar to RelA-associated
inhibitor (Inhibitor of ASPP
protein)
XM_145419 25 mM _  10 mM _ 
D7 RIKEN clone:A630023020:CLAST4 Protein homolog AK041598 50 mM
  50 mM _ 
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interactionNo interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
No interaction
PHD1-
Interactor No. Protein
Accession
Nucleotide Phenotype PHD1 Phenotype PHD2 Phenotype PHD3 Phenotype PH-4 (83-502)
No interaction
ß-Gal3-AT Uracil Uracil β-Gal
Interaction of HIF prolyl hydroxylases with potential PHD1-Interactors in a Yeast Two Hybrid Assay
3-AT Uracil β-Gal 3-ATß-Gal 3-AT Uracil
Table 13: Interaction of HIF prolyl hydroxylases with potential PHD1 interactors in a yeast
two-hybrid assay II
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Recombination of potential interactors in pDONR221 and expression
vectors
Eight preys were chosen to proceed with further analysis. The choice was made
based on database search, known protein function, expression pattern and
strength of interaction in yeast. These interactors were recombined into the
pDONR221, enabling recombination into various expression vectors and were
tested for in vitro interaction in a GST pull-down assay. Table 14 shows the 8
potential PHD1 interactors chosen for in vitro interaction testing:
10 (B3) RIKEN cDNA 4930404K22 gene
Similar to Spermidine / spermine
N(1)-acetyltransferase (Rattus
norvegicus)
XM_136025 P21673 3 25 mM _ X Testis
12 (B4) Cerebellar degeneration-related 2(Cdr2)
Unknown, cdr2 gene expressed in
paraneoplastic cerebrellar
degeneration (PCD)
NM_007672 Q01850 3 50 mM  X ubiquitous
15 (C1) Speriolin Spermatogenic cell-specificcentrosomal protein AB032199 Q76KD6 3 25 mM
 X Testis, mammary gland
18 (C4) Tripartite motif-containing 45 (Trim45) unknown BC057358 Q6PFY8 1 25 mM _ X ubiquitous
45 (H2)
Wdr59 protein: Hypothetical Laminin-
type EGF-like domain /
Cytochrome c family heme-binding site
/ G-protein beta WD-40 repeats
containing protein
unknown BC066082 Q6NZK7 1 50 mM  XX
A3 Tripartite motif protein 37 (Trim 37) RING-B-box-coiled-coil protein BC059070 Q6PCX9 1 25 mM _ X ubiquitous
B4 / D6 Eukaryotic translation initiation factor4E nuclear import factor 1 (Eif4enif1)
Translation initiation factor: Binds to
the mRNA 5‘ cap structure
m7GpppN and promotes ribosome
binding to the mRNA in the
cytoplasm
BC033410 Q8CFW0 2 25 mM  X ubiquitous
C2 Tubby super-family protein (Tusp) /tubby like protein 4 (Tulp4)
Tubby gene family: All proteins share
a highly conserved carboxyl terminus
but the N-terminal is poorly
conserved.
AF219945 Q9JIL5 1 25 mM _ XX ubiquitous
Phenotype yeast retransformation
Uracil ß-Gal3-AT
cDNA source /
expression
PHD1 interactors tested for in vitro interaction in GST pull down assay
PHD1-
Interactor
No.
Protein AccessionNucleotide
cDNA found x-fold
in screeningPossible function
Accession
Protein
Table 14: Summary of PHD1 interactors tested for in vitro interaction in a GST-pull down
assay
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In vitro interaction of PHD1 interactors in a GST pull-down assay
The pDEST17-prey plasmids containing the potential interactors were
transcribed and translated using a coupled in vitro transcription and translation
system. GST-PHD1 was bacterial expressed in BL-21AI E. coli and purified by
fast performance liquid chromatography using a GSTrap FF column. A strong in
vitro interaction with GST-PHD1 was observed for an unknown Riken
cDNA4930404K22 clone, the testis-specific Speriolin protein and a hypothetical
laminin-type EGF-like homolog termed Wdr59. Cdr2, Trim37 as well as Tulp4
showed a weak interaction with GST-PHD1 in vitro. No interaction was observed
between GST-PHD1 and Trim45 and Eif4enif1, respectively (Fig. 11).
Figure 11: In vitro interaction of potential PHD1 interactors in a GST pull down assay
(A) Purification of recombinant GST-PHD1 expressed in BL21AI E.coli (B) Protein-protein
interaction of in vitro transcribed and translated (IVTT) 35S-labeled potential PHD1 interactors
and recombinant GST-PHD1 fusion proteins, or GST alone were analyzed by GST pull-down
with glutathione sepharose. Bound proteins and input controls (5%) were separated by SDS-
PAGE and visualized by autoradiography.
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Matchmaker/Dualsystems yeast two-hybrid screening
Library amplification
The human testis cDNA library (Clontech) was obtained as bacterial glycerol
stock with an expected number of 3.5  106 independent clones. A screening
number of twice the size of the original library, meaning 7  106 clones and 30
000 colonies per 15-cm plate was aimed. This corresponded to a scale of 233
dishes each 150 l culture volume (total volume of 34.5 ml LB media). The
cDNA library was obtained with a volume titer of 3.37  109 cfu/ml. The quotient
of the number of clones to screen (7  106 clones) and the library titer (3.37 
109 cfu/ml) resulted in 2.07 l library volume. An overnight culture of 2.5 l
library volume (bacteria culture) in 36 ml LB medium including ampicillin for
selection was plated on the next day on 234 plates and cultivated for 48 hours at
30°C. In total, 6.68  106 clones were scraped and pooled in medium, incubated
with shaking for 1 hour at 37°C and finally centrifuged for 15 minutes at 4°C at 8
000 rpm. Library plasmids were isolate by DNA plasmid preparation.
Self-activation and transformation control
The following combinations of plasmids were tested in a small scale
transformation to exclude self-activation of the bait. The vector pLexA was used
as an additional transformation control (Table 15).
Plasmid 1 Plasmid 2 Selection Purpose
pLexA - SC -leu Transformation control
- - SC –leu -trp Transformation control
pLexA pACT2 SC –leu -trp Self activation control
pLexAPHD1 pACT2 SC –leu -trp
Self activation control of
pLexAPHD1
pLexALaminC pACT2-largeT SC –leu -trp Interaction negative control
pLexAp53 pACT2-largeT SC –leu -trp Interaction positive control
Table 15: Self activity and transformation controls
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Titration of the 3-AT concentration
To determine the 3-AT concentration necessary to suppress basal levels of
HIS3 expression, four clones of DSY-1 containing the following plasmids were
plated on selection plates with different concentration of 3-AT ranging from 1
mM to 15 mM 3-AT.
1. pLexA-LaminC + pACT2-largeT
2. pLexA-p53 + pACT2-largeT
3. pLexA
4. pLexA + pACT2
5. pLexAPHD1 + pACT2
6. pLexAPHD1
The titration resulted in an optimal 3-AT concentration of 2.5 mM 3-AT, where no
growth of yeast except the positive interaction control pLexA-p53 + pACT2-
largeT was observed.
Matchmaker human testis cDNA library screening
In total, 50 g of the human testis cDNA library were screened with a
transformation efficiency of 1.2  104 clones/g library. The protocol followed the
Gateway screening conditions and in total 280 potential interactors were
retested and confirmed on 2.5 mM 3-AT dishes and later the phenotype on
plates containing increasing concentrations of 3-AT was determined (Table 16 –
22). 40 clones were chosen, plasmid DNA was isolated, transformed for
amplification and selection into XL-1-Blue E. coli. These 40 clones were
confirmed in a retransformation assay and sequenced for further analysis (Table
16).
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+ 3-AT b-Gal + 3-AT b-Gal
1 P 5 mM +++ P P 50 ng/μl P 5 mM +++ ─ P
2 P 7.5 mM + P P 200 ng/μl P 10 mM ++ ─ P
3 P 10 mM +++ P P 100 ng/μl P 15 mM +++ ─ P
4 P 25 mM +++ P P 100 ng/μl P 25 mM +++ ─ P
5 P 15 mM ++ P P 100 ng/μl P 15 mM ++ ─ P
6 P 15 mM +++ P P 400 ng/μl P 15 mM +++ ─ P
7 P 15 mM +++ P P 50 ng/μl P 25 mM +++ ─ P
8 P 25 mM ++ P P 300 ng/μl P 25 mM +++ ─ P
9 P 10 mM ++ P P 300 ng/μl P 10 mM +++ ─ P
10 P 2.5 m + P P 200 ng/μl P 2.5 mM + ─ P
11 P 2.5 m + P P 300 ng/μl P 2.5 mM ─ ─ P
12 P 2.5 m + P P 300 ng/μl P 2.5 mM ─ ─ P
13 P 10 mM +++ P P 300 ng/μl P 10 mM +++ ─ P
14 P 15 mM +++ P P 50 ng/μl P 25 mM +++ ─ P
15 P 15 mM +++ P P 300 ng/μl P 25 mM +++ ─ P
16 P 25 mM +++ P P 100 ng/μl P 2.5 mM + ─ P
17 P 10 mM ++ P P 200 ng/μl P 15 mM ++ ─ P
18 P 25 mM +++ P P 200 ng/μl P 25 mM +++ ─ P
19 P 15 mM +++ P P 300 ng/μl P 15 mM ++ ─ P
20 P 10 mM +++ P P 100 ng/μl P 25 mM +++ ─ P
21 P 15 mM +++ P P 200 ng/μl P 15 mM ++ ─ P
22 P 2.5 m + P P 100 ng/μl P 2.5 mM + ─ P
23 P 2.5 m + P P 50 ng/μl P 2.5 mM + ─ P
24 P 2.5 m + P P 200 ng/μl P 2.5 mM ─ ─ P
25 P 25 mM +++ P P 200 ng/μl P 25 mM +++ ─ P
26 P 2.5 m / P P 50 ng/μl P 2.5 mM ─ ─ P
27 P 7.5 mM ++ P P 200 ng/μl P 10 mM ++ ─ P
28 P 5 mM ++ P P 50 ng/μl P 7.5 mM ++ ─ P
29 P 15 mM +++ P P 100 ng/μl P 15 mM +++ ─ P
30 P 25 mM +++ P P 200 ng/μl P 25 mM +++ ─ P
31 P 10 mM +++ P P 50 ng/μl P 15 mM +++ ─ P
32 P 7.5 mM ++ P P 100 ng/μl ─ ─ ─ ─ P
33 P 15 mM +++ P P 50 ng/μl P 15 mM ++ ─ P
34 P 2.5 mM ++ P P 50 ng/μl P ─ ─ ─ P
35 P 2.5 mM / P P 50 ng/μl P 2.5 mM ─ ─ P
36 P 5 mM + P P 50 ng/μl P 2.5 mM + ─ P
37 P 25 mM +++ P P 50 ng/μl P 25 mM +++ ─ P
38 P 25 mM +++ P P 50 ng/μl P 15 mM ++ ─ P
39 P 10 mM ++ P P 50 ng/μl P 15 mM +++ ─ P
40 P 10 mM + P P 50 ng/μl P 10 mM +++ ─ P
Phenotype re-transformationPhenotype
# Glycerolstock
DNA isolated
from yeast
E.coli
transformation
DNA conc.
approx.
ng/ml
Yeast re-
transformation activates itself Sequencing
Table 16: Phenotype of the first 40 potential interactors of PHD1 in pLexA yeast two-
hybrid screening
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+ 3-AT β-Gal
41 P 7.5 mM —
42 P 15 mM +
43 P 2.5 mM ++
44 P 10 mM +++
45 P 10 mM ++
46 P 7.5 mM +
47 P 2.5 mM —
48 P 5 mM —
49 P 25 mM +++
50 P 5 mM ++
51 P 2.5 mM —
52 P 5 mM +++
53 P 10 mM +++
54 P 15 mM +++
55 P 25 mM ++
56 P 5 mM ++
57 P 7.5 mM ++
58 P 5 mM +
59 P 2.5 mM —
60 P 2.5 mM +
61 P 15 mM ++
62 P 2.5 mM —
63 P 2.5 mM ++
64 P 2.5 mM ++
65 P 10 mM ++
66 P 15 mM ++
67 P 10 mM ++
68 P 7.5 mM ++
69 P 10 mM +
70 P 10 mM +
71 P 2.5 mM +
72 P 2.5 mM +
73 P 2.5 mM +
74 P 15 mM +++
75 P 10 mM +
76 P 25 mM ++
77 P 2.5 mM ++
78 P 5 mM +
79 P 15 mM +
80 P 5 mM +++
# Glycerol stock
Phenotype
Table 17: Phenotype of potential PHD1 interactors in pLexA yeast two-hybrid assay I
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+ 3-AT β-Gal
81 P 5 mM +
82 P 15 mM +++
83 P 7.5 mM —
84 P 15 mM +++
85 P 25 mM +++
86 P 25 mM ++
87 P 5 mM +
88 P 15 mM ++
89 P 5 mM ++
90 P 7.5 mM ++
91 P 5 mM +
92 P 10 mM +
93 P 10 mM +
94 P 10 mM +
95 P 5 mM +
96 P 5 mM ++
97 P 7.5 mM ++
98 P 5 mM ++
99 P 7.5 mM +
100 P 5 mM —
101 P 25 mM +++
102 P 2.5 mM +
103 P 2.5 mM +
104 P 5 mM +
105 P 15 mM +++
106 P 25 mM +++
107 P 15 mM +++
108 P 10 mM +
109 P 15 mM ++
110 P 10 mM ++
111 P 5 mM +
112 P 5 mM ++
113 P 5 mM +
114 P 10 mM +++
115 P 10 mM +++
116 P 25 mM ++
117 P 10 mM ++
118 P 10 mM ++
119 P 15 mM ++
120 P 25 mM +++
# Glycerol stock
Phenotype
Table 18: Phenotype of potential PHD1 interactors in pLexA yeast two-hybrid assay II
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+ 3-AT b-Gal
121 P 25 mM +++
122 P 10 mM ++
123 P 5 mM ++
124 P 2.5 mM +
125 P 2.5 mM +
126 P 5 mM +
127 P 2.5 mM +
128 P 2.5 mM +
129 P 25 mM +++
130 P 5 mM ++
131 P 5 mM ++
132 P 7.5 mM ++
133 P 2.5 mM +
134 P 25 mM +++
135 P 10 mM +++
136 P 10 mM +++
137 P 15 mM ++
138 P 15 mM ++
139 P 5 mM +
140 P 5 mM +
141 P 15 mM +++
142 P 5 mM ++
143 P 5 mM +
144 P 25 mM ++
145 P 15 mM +++
146 P 10 mM +++
147 P 2.5 mM ++
148 P 10 mM +++
149 P 15 mM +++
150 P 5 mM ++
151 P 2.5 mM ++
152 P 2.5 mM +
153 P 10 mM +++
154 P 5 mM ++
155 P 10 mM ++
156 P 25 mM ++
157 P 5 mM ++
158 P 10 mM +++
159 P 7.5 mM +++
160 P 7.5 mM +
# Glycerol stock
Phenotype
Table 19: Phenotype of potential PHD1 interactors in pLexA yeast two-hybrid assay III
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+ 3-AT b-Gal
160 P 7.5 mM +
161 P 5 mM +
163 P 7.5 mM ++
164 P 10 mM ++
165 P 25 mM +++
166 P 15 mM +++
167 P 2.5 mM +
168 P 2.5 mM +
169 P 25 mM +++
170 P 15 mM +++
171 P 15 mM ++
172 P 15 mM +++
173 P 15 mM +++
174 P 7.5 mM +++
175 P 2.5 mM ++
176 P 5 mM +
177 P 5 mM +
178 P 25 mM +++
179 P 10 mM ++
180 P 5 mM +
181 P 10 mM +++
182 P 10 mM ++
183 P 10 mM ++
184 P 10 mM ++
185 P 5 mM +
186 P 10 mM +++
187 P 15 mM +
188 P 5 mM +
189 P 5 mM +
190 P 10 mM ++
191 P 10 mM ++
192 P 15 mM +++
193 P 15 mM ++
194 P 25 mM +++
195 P 15 mM ++
196 P 10 mM ++
197 P 15 mM ++
198 P 15 mM +++
199 P 2.5 mM +
200 P 15 mM +++
# Glycerol stock
Phenotype
Table 20: Phenotype of potential PHD1 interactors in pLexA yeast two-hybrid assay IV
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+ 3-AT b-Gal
201 P 5 mM ++
202 P 7.5 mM +++
203 P 2.5 mM +++
204 P 7.5 mM +
205 P 7.5 mM ++
206 P 5 mM +
207 P 7.5 mM —
208 P 5 mM +
209 P 25 mM +++
210 P 2.5 mM +
211 P 2.5 mM +
212 P 5 mM +
213 P 10 mM ++
214 P 5 mM +
215 P 25 mM +++
216 P 25 mM +++
217 P 10 mM ++
218 P 25 mM +++
219 P 5 mM +
220 P 5 mM +
221 P 10 mM +++
222 P 7.5 mM +
223 P 5 mM ++
224 P 2.5 mM ++
225 P 10 mM +++
226 P 15 mM +++
227 P 10 mM +
228 P 15 mM ++
229 P 2.5 mM ++
230 P 5 mM ++
231 P 7.5 mM ++
232 P 7.5 mM +++
233 P 2.5 mM +
234 P 15 mM —
235 P 5 mM +
236 P 7.5 mM +++
237 P 5 mM —
238 P 5 mM +++
239 P 5 mM +++
240 P 7.5 mM —
# Glycerol stock
Phenotype
Table 21: Phenotype of potential PHD1 interactors in pLexA yeast two-hybrid assay V
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+ 3-AT b-Gal
241 P 5 mM ++
242 P 15 mM ++
243 P 10 mM —
244 P 2.5 mM +
245 P 15 mM +++
246 P 5 mM +
247 P 10 mM ++
248 P 25 mM +++
249 P 15 mM +++
250 P 5 mM ++
251 P 5 mM ++
252 P 5 mM +
253 P 10 mM ++
254 P 7.5 mM +
255 P 5 mM +
256 P 10 mM +++
257 P 7.5 mM +++
258 P 5 mM —
259 P 10 mM +++
260 P 7.5 mM ++
261 P 7.5 mM +
262 P 15 mM +++
263 P 2.5 m ++
264 P 15 mM +++
265 P 5 mM ++
266 P — —
267 P 10 mM ++
268 P 25 mM +++
269 P 10 mM ++
270 P 10 mM +++
271 P 25 mM +++
272 P 15 mM +
273 P 2.5 mM +
274 P 5 mM ++
275 P 5 mM ++
276 P 25 mM +++
277 P 10 mM ++
278 P 2.5 mM +
279 P 15 mM ++
280 P 10 mM ++
# Glycerol stock
Phenotype
Table 22: Phenotype of potential PHD1 interactors in pLexA yeast two-hybrid assay VI
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Table 23 represents the sequencing results of potential interactor of
pLexAPHD1.
2 DEAD box polypeptide 5(DDX5)
DEAD box proteins,
characterized by the conserved
motif Asp-Glu-Ala-Asp (DEAD)
are putative RNA helicases.
NM_004396 AAP36310 1 10 mM ubiquitous
4 Karyopherin (importin) beta3
Play a central role in
nucleocytoplamic transport BC045640 AAC51317 3 25 mM ubiquitous
5 TCP10L t-complex 10(mouse)-like
Seems to be a leucin zipper
transcription factor which is
involved in cell proliferation and
differentation in the liver and
testis.
AF115967 NP_653260 1 15 mM Liver, testis
6 Hypothetical proteinFLJ25351 unknown BC030659 BAB71654 1 15 mM
testis, germ
cell tumors
8 Testis-development relatedNYD-SP20D unknown AY035868 AAH29483 1 25 mM
testis, germ
cell tumors
10 Clone CS0DF015YB17 /Clusterin isoform unknown CR625885 NP_001822 1 2.5 mM
13 Bromodomain adjacent tozinc finger domain, 2A unknown BC008965 Q9UIF9 1 10 mM ubiquitous
15 Clone FLJ35821 fis unknown AK093140 NP_689802 1 25 mM testis, stemcells
16 KIAA0090 protein unknown BC016303 NP_055862 1 2.5 mM ubiquitous
17 Thyroid hormone receptorinteractor 6 (Trip6)
Trip6 functions at a point of
convergence between the
activated LPA(2) receptor and
downstream signals involved in
cell adhesion and migration
NM_003302 AAK21007 1 15 mM ubiquitous
19 Cerebellar degeneration-related protein 2 (Cdr2)
Unknown, cdr2 gene expressed
in paraneoplastic cerebrellar
degeneration (PCD), in contrast
to other cdr genes
BC017503 NM_007672
Found in
ProQuest /
Gateway
Screening
15 mM ubiquitous
21 Zinc finger protein 198 unknown BC036372 AAH36372. 1 15 mM ubiquitous
22
General transcription factor
IIIC, polypeptide 4 (notice:
weak similarity)
unknown BC060821 NP_036336 1 2.5 mM ubiquitous
25 RAR-related orphanreceptor C
DNA-binding transcription factor
and it is a member of a subfamily
of nuclear hormone receptors.
The specific of this protein are
not known;
BC031554 NP_001001523 1 25 mM ubiquitous
27
Histone-lysine N-
methyltransferase (SET
domain bifurcated (ERG-
associated protein with
SET domain)
The set domain is a highly
conserved, approximately 150 aa
implicating modulation of
chromatin structure.
BC028671 Q15047 1 10 mM ubiquitous
28 cDNA clone MGC: 72082 unknown BC062735 AAH54871 1 7.5 m testis, germcell tumors
30 DnaJ (Hsp40) homolog,subfamily A, member 3
Belongs to the conserved HSP40
family of proteins BC011855 AAL35323 1 25 mM ubiquitous
38 Hypothetical proteinMGC33948 unknown BC029536 AAH29536 1 15 mM testis
40 Acrosin binding protein
Protein is located in the sperm
acrosome and is thought to
function as a binding protein to
proacrosin for packaging and
condensation of the acrosin
zymogen.
BC033010 BAB39388 1 10 mM
testis,
prostate,
ubiquitous
++
+++
++
+++
++
+
+++
++
++
+
+++
+++
+++
+++
+
++
Possible function
+++
++
Potential interactors of pLexAPHD1 in hTestis cDNA-Library Screening (Matchmaker/Dualsystems)
++
ß-Gal
cDNA source
/ expressionProtein
Accession
Nucleotide
PHD1-
Interactor
No.
Phenotype yeast
retransformation
Accession
Protein
cDNA x-fold
in
screening
3-AT
Table 23: Potential interactors of pLexAPHD1 in htestis cDNA library screening
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18 clones were further tested for pLexAPHD3 interaction (Table 24). Even
though pLexAPHD3 showed no self-activity on 3-AT plates, it showed self-
activity in X-gal assays. No determination of the X-gal phenotype therefore took
place.
Phenotype
+ 3-AT
2 DEAD box polypeptide 5 (DDX5) 10 mM
4 Karyopherin (importin) beta 3 25 mM
6 Hypothetical protein FLJ25351 25 mM
8 Testis-development related NYD-SP20D 25 mM
10 Clone CS0DF015YB17 10 mM
13 Bromodomain adjacent to zinc finger domain, 2A 25 mM
15 Clone FLJ35821 fis 15 mM
16 KIAA0090 protein none
17 Thyroid hormone receptor interactor 6 (Trip9) none
19 Cerebellar degeneration-related protein 2 (Cdr2) 10 mM
21 Zinc finger protein 198 25 mM
22 General transcription factor IIIC, polypeptide 4 10 mM
25 RAR-related orphan receptor C 15 mM
27 Histone-lysine N-methyltransferase 15 mM
28 Clone MGC: 72082 15 mM
30 DnaJ (Hsp40) homolog, subfamily A 15 mM
38 Hypothetical protein MGC33948 15 mM
40 Acrosin binding protein 15 mM
Interaction of potential PHD1 interactor with HIF prolyl hydroxylase 3
PHD1
Interactor-No. Protein
Table 24: Interaction of potential PHD1 interactors with HIF prolyl hydroxylase 3
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Summary
To identify new potential interactors of the HIF prolyl-4-hydroxylase 1 (PHD1)
human and mouse testis cDNA libraries were screened independently by yeast
two-hybrid methodology. In total, more than 400 potential interactors of PHD1
were found, 10% of them were further investigated and in vitro interaction tests
were carried out with 8 interactors. Additional 40 interactors were tested for
interaction with PHD2, 3 and PH-4. Clones of interest were cloned or
recombined into bacterial and mammalian expression vectors. The cerebellar
degeneration-related protein 2 (Cdr2) was found in both independent
screenings, twice as full length mouse sequence and once as human C-terminal
fragment. Previous studies reported that Cdr2 mRNA is ubiquitously expressed
whereas the protein is limited to the brain and to the testis, both organs with low
oxygen partial pressure. Cdr2 was originally termed due to its antibodies in a
rare autoimmune disease called paraneoplastic cerebellar degeneration (PCD).
PCD appears when ovarian and breast tumors start to express Cdr2. The
consequence is that a CD8+ cytotoxic T-cells mediated immune response is
initiated which leads to tumor immunity and cerebellar degeneration. PCD is one
of the rare cases where naturally occurring tumor immunity becomes visible. As
an interactor of PHD1 in yeast, we assumed that Cdr2 might be a substrate of
PHD1 and thereby is regulated on a posttranscriptional level. We decided to
choose Cdr2 for further analysis to investigate this postulated mechanism and to
understand more about Cdr2 ectopic expression in tumors and tumor immunity.
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Protein stability of the onconeuronal antigen Cdr2 is regulated by PHD1
Verena S. Hofmann, Balamurugan Kuppusamy, Daniel P. Stiehl, Roland H.
Wenger and Gieri Camenisch
Institute of Physiology and Zürich Center for Integrative Human Physiology
(ZIHP), University of Zürich (UZH), CH-8057 Zürich, Switzerland
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Abstract
The heterodimeric transcription factor HIF is a key regulator of the hypoxic
response, regulating the expression of a variety of genes, involved in the
maintenance of the oxygen homeostasis. Under normoxic conditions, two
proline residues within the HIF- subunit are hydroxylated by HIF prolyl-4-
hydroxylase domain-containing enzymes (PHDs), which target HIF- for
degradation by the ubiquitin-proteasome pathway. This is due to the
dependency of PHDs on molecular oxygen as a co-substrate. In contrast, HIF-
hydroxylation is inhibited in hypoxia, leading to the stabilization and activation of
HIF.
We recently discovered the onconeural protein Cerebellar degeneration-related
protein 2 (Cdr2) as an interactor of the HIF prolyl hydroxylase 1 (PHD1) found in
two independent yeast two-hybrid screenings. The physiological function of Cdr2
is unknown, but the protein got its name because of the presence of its
antibodies in a disease called paraneoplastic cerebellar degeneration (PCD). In
PCD breast or ovarian tumors express the onconeural antigen Cdr2 which leads
to an immune response to Cdr2 associated with tumor immunity and an
autoimmune cerebellar degeneration. Whereas Cdr2 transcripts are found in
most tissues, protein expression is restricted to the brain and testis as well as to
ovarian and breast cancer tumors - all known tissues with a low oxygen partial
pressure. We confirmed the interaction of PHD1 and Cdr2 in vitro and showed
that Cdr2 is not regulated on the mRNA level but the protein levels are
significantly elevated under hypoxic conditions, as well as upon PHD and
proteasome inhibition in transiently transfected cells. Mapping of the hCdr2
protein sequence revealed two conserved proline clusters, which might be
hydroxylated under normoxia. Our data suggest that Cdr2 protein is limited to
the brain and the testis due to hypoxic conditions in these organs. Furthermore it
is known that solid tumors show low oxygen partial pressure in comparison to
their tissue of origin. We generated polyclonal and monoclonal antibodies
against Cdr2 were able to detect endogenous Cdr2 in several breast and
ovarian cancer cell lines. Unfortunately, we could not confirm the observed
stabilization of Cdr2 under hypoxia and PHD inhibition for endogenous Cdr2.
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Introduction
1 The onconeural antigen Cdr2
The onconeural antigen Cdr2 was first identified in context with a human
neurodegenerative disease that is associated with cancer and with anti-tumor
immunity. This paraneoplastic cerebellar degeneration (PCD) syndrome occurs
in patients with gynecological tumors including breast or ovarian tumors. PCD is
characterized by the presence of specific autoantibodies named anti-Yo
(Anderson et al. 1988). Sera of these patients identified in total three cerebellar
degeneration related antigens (Cdr1-3). Cdr1 has a molecular weight of 34 kDa
and is composed of nearly identical hexapeptide repeats, making more than
90% of the protein (Dropcho et al. 1987). Cdr2 was cloned independently from
HeLa cells and from a human cerebellar cDNA library and encodes a protein
which contains a coiled coil and leucine zipper domain in the N-terminus. Cdr3
shares around 45% amino acid homology with Cdr2 and was also cloned from a
HeLa expression library (Corradi et al. 1997). To investigate the expression
pattern of these different genes and to address which gene encodes the PCD
tumor antigen, Corradi et al. carried out a RT-PCR analysis of PCD tumors.
They showed that although all three Cdr transcripts could be detected in the
cerebellum, only Cdr2 mRNA was detected in the PCD ovarian tumors (Corradi
et al. 1997). Figure 12 shows an alignment of human Cdr1, Cdr2 and Cdr3
protein sequences. Whereas Cdr2 and Cdr3 show 44 % protein homology, Cdr2
and Cdr1 have only 13 % matching aminoacids.
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Figure 12: Alignment of hCdr1, hCdr2 and hCdr3 Cdr2 and Cdr3 show 44 % matching amino
acids (blue) whereas Cdr2 and Cdr1 show only 13 % matching aminoacids (blue)
1.1 Cdr2 mRNA and protein expression pattern
Corradi et al. analyzed the Cdr2 expression pattern in mice and showed that
Cdr2 mRNA is ubiquitously expressed (Fig. 13A), whereas the protein is
absolutely restricted to the brain and to the testis (Fig. 13B) (Corradi et al. 1997).
Figure 13: A. Expression pattern of mouse Cdr2 mRNA in different tissues; B. Tissue
distribution of mouse Cdr2 protein (Corradi et al. 1997)(Cb: Cerebellum, Cx: Cortex, Lu:
Lung, Li: Liver, Sp: Spleen, Kd: Kidney, Ts: Testis, Ov: Ovary, Ht: Heart;
Sequence analysis of the brain and spleen Cdr2 cDNAs showed 100% identity
suggesting a tissue-specific post-transcriptional regulatory mechanism. Analysis
B.
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of Cdr2 expression by in situ hybridization localized Cdr2 mRNA in cerebellar
Purkinje neurons as well as in cells of the outermost layers of the seminiferous
tubules of the testis (Corradi et al. 1997). Immunohistochemical analysis
detected Cdr2 protein in cerebellar Purkinje neurons, brainstem neurons and
spermatogonia (Corradi et al. 1997). Analysis of Cdr2 protein expression in
gynecological tumors obtained from neurologically normal cancer patients
revealed that five out of nine representative ovary tumors expressed a 52 kDa
protein, migrating at the same position as Cdr2 from Purkinje cells, loaded as a
positive control. In addition, analysis of breast tumors from patients without PCD
showed in some of the tumors an expression of Cdr2. These findings suggest an
ectopic expression of Cdr2 in a large number of gynecological tumors
independent of the presence of paraneoplastic neurological degeneration
(Darnell et al. 2000).
1.2 What is the physiological function of Cdr2 ?
So far, the physiological function of Cdr2 has not been revealed. Some reports
described Cdr2 interaction partners that could lead to assumptions about the
physiological function. Okano et al. used the Cdr2 leucine zipper dimerization
domain in a yeast two-hybrid screen to identify potential interactors (Okano et al.
1999). They showed that Cdr2 interacted specifically with c-Myc in yeast and in
vitro. Although c-Myc is known as a nuclear transcription factor, its localization
can vary between the cytoplasm and nucleus in relation to cellular proliferation
and differentiation in cell lines (Vriz et al. 1992), in vivo (Bai et al. 1994) and in
human tumors (Royds et al. 1992). Immunohistochemical examination of rat
brain sections showed a significant co-localization of Cdr2 and c-Myc in the
cytoplasm of Purkinje neurons. This finding was confirmed by additional
confocal microscopy in rat cerebellar sections (Okano et al. 1999).
Overexpression of Cdr2 in mouse neuroblastoma cells (N2A) revealed a striking
redistribution of c-Myc into the cytoplasm, where co-localization with Cdr2 was
observed. Cdr2 interacted with c-Myc and changed the subcellular localization of
c-Myc to the cytoplasm. Functionally, the interaction of Cdr2:c-Myc attenuated c-
Myc-dependent reporter gene expression. PCD disease antisera inhibited the
interaction of Cdr2 with c-Myc which led to the following hypothesis: the PCD
immune response might be able to block the ability of Cdr2 to down-regulate c-
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Myc regulated gene expression which could lead to excess signaling along a
pathway involved in neuronal apoptosis. Dysregulation of cell cycle pathways in
Purkinje neuronal apoptosis has been implicated in cerebellar degeneration
(Feddersen et al. 1992). Furthermore, it has been shown that nerve growth
factor (NGF) is able to prevent c-Myc-induced apoptosis in fibroblasts supporting
the suggestion that the transcription factor c-Myc can mediate neuronal
apoptosis (Ulrich et al. 1998).
It has previously been shown that c-Myc modulates cell cycle pathways or
apoptosis. For instance, c-Myc is an activator of cdc25A (Galaktionov et al.
1996). Cdc25 family members are proteins that act on several downstream
targets which lead to the phosphorylation of the retinoblastoma gene product
(pRb) and the release of the transcription factor E2F, a common final step in S-
phase entry. Additionally, c-Myc is able to induce ARF (Zindy et al. 1998) an
inducer of p53-mediated apoptosis (Prives 1998). So, Okano’s et al. assumption
is that abundant c-Myc entry into the nucleus in case of PCD induces
inappropriate cell cycle signaling and Purkinje cell apoptosis. Figure 14
represents a model for the role of Cdr2 antibodies in PCD pathogenesis.
Figure 14: A model for the role of Cdr2 antibodies in PCD pathogenesis (Okano et al.
1999). Cdr2 interacts with c-Myc in Purkinje cell cytoplasm, and thereby regulates c-Myc entry
into the nucleus, where it acts to promote transcription and transduces neuronal signaling.Cdr2
antibodies in PCD patients are able to disrupt this interaction which leads to dysregulated entry
of c-Myc into the nucleus. Aberrant c-Myc-induced gene transcription might lead to inappropriate
cell cycle signaling and Purkinje cell apoptosis.
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In the case of gynecologic tumors it is still not clear why Cdr2 is co-expressed
with c-Myc, whose activity promotes tumor progression. Evan and Littlewood
suggested that c-Myc overexpression is a two-edged sword in tumor cells, on
one hand promoting tumor progression and under some circumstances inducing
tumor cell apoptosis (Evan and Littlewood 1998). They assume that the
inhibition of c-Myc-dependent transcription by Cdr2 may attenuate c-Myc
function in vivo. Therefore, it would be of great interest to investigate if a
common function of Cdr2 in tumor cells and neurons might be the inhibition of c-
Myc, thereby inhibiting the induction of apoptosis. To emphasize this importance
it has to be mentioned that Cdr2 expression is found in more than 60% of
ovarian tumors and more than 25% of breast tumors (Darnell et al.; unpubl.)
A further publication by Takanaga et al. identified a serine/threonine protein
kinase (PKN) as interactor of PCD17 and Cdr2 (Takanaga et al. 1998). PCD17
and Cdr2 have exactly the same sequence except the 14 amino acids of the C-
terminal region, and PCD17 lacks the N-terminal 67 amino acid residues of Cdr2
(Sakai et al. 1993). PKN has a catalytic domain which shows homology with
protein kinase C (PKC) family members and contains in addition a unique
regulatory region harboring repeats of leucine-zipper-like sequence (Takanaga
et al. 1998). PKN was the first identified serine/threonine protein kinase that can
bind to and be activated by the small GTPase Rho and in addition PKN can also
be activated by fatty acids such as arachidonic acid in vitro (Kitagawa et al.
1995; Amano et al. 1996). Upon arachidonic acid activation, PKN was able to
phosphorylate the C-terminal part of PCD17. The presence of two putative DNA
binding motifs as well as the leucine zipper-like motif in the N-terminal domain of
PCD17 suggests that PCD17 might act as transcription factor. Some
transcription factors are using leucine zipper motifs as homo- or
heteromdimerization and Takanaga et al. therefore tested whether PCD17 could
dimerize. In vitro translated PCD17 bound to GST-PCD1-316 and GST-PCD1-134
but not to GST-PCD136-316, suggesting that PCD17 can form a homodimer in the
N-terminal region. Furthermore a chloramphenicol acetyl transferase (CAT)
activity reporter assay revealed a transcriptional activity of PCD17 in mammalian
cells, comparable to that of CREB induced by cAMP as a positive control.
Taken together, Takanaga et al. suggest that the binding of anti-Cdr2 antibodies
in PND patients to the leucine zipper region of PCD17, which was shown before
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as the epitope, might repress gene transcription by inhibiting the
homodimerization or the interaction with PKN (Takanaga et al. 1998). However,
Darnell’s group has not been able to show Cdr2 phosphorylation (Okano et al.
1999).
Furthermore, Sakai et al. identified the nuclear factor-kappa B (NF-B) as an
additional interactor of PCD17 (Sakai et al. 2001). NF-B is known as a widely
expressed transcription factor and involved mainly in regulating the immune
response to infection. It is activated through cytokines, free radicals and
bacterial or viral antigens. Target genes of NF-B include among others the
cytokines TNF-, IL-2, IL-6 and interferon and the cell surface molecules VCAM-
1, ICAM-1 and MHC class I and II. Sakai et al. investigated the effect of PCD17
on the transcriptional activity of NF-B. Therefore they used a luciferase reporter
assay and showed that the PCD17 can suppress basal or activated NF-B-
dependent transcriptional activity. Additionally, DNA binding of constitutive NF-
B complexes was decreased in the nucleus of TNF--stimulated
neuroblastoma cells. Because PCD17 is a cytoplasmic protein and does not
bind to classical NF-B consensus site, indirect influence on the nuclear
translocation of NF-B in response to TNF- was proposed. Corresponding to
the interaction study of Cdr2 and c-Myc it has been suggested that the anti-
apoptotic activity of NF-B might be decreased in neurons expressing abundant
PCD17 and thereby rendering these cells susceptible to c-Myc-induced
apoptosis.
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2 The role of Cdr2 in paraneoplastic neurological disorders
(PNDs)
2.1 Definition of PNDs
PNDs are defined as diverse group of human neurodegenerative diseases that
are associated with cancer and with anti-tumor immunity. Patients with breast,
ovarian or lung tumors start to express proteins that are under physiological
conditions exclusively found in neuronal cells. The neoplastic expression of
these so-called onconeural antigens elicits an immune response which
suppresses tumor growth. However, immune cells can by an unknown
mechanism overcome the blood-brain-barrier and recognize the endogenous
proteins in neuronal cells. This autoimmune response leads to
neurodegenerative syndromes associated with symptoms such as progressive
gait ataxia, dysarthria or nystagmus (Albert and Darnell 2004). When
neurological symptoms start, most patients have not yet been diagnosed with
cancer (de Beukelaar and Sillevis Smitt 2006).
2.2 Classification of PNDs
PND syndromes
Traditionally, PNDs are classified according to the neurological symptoms by
which they were identified in the clinics. However, it has to be emphasized that
many patients do not fit into this scheme because their symptoms are apparent
in more than one defined syndrome. Therefore, all paraneoplastic disorders can
be seen as a subset of diffuse and multifocal “paraneoplastic encephalomyelitis”
or “paraneoplastic encephalomeyloneuritis” (Dropcho 2005). A paraneoplastic
encephalomyelitis is characterized by the involvement of several areas of the
nervous system, for example the limbic system, brainstem, cerebellum, spinal
cord (myelitis) or autonomous nervous system.
PND antigens
The antigens of a large number of antibodies associated with paraneoplastic
syndromes have been identified and the corresponding genes have been cloned
and sequenced. The classification is based on this information and serves as an
alternative possibility of classification of these disorders. Table 25 represents an
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overview about the so far identified antineuronal antibody-associated
paraneoplastic disorders.
Table 25: Anti-neuronal antibody-associated paraneoplastic disorders (Darnell and Posner
2003)
The physiological functions of the neuronal antigens are manifold. PND antigens
include nerve-terminal vesicle-associated proteins such as the breast
cancer/stiff-person PND antigen amphiphysin and RNA-binding proteins such as
the Nova antigen that regulates alternative splicing in neurons (Darnell 2004).
2.3 Proposed pathogenesis of PNDs
It is believed that PNDs are initiated when tumor cells start to synthesize
proteins which are normally limited to neurons. The expression of these
onconeural antigens, such as Cdr2, has the potential to trigger an anti-tumor
immune response. Some of these onconeural antigens are also expressed in
normal testis, an organ that is like the brain, known as an immunologically
privileged tissue. Although the tumor antigen is identical to the neural antigen it
causes for unknown reasons an immune response. Apoptotic tumor cells can be
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phagocytosed by dendritic cells that migrate to lymph nodes and activate
antigen-specific CD4+, CD8+ and B cells by cross-presentation of the antigen to
immune cells. It is believed that the cytotoxic CD8+ T cells are mostly
responsible for the suppression of tumor growth by inducing apoptotic death via
granzyme-mediated pathways. The antibodies and the CD8+ T cells overcome
the blood-brain-barrier and attack neurons that express the antigens under
physiological conditions (Darnell and Posner 2003; Albert and Darnell 2004).
Figure 15 summarizes the proposed pathogenesis of PNDs.
Figure 15: Proposed pathogenesis of paraneoplastic neurological disorders (Darnell and
Posner 2003)
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2.4 Characteristics of PND-associated tumors
PND-associated tumors are classically diagnosed when patients ask medical
advice due to neurological symptoms. Tumors in paraneoplastic neurologic
disorders show histologically no difference from other tumors except a heavy
infiltration of inflammatory cells (Darnell and Posner 2003; Darnell and Posner
2003). Several reports show a more benign cancer course in PND patients
compared to control groups with non-PND-associated tumors (Albert and
Darnell 2004). PND-associated tumors are often limited in growth and the
metastatic potential seems to be decreased compared to non-PND tumors. This
leads to a better prognosis for PND patients relative to patients with
histologically identical tumors without PND association. However, anti-tumor
immune response is not very efficient in PNDs. A study of Rojas et al. showed
that around 50% of PND patients die from their cancer and the other half die
from neurological degeneration (Rojas et al. 2000). These data indicate that the
PND associated anti-tumor immunity is incomplete.
2.5 Immunology of PNDs
In 2003, Posner et al. defined the following characteristics of autoimmunity in
CNS paraneoplastic syndromes (Table 26) (Posner 2003).
Table 26: Evidence for autoimmunity in CNS paraneoplastic syndromes (Posner 2003)
The role of antibodies and immune cells in PNDs will be introduced in the
following chapters.
2.5.1 Antibodies in PND
High titers of antibodies against onconeural antigens are present in all PND
patients in the blood and the cerebrospinal fluid and are used as diagnostic
markers for PND. However, there is no clear role for antibodies in the
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pathogenesis of the disease. PND antigens are found intracellularly in neuronal
cells and a variety of studies in patients showed that plasmapheresis, the
removal of these antibodies from the blood, had no influence on disease
progression (Furneaux et al. 1990; Graus 1992). Additionally, mouse models for
PND in which recombinant proteins of onconeural antigens were injected or
PND antibodies passively transferred into mice did not lead to the onset of the
disease (Sakai et al. 1995; Sillevis Smitt et al. 1996; Sakai et al. 2001). Based
on these data, the role for a cellular immune response in the pathogenesis of the
disorder was investigated (Roberts and Darnell 2004). Indeed, clear evidence
for a cellular immune response has been found in paraneoplastic cerebellar
degeneration (PCD) patients. Antigen-specific cytotoxic T lymphocytes (CTL)
isolated from these patients were able to recognize peptides derived from the
antigen Cdr2 without additional in vitro stimulation (Albert et al. 1998; Albert et
al. 2000; Tanaka et al. 2001).
2.5.2 Cytotoxic T cells mediate the PND tumor immune response
One important characteristic of PND antigens is the fact that they are typically
intracellular proteins. Antibodies generally mediate immune responses against
extracellular proteins, whereas immunity against intracellular antigens is
mediated by T cells. This led to the conclusion that tumor reactive T cells were
finally responsible for mediating the anti-tumor immune responses to
intracellular PND antigens. Studies using peripheral blood obtained from PND
patients showed the presence of PND-antigen-specific CD8+ cytotoxic T
lymphocytes. These T cells were able to lyse target cells which presented
processed Cdr2 peptides on major histocompatibility complex class I (MHC I)
molecules (Albert et al. 1998). CD8+ T cell immunity is based on the recognition
of antigenic peptides in association with MHC I on the surface of host cells by T
cell receptors (TCR) present on cytotoxic T cells. T cell receptors bind to a triad
of three proteins on the surface of the tumor cells: MHC I molecule, 2
microglobulin and a short peptide derived from the proteolytically degraded
antigen associated with the MHC I molecule (Fig. 16) (Albert and Darnell 2004).
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Figure 16: CD8+ T cell immunity (Albert and Darnell 2004)
TCR on CD8+ cytotoxic T cells is able to recognize the MHC I associated antigen peptide on the
surface of a host cell. TCR binds to a triad of three proteins on the surface of target cell: MHC I
molecules, 2 microglobulin and short peptide derived from proteolytically degraded antigen.
Association of small antigenic peptides with MHC I molecules takes place in the endoplasmatic
reticulum (ER) before displayed on the surface.
2.5.3 Antigen cross-presentation by dendritic cells in PND tumor immunity
Prerequisite for an activation of CD8+ T cells is the antigen presentation via
MHC I-peptide complex on antigen-presenting cells (APCs). Classically, only
self and viral proteins were thought to have access to the class I pathway of
APCs. In PNDs it has been shown that dendritic cells (DCs) are the main acting
APCs, but the examination of antigen expression (Cdr2, NOVA and Hu)
revealed no endogenous PND antigen expression (Buckanovich et al. 1996;
Corradi et al. 1997; Okano and Darnell 1997). This paradox of necessary
induction of the CD8+ T cells by antigen-presenting cells expressing MHC I-
peptides complexes and a missing endogenous expression in dendritic cells of
these antigens lead to the question, how else dendritic cells can gain access to
PND antigens in order to activate a CD8+ T cell response against tumors?
Recent studies revealed that antigens derived from apoptotic tumor cells can be
cross-presented by dendritic cells for the generation of MHC I-peptide
complexes (Albert et al. 1998). Cross-presentation is defined as the ability of
certain APCs to phagocytose, process and present extracellular antigens with
MHC I molecules to CD8+ T cells. This capability is necessary for antigen
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presentation of tumor antigens from non APCs. APCs like dendritic cells and in
some cases macrophages are specially equipped for cross-presentation which
is linked to the cell’s capacity to phagocytose (Guermonprez et al. 2002).Recent
generation of a mouse model to investigate activation of T cells to antigens
derived from apoptotic cells showed that dendritic cells process antigens from
cells that contain fully or partially processed proteins (Blachere et al. 2005).
A study of the autoimmune disease systemic lupus erythematosus (SLE)
showed that keratinocytes exposed to ultraviolet irradiation undergo apoptosis
which allows the lupus antigen Ro to be extruded from the dying cell in
membranous bodies (Casciola-Rosen et al. 1994). This led to the hypothesis
that antigens that are derived from apoptotic cells could be internalized by DCs
which finally leads to the activation of antigen-specific T cells. In a recent study
dendritic cells lacking the transporter associated with antigen processing (TAP)
were used (Blachere et al. 2005). TAP is necessary for peptide delivery from the
cytosol into the lumen of the endoplasmatic reticulum (ER). In the ER, these
peptides are loaded on MHC I molecules for presentation on the cell surface.
Blachere et al. showed that TAP-/- dendritic cells had still access to the MHC I
pathway when phagocytosed by apoptotic cells. They observed that apoptotic
cells are able to process the antigen within the dendritic cell using their own
proteasome and TAP. When TAP was missing in apoptotic cells and dendritic
cells the capability of cross presentation was completely lost. In conclusion,
these data suggest two distinct pathways for the processing of exogenous
epitopes. In the first pathway processing of exogenous antigens is dependent on
the expression of a functional TAP by the DC. The internalized antigen
undergoes the phagosome-to-cytosol pathway in which the protein is cleaved
proteasomally into peptides and released into the cytosol. Peptide translocation
from the cytosol into the lumen of the ER is accomplished by the DC’s TAP. The
MHC class I molecules are then loaded with the peptide in the lumen of the ER
and reach the cell surface through the secretory pathway. The second pathway
is called retrograde transport pathway. This antigen cross-presentation pathway
utilizes the proteasome and transporter activity present in the dying cell for the
generation of MHC I-peptide complexes. Apoptotic cells are phagocytosed by
dendritic cells and ER chaperones within the apoptotic cell facilitate the delivery
of peptide epitopes to dendritic cells. Both pathways finally lead to the
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presentation of the tumor antigen on the dendritic cells which activates an
antigen-specific CD8+ T cell immune response and may support the CD8+ T cell
mediated anti-tumor immunity in PNDs (Blachere et al. 2005).
2.5.4 CD4+ T cells determine CD8+ T cell activation or tolerance
The cross-presentation pathway in dendritic cells is not automatically linked to T
cell activation but can also lead to T cell tolerance (Heath and Carbone 2001;
Guermonprez et al. 2002). A cell-based system using model antigens revealed
that T cell activation is dependent on the presence of CD4+ T helper cells. In the
absence of CD4+ T helper cells, DCs were found to cross-present antigens to
CD8+ T cells and trigger a tolerance pathway in which CD8+ T cells divide
several times, but finally die an apoptotic cell death (Albert et al. 2001). Studies
on transgenic mice confirmed these data and indicate that the presence versus
the absence of antigen-reactive CD4+ T cells determines CD8+ T cell activation
or tolerance (Albert et al. 2001).
2.6 Paraneoplastic neurological degenerations: keys to tumor immunity
In 1909 Paul Ehrlich was the first who described the concept of immune
surveillance suggesting that the immune system could repress a potentially
“overwhelming frequency” of carcinomas.
Thomas and Burnet adopted this idea in the mid 1950s and proposed that
immune mechanisms could act as natural defense against tumor cells (Burnet
1957). This assumption was based on considerations of graft rejection and the
newly recognized ability of T cells to survey the body for virally infected cells and
kill them. The dilemma of this insight was and still is that if cellular immunity
recognizes and eliminates tumor cells, the phenomenon would not be apparent
through clinical signs or symptoms and therefore difficult to study. PNDs may
provide the best known examples for naturally occurring human tumor immunity.
Most PND patients are unaware that they have a latent malignancy. In some
rare cases even neoplasms have been documented to vanish without treatment
after the onset of the neurological disease (Darnell and DeAngelis 1993).
However, most cases show an incomplete anti-tumor immune response and
patients still die to 50% due to their cancer (Rojas et al. 2000). Dalmau et al.
showed 1992 that the expression of PND-associated antigens is not limited to a
few tumors. The PND-associated antigen Hu was shown to be expressed in
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100% of small lung cancer samples (Dalmau et al. 1992), but it is rarely targeted
by the immune system in patients with PND. The Cdr2 antigen is detectable in
60% of ovarian tumors and approximately 25% of breast tumors, but is only
rarely targeted in patients, leading to cerebellar degeneration (Peterson et al.
1992). When Dalmau et al. examined a group of small lung cancer patients who
developed no PNDs they showed that 85% of these patients fail to mount an
antitumor response. About 15 – 20% of patients developed an antitumor
immune response, which was at least partially effective, but no PND symptoms
(Dalmau et al. 1990). These data are contradictive to the idea that anti-tumor
responses are a very rare phenomenon or that they have to be associated with
autoimmunity. However, they stay invisible when not associated with PNDs.
Another study of different cancer populations that develop PND immune
responses is necessary to understand how anti-tumor immunity develops and
what is required to tip the balance toward autoimmunity (Albert and Darnell
2004).
89
Material and Methods
Multiple amino acid deletion by PCR
Multiple amino acid deletions of constructs were carried out by PCR using the
following primer, reaction mixture and cycling parameters.
 pENTR4-hCdr2 1-454 265-314 was generated using the template
pENTR4-hCdr2 1-454 and primer pc_1_del_forward and pc_1_del_reverse.
 pENTR4-hCdr2 216-454 265-314 was generated using the template
pENTR4-hCdr2 216-454 and primer pc-1_del_forward and pc_1_del_reverse.
 pENTR4-hCdr2 216-397 was generated using template pENTR4-hCdr2
216-454 and primer pc_2_del_forward and pc_2_del_reverse.
Primer Sequence (5 3)
pc_1_del_forward
pc_1_del_reverse
CGA CAG ATG TTG CAG TCA GAG CTC AGC AGC TTG GCA GGG AGT
ACT CCC TGC CAA GCT GCT GAG CTC TGA CTG CAA CAT CTG TCG
pc_2_del_forward
pc_2_del_reverse
GAG TGA ACT CCC AGT CTG AGT AAG CCT ATT GCC TAT CGC CTC
GAG GCG ATA GGC AAT AGG CTT ACT CAG ACT GGG CGT TCA CTC
PCR Reaction Mixture Volume
Plasmid (50 – 100 ng) x l
Pfu-Turbo-Buffer 10  (Stratagene) 5 l
Deletion Primer forward (10 M) 1.25 l
Deletion Primer reverse (10 M) 1.25 l
dNTP mix (50 M each nucleotide) 1 l
ddH2O up to 50 l x l
Turbo-Pfu-DNA polymerase (2.5 U/l) (Stratagene) 1 l
Number of Cycles Temperature Time
1 95°C 1 min
20
95°C
55°C
72°C
30 sec
1 min
1 min/kb of plasmid length
1 72°C 7 min
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The reaction mixture was digested with DpnI for 2 h at 37°C and 5 l of the PCR
product were transformed into E. coli Top10 bacteria. Purified plasmids were
sequenced.
RNA isolation and purification
Up to 3 x 107 cells were lysed by scraping in 3 ml solution D in 12 ml tubes. For
RNA extraction the following solutions were added sequentially on ice and the
suspension was vortexed thoroughly in between: 0.3 ml of 2 M NaAc pH 4.0, 3.0
ml of water-saturated phenol and 0.6 ml chloroform-isoamyl alcohol mixture
(49:1). The well-mixed suspension was cooled on ice for 20 minutes and
centrifuged at 10 800 rpm for 20 minutes at 4°C. The aqueous phase was
precipitated in a fresh 12 ml tube with 3 ml isopropanol at -20°C for 1 hour.
Afterwards, the RNA was pelleted by centrifugation (10 800 rpm, 20 minutes at
4°C) and the supernatant was removed completely. The RNA pellet was
dissolved in 0.3 ml solution D, transferred into a fresh Eppendorf tube and again
precipitated with 0.3 ml isopropanol at -20°C for 1 hour. The solution was
centrifuged again for 20 minutes at 10 800 rpm at 4°C and the pellet washed by
vortexing in 75% ethanol (-20°C). After repeated centrifugation, the RNA pellet
was air dried for up to 1 hour and dissolved in 50 l DEPC-treated water. The
resuspended RNA was heated for 15 minutes at 56°C to assist solubilization
and finally stored at -80°C.
Solution D
4 M Guanidine thiocyanate
25 mM Sodium citrate (pH 7.0)
0.5% Sarcosyl
RNA quantification
RNA concentration was measured at OD260. Additionally, 5 g RNA were loaded
on an agarose gel. Therefore 2.5 g agarose were diluted in 185 g DEPC-H2O,
melted in the microwave and cooled down briefly to about 75°C under tap water.
25 ml 10  MOPS and 40 ml 37% formaldehyde were added and the gel was
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poured into a gel chamber. 1 volume RNA was mixed with 3 volumes sample
buffer containing additionally 1/100 volume ethidium bromide, heated at 56°C for
15 minutes, 1/10 volume of bluemix was added and the samples were loaded
immediately on the gel. The gel was run for 30 minutes at 40 V and RNA was
detected by UV light.
10 x MOPS Sample Buffer
0.4 M Morpholinopropanesulfonic acid (pH 7.0) 192 l 37% formaldehyde
0.1 M Sodium acetate x 3 H2O 600 l 100% formamide
10 mM Na2EDTA x 2 H2O 120 l 10 x MOPS
Fill up to 1 l with DEPC-H2O
Bluemix
50% Glycerol
1 mM EDTA
0.1% Bromphenolblue
0.1% Xylene cyanol ff
First-strand cDNA synthesis
The following components were added to a nuclease-free Eppendorf tube:
 1.5 l oligo(dT)12-18 (0.2 µg/µl) (Stratagene)
 5 µg of total RNA
 x l of DEPC-treated H2O for a total reaction volume of 50 l
The mixture was heated for 5 minutes at 65°C and slowly cooled down to room
temperature for 10 minutes allowing the primers to anneal to the RNA. The
following components were added to the mixture:
 2 µl of 10 mM dNTP mix (Sigma)
 1 µl Ribonuclease Inhibitor (40 U/µl) (Fermentas)
 0.5-1 µl of StrataScript reverse transcriptase (200 U/µl) (Stratagene)
The reaction was mixed gently and incubated at 42°C for 1 hour. To inactivate
the reaction, the mixture was heated to 90°C for 5 minutes, kept on ice and
diluted 1:2 with sterile H2O and stored at -20°C until quantitative PCR analysis.
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Quantitative PCR (qPCR)
2 l cDNA of each sample were distributed in a 96-well-qPCR plate (Abgene). 1
 102 – 1  108 copies of a corresponding plasmid were pipetted as standard into
additional wells. According to the manufacture’s manual, a master mix including
the following components per well was added:
Syber Green Mixture (Sigma) 12.5 l
ROX Dye (Sigma) 0.1 l
10 M forward primer 1 l
10 M reverse primer 1 l
H2O 8.5 l
Final volume/well 23 l
qPCR thermal profile
Number of Cycles Temperature Time
1 95°C 10 min
40
95°C
60°C
72°C
30 sec
1 min
1 min
1
55°C
95°C
30 sec
1 min
q-PCR-Primer Sequence (5  3)
hCdr2 forward
hCdr2 reverse
GTA TGA CCT CCG CCA ACA CT
CTG CAA CAT CTG TCG CAT CT
hPHD1 forward
hPHD1 reverse
CTG GGC AGC TAT GTC ATC AA
AAA TGA GCA ACC GGT CAA AG
hPHD2 forward
hPHD2 reverse
GAA AGC CAT GGT TGC TTG TT
TTG CCT TCT GGA AAA ATT CG
hPHD3 forward
hPHD3 reverse
ATC GAC AGG CTG GTC CTC TA
CTT GGC ATC CCA ATT CTT GT
hL28 forward
hL28 reverse
GCA TCT GCA ATG GAT GGT C
ACA AGA ACT CCT AGT ACA CA
mCdr2 forward
mCdr2 reverse
CTG AAG TCT TCC AGC CAA GG
GCT CCA GCT CAC TGT TCT CC
mPHD1 reverse
mPHD1 forward
TTG CCT GGG TAG AAG GTC AC
GCT CGA TGT TGG CTA CCA CT
mPHD2 forward
mPHD2 reverse
GCA ACG GAA CAG GCT ATG TC
CTC GCT CAT CTG GCA TCA AAA
mPHD3 forward
mPHD3 reverse
CAA CTT CCT CCT GTC CCT CA
GGC TGG ACT TCA TGT GGA TT
mS12 forward
mS12 reverse
GAA GCT GCC AAA GCC TTA GA
AAC TGC AAC CAA CCA CCT TC
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Bacterial expression of recombinant proteins
Three different expression systems were used for bacterial expression of
recombinant proteins. Recombinant proteins were either fused to Glutathione-S-
transferase (GST), hexa-histidine (HIS)6 or maltose-binding protein (MBP). The
plasmids were transformed into the corresponding bacterial strain as describe in
the following table, an overnight culture containing the corresponding antibiotic
and if necessary 0.1% glucose was inoculated with a single colony. On the next
day, the overnight culture was diluted 1:40 and grown at 37°C to an OD600 of 0.4.
Expression was induced either by arabinose or isopropyl β-D-1-
thiogalactopyranoside (IPTG) depending on the expression system. The
bacteria were induced for 3 - 4 hours at 37°C. Afterwards, the bacterial culture
was centrifuged at 8 000 rpm for 15 minutes at 4°C and pellets were stored at -
20°C until purification.
The following table 27 shows an overview of the used expression systems:
GST-fusion system
(Invitrogen)
(HIS)6-fusion system
(Invitrogen)
MBP-fusion system
(NewEnglandBiolabs)
Bacterial strain BL21-AI BL21-AI TB1
Genotype
Bacteria strain
F- ompT hsdSB (rB
-
mB
-) gal dcm
araB::T7RNAP-tetA
F- ompT hsdSB (rB
-mB
-)
gal dcm araB::T7RNAP-
tetA
F- ara (lac-proAB)
[80dlac(lacZ)M15]
rpsL(StrR) thi hsdR
Induction by Arabinose Arabinose IPTG
Repression of
expression
0.1% Glucose 0.1% Glucose -
Table 27: Bacterial expression systems
LB Medium
1% Tryptone
0.5% Yeast extract
0.5% NaCl
Lysis of bacteria
Bacterial pellets of a 2 l culture were resuspended either in 8 ml PBS (GST-
fusion and HIS6-fusion proteins) or 8 ml column buffer (MBP-fusion protein) with
EDTA-free protease inhibitors (Roche). Bacterial lysis was carried out by
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disruption of bacteria in a French press at 2.7 kbar or chemical lysis using 0.5%
NP-40 added to the resuspension or column buffer. After chemical lysis, the
bacterial suspension was rotated on ice for 30 minutes and afterwards sonicated
for 3  30 pulses. In case of FPLC purification, the lysate was centrifuged at 40
000 rpm for 1 hour at 4°C whereas for batch purification a centrifugation step at
12 000 rpm for 1 hour at 4°C was carried out.
Purification of recombinant proteins
Biologic Duo Flow fast performance liquid chromatography (FPLC)
GST-fusion proteins
After centrifugation, the supernatant of the lysate was loaded on a GSTrap FF
column (Amersham) with a flowrate of 0.2 ml/min to bind the fusion protein to
the glutathione sepharose matrix. The 2-buffer system consisted of a buffer A (1
 PBS) as washing buffer and a buffer B (32.5 mM glutathione/50 mM Tris/Cl pH
8.0) used as elution buffer.
(HIS)6-fusion proteins
After centrifugation the supernatant was loaded on a HiTrap chelating HP
column (Amersham) with a flowrate of 0.2 ml/min. The column was manually
prepared in advance by loading 0.1 M NiSO4. The 2-buffer system consisted of a
buffer A (His6) binding buffer and a buffer B (His)6 elution buffer including 0.5 M
imidazole.The following program run represents the general protein purification
steps used for GST-and (HIS)6–fusion protein purification by FPLC.
Step Number Step
1 Isocratic flow with 100% buffer A at 1.00 ml/min for 10.0 ml
2 Dynamic loop: Inject x ml sample at 0.2 ml/min
3 Isocratic flow with 100% buffer A at 1.00 ml/min for 10.0 ml
4 Elution with 100% buffer B at 1.00 ml/min for 10.0 ml
5 Isocratic flow with 100% buffer A at 1.00 ml/min for 10.0 ml
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Batch purification
(HIS)6-fusion proteins
0.5 ml Ni-NTA-agarose beads (Qiagen) were washed three times with bead
binding buffer and the lysate was added to the beads and rotated for 2 hours at
4°C. Afterwards, the beads were washed four times with 20 ml/10 ml/1.5 ml/1.5
ml bead binding buffer, each time rotating for 10 minutes at 4°C. (His)6-fusion
proteins were eluted with twice 300 l (His)6 elution buffer.
MBP-fusion proteins
1.5 ml amylose beads (NEB) were washed three times with column buffer and
the lysate was added to the beads and rotated for 2 hours at 4°C. Beads were
washed afterwards four times with 25 ml column buffer, each time rotating for 10
minutes at 4°C. MBP-fusion proteins were eluted with 3 ml column buffer
including 10 mM maltose (MBP elution Buffer). The elution was repeated twice
each time with 2 ml MBP elution buffer.
MBP column buffer MBP elution buffer
20 mM TrisCl pH 7.4 = MBP-column buffer
200 mM NaCl + 10 mM D-Maltose
1 mM EDTA
SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
For SDS-PAGE the following volumes dependent on the percentage of the gel
were mixed in a 50 ml tube. Polymerization took place within 30 minutes and
proteins were separated by gel electrophoresis at 100 – 200 V.
(His)6 binding buffer (His)6 elution buffer
0.02 M Na3PO4 0.02 M Na3PO4
0.5 M NaCl 0.5 M NaCl
0.5 M Imidazole, pH 7.4
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Separating gel Stacking gel
1.5 M Tris/Cl pH 8.7 7.5 ml 1 M Tris/Cl pH 6.8 1.25 ml
30% Acrylamide 5-20 ml 30% Acrylamide 1.67 ml
10% SDS 300 l 10% SDS 100 l
1% Bisacrylamide 7.8-2 ml 1% Bisacrylamide 1.30 ml
H2O ad 30 ml H2O ad 10 ml
10% APS 200 l 10% APS 100 l
TEMED 20 l TEMED 10 l
Gel percentage 5.0% 7.5% 10.0% 12.5% 15.0% 17.5% 20.0%
30% Acrylamide 5.0 7.5 10.0 12.5 15.0 17.5 20.0 ml
1% Bisacrylamide 7.8 5.8 3.9 3.1 2.6 2.2 2.0 ml
10 x SDS-PAGE Running Buffer (1 l) 10 x Sample Buffer
Tris 30 g 0.4 M Tris/Cl pH 6.8
Glycine 144 g 10% SDS
1 mM EDTA 0.5 M -ME
SDS(1%) 10 g
Semi-dry electrophoretic transfer/immunoblotting
Proteins were blotted to a nitrocellulose membrane (0.2 m) (GE Healthcare)
between three layers of filter paper soaked in blotting buffer at 10 – 20 Vconst for
1 – 2 hours. Afterwards, the nitrocellulose membrane was briefly rinsed in PBS
and stained for 5 minutes in Ponceau S solution. After complete destaining in
PBS the nitrocellulose membrane was blocked in 5% non-fat milk powder in
PBS for at least 30 minutes at room temperature. Primary antibodies were
added and the blot was rotated either overnight at 4°C or for a maximum of 2
hours at room temperature. The antibody solution was removed and the
membrane washed three times 10 minutes with an excess volume of PBS with
0.5% Tween. The membrane was afterwards incubated with the horse-radish-
peroxidase- (HRP-) coupled secondary antibodies at the desired dilution for one
hour at room temperature. The washing procedure as above was repeated. The
detection of the antigen took either place using a commercially available
chemiluminescent HRP substrate (Pierce) following the supplier’s reference or a
self-prepared substrate was used with the following components: 10 ml 100 mM
97
Tris/Cl pH 8.5, 3 l 30% H2O2, 50 l 250 mM luminol and 25 l 90 mM p-
coumaric acid. The solution was equally distributed over the nitrocellulose
membrane and incubated for 1 minute at room temperature. Excess liquid was
removed and the membrane immediately wrapped into saran foil and exposed
either to x-ray film or a charge-coupled device (CCD) camera.
Blotting Buffer Ponceau S
25 mM Tris 0.2% Ponceau S
192 mM Glycine 3% Trichloracid
20% MeOH 3% Sulfosalicylic acid
0.04% SDS
Cell Culture
Transient transfection of eukaryotic cells using polyethylenimine (PEI)
DNA solution used for transient transfections was heated at 68°C for 20 minutes
to avoid contamination of the cells. For a 10-cm dish culture the following
amount of DNA and PEI were used. Depending on the size of the dish the
amounts were adapted according to table 28.
Solution A: 3 g DNA in 100 l 150 mM NaCl
Solution B: 15 l 1 mg/ml PEI plus 85 l 150 mM NaCl
Both solutions were incubated for 5 minutes at room temperature. Solution B
was added to Solution A, briefly vortexed and incubated for 25 – 30 minutes at
room temperature. Culture media was replaced with fresh one and PEI-DNA-mix
was added dropwise to 50% - 75% confluent cells in a 10-cm dish. The cells
were incubated for 16 up to 48 hours before further experiments.
Table 28: PEI transfection in different scales
Culture
format
Media per
well [ml]
DNA [g]
Final volume of
DNA dilution [l]
PEI [l] of
1mg/ml
Final volume of
PEI dilution [l]
24-well 0.5 0.5 - 1.0 50 2.5 - 5 50
12-well 1 0.5 - 1.5 50 2.5 - 7.5 50
6-well 2.5 1.0 - 3.0 100 5.0 - 15.0 100
100 mm plate 10 2.0 - 4.0 100 10.0 - 20.0 100
150 mm plate 18 4.5 - 10.0 200 22.5 - 50.0 200
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DMEM high glucose® (Sigma) McCoy’s 5A medium + L-Glutamine
10% (vol/vol) Fetal calf serum (FCS) 10% (vol/vol) Fetal calf serum (FCS)
1% (vol/vol) Penicillin/Streptomycin 1%(vol/vol) Penicillin/Streptomycin
Dual-Luciferase reporter assay system (Promega)
10 l of whole cell lysates (WCL) were distributed in a 96-well plate and 10 l of
the LANII, a mix of luciferin (luciferase substrate), ATP and magnesium, were
added. Firefly luminescence was detected in a 96-well luminometer (Berthold)
and 10 l of the Stop&Glo substrate (1:50) were added to measure renilla
luminescence.
Preparation of whole cell extracts
Cells were washed twice with ice-cold PBS, scraped into an ice-cold Eppendorf
tube and centrifuged at 14 000 rpm for 30 seconds at 4°C. The supernatant was
removed and depending on the size of dish 100 – 200 l of cell lysis buffer were
added. The cells were incubated on ice for 10 minutes with briefly vortexing
every 2 minutes. The cell extract was centrifuged for 15 minutes at 14 000 rpm
at 4°C and the supernatant was transferred to a fresh Eppendorf tube and
stored at –80°C until analysis.
Cell lysis buffer for whole cell extracts 10  PBS (1 l)
10 mM Tris (pH 8.0) 80 g NaCl
1 mM EDTA (pH 8.0) 2 g KCl
400 mM NaCl 14.4 g Na2HPO4
0.1% NP-40 2.4 g KH2PO4
Preparation of mouse tissue extracts
The tissue was dissected from adult C57B6 mice and immediately deep frozen
in liquid nitrogen and stored at -80°C or processed by homogenization in a
Polytron (Kinematica) in 1  PBS including EDTA-free protease inhibitors on ice.
The volume of PBS was adapted depending on the size of the organ or tissue
between 200 – 400 l. Extracts were incubated on ice for 15 minutes with briefly
vortexing every 2 minutes and final centrifugation for 15 minutes at 14 000 rpm
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at 4°C. Supernatants were transferred into fresh ice-cold Eppendorf tubes,
aliquoted and stored at -80°C until analysis.
Immunofluorescence analysis
Cells were cultivated on coverslides, washed twice with ice-cold PBS and fixed
for 30 minutes with 4% paraformaldehyde. Afterwards, the cells were washed
three times with PBS and 20 mM glycine in PBS was added twice for 5 minutes
each at room temperature to quench free aldehyde groups. Cells were
permeabilized by 0.1% saponin-glycine in PBS for 20 minutes at room
temperature and washed three times with PBS. Primary antibodies were diluted
in 0.1% saponin-PBS and the cover-slide was incubated for 1 hour at 37°C
upside down on parafilm in a 150 mm dish in 30 l antibody solution. A wet
tissue was added to the incubation chamber for optimal humidity. The coverslide
was transferred back to the 12-well plate and washed three times with PBS. The
secondary antibodies, also diluted in saponin-PBS, were added directly into the
well (100 l/well) and the plates were incubated for 30 minutes in the dark to
avoid bleaching. To continue with nuclear 4,6-diamidino-2-phenylindol (DAPI)
stain, cells were washed three times with PBS and 100 l DAPI staining solution
(1 ng/l) were added per well and incubated for 30 minutes at room temperature
in the dark. The coverslide was washed three times with 5 minutes incubation
time in between and finally mounted with 100 l Mowiol on an object slide, dried
overnight at room temperature and stored at 4°C until analysis by confocal laser
scanning microscopy (SP1, Leica Microsystems).
4% Paraformaldehyde Mowiol
4 g Paraformaldehyde 2.4 g Mowiol 4-88
Dissolve in 100 ml PBS, stir and
warm to 60°C, then add afew
drops of 4°C 10 M NaOH until it is
completely dissolved, cool to
room temperature and adjust pH
to 7.4 with 37% HCl
6 g Glycerol stirr to mix
add 6 ml H2O and mix for several hours at
room temperature; add 12 ml 0.2 M Tris
(pH 8.5), heat to 50°C for 10 minutes, with
occasional mixing, after Mowiol has
dissolved, clarify by centrifugation at 5000
x g for 15 minutes, add 2% DABCO (1.4-
diazobicyclo[2,2,2]-octane)
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Results
Identification of Cdr2 as PHD1 interactor by yeast two-hybrid screenings
Cdr2 was identified in two independent yeast two-hybrid screenings using a
mouse and a human testis cDNA library (see pages 45 and 60). Full length
mouse Cdr2 (mCdr2) was cloned twice and a human Cdr2 (hCdr2) fragment
(hCdr2 aa216-454) once. Alignment of mCdr2 and hCdr2 sequences revealed
89% homology with a highly conserved C-terminus. Figure 17 shows mouse and
human Cdr2 full length and the identified hCdr2 fragment 216-454.
Figure 17: Alignment of hCdr2 and mCdr2 protein sequences
Letters in red represent amino acid mismatches between human and mouse Cdr2 protein
sequence. Bold letters correspond to the found hCdr2 sequence in the
Matchmaker/Dualsystems screening.
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Interaction of Cdr2 and PHDs in yeast
pEXPAD502Cdr2 was transformed in Mav203 yeast strain containing either
pDEST32PHD1, pDEST32PHD2 or pDEST32PHD3. As positive control yeast
cells were transformed with pDEST22HIF-2404-569 and pDEST32PHD1 and
to exclude self activity of PHD1, pDEST32PHD1 was transformed together with
pEXP-AD502 library vector. All combinations of yeast were plated on agar plates
with increasing concentrations of 3-AT as well as on uracil-lacking plates. An X-
gal assay was carried out to examine the third reporter gene, -galactosidase.
PHD1/Cdr2 showed growth up to 25 mM 3-AT and on uracil-lacking plates and a
strong blue staining in the X-gal assay was observed (Fig. 18). Whereas no
interaction was seen between PHD2 and Cdr2 , PHD3 weakly interacted with
Cdr2 in the presence of up to 10 mM 3-AT (data not shown).
Figure 18: Interaction of Cdr2 and PHDs in yeast. Yeast reporter strain Mav203 expressing
different Gal4-DBD and Gal4-AD fusion proteins was assayed for histidine and uracil auxotrophy
as well as for -galactosidase activity.
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In vitro interaction of Cdr2 and PHD1 in GST pull-down assay
Bacterially expressed and purified GST-PHD1 was incubated with in vitro
transcribed and translated (IVTT) 35S-Cdr2 and with glutathione sepharose. As
positive control served GST-HIF-1530-826 incubated with 35S-PHD2 and GST
alone was used as non-interaction control. PHD1 showed a weak interaction
with Cdr2 compared to the positive control (Fig. 19).
Figure 19: PHD1 and Cdr2 interact in GST pull-down assays. Protein-protein interaction of in
vitro transcribed and translated (IVTT) 35S-labeled Cdr2 or PHD2 and recombinant GST-PHD1
or GST-HIF-1530-826 fusion proteins, or GST alone were analyzed by GST pull-down with
glutathione sepharose. Bound proteins and input controls (5%) were separated by SDS-PAGE
and visualized by autoradiography.
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Expression of Cdr2 mRNA
Expression pattern of Cdr2 and PHD1 in mouse tissues
Cdr2 mRNA was shown to be present in almost all tissues with higher
expression levels in the brain and in the testis (Corradi et al. 1997). To confirm
these literature data as well as to compare tissue expression patterns of Cdr2
and PHD1, quantitative PCR was performed. Cdr2 and PHD1 were ubiquitously
expressed with higher mRNA levels in testis and brain. Additionally, PHD1
expression levels were higher compared to Cdr2 in skeletal muscle, liver and
kidney. Surprisingly, Cdr2 mRNA was similarly high in the bone marrow as in the
testis (Fig. 20).
Figure 20: Tissue distribution of mCdr2 and mPHD1 mRNA. RNA was extracted from mouse
tissues and PHD1 as well as Cdr2 mRNA levels determined by quantitative PCR and normalized
to S12 mRNA. Note the different scales.
Cdr2 is not transcriptionally regulated in hypoxia
The fact that Cdr2 is ubiquitously expressed but the protein could only be
detected in the brain and the testis, indicated that Cdr2 must be post-
transcriptionally regulated (Corradi et al. 1997). Brain and testis are tissues with
relatively low pO2 values and we therefore hypothesized that Cdr2 protein might
be PHD-dependently regulated under different oxygen conditions. To test
whether Cdr2 mRNA is induced under hypoxic conditions, human tumor cell
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lines were incubated under normoxic (20% O2) or hypoxic (0.2% O2) conditions
or treated with the PHD inhibitor dimethyloxalylglycine (DMOG). Whereas Cdr2
gene expression was not upregulated in hypoxia or after DMOG treatment in
none of the cell lines tested, PHD3 mRNA levels were highly elevated in a HIF-
dependent manner (Fig. 21).
Figure 21: No hypoxic upregulation of Cdr2 mRNA in human cell lines. HeLa, SKOV3,
BT474, OVCAR3 and HCT116 cells were cultured either at 20% or 0.2% oxygen or treated with
2 mM DMOG respectively 1 mM DMOG for SKOV3 for 20 hours. mRNA levels of Cdr2 and
PHD3 were quantified by real-time quantitative PCR and normalized to ribosomal L28 mRNA.
Data are mean ± SEM of n = 3 independent experiments.
Possible HIF-1-dependent Cdr2 regulation was analyzed in mouse embryonic
fibroblasts (MEFs) either HIF-1 wild-type (HIF-1+/+) or HIF-1-deficient (HIF-
1-/-). As expected, Cdr2 mRNA levels were not regulated in a HIF-1- or
oxygen-dependent manner, whereas CAP43, a well-known target gene of HIF,
was upregulated under hypoxic conditions (Fig. 22).
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Figure 22: Cdr2 gene expression is not regulated by HIF-1. MEF-HIF-1a +/+ and MEF-HIF-
1a -/- cells were cultured either at 20% or 2% oxygen for 4 to 256 hours. Cdr2 and CAP43
mRNA levels were quantified by realt-time quantitative PCR and normalized to S12 mRNA
levels.
PHD-dependent Cdr2 protein stabilization in transient transfection assays
To investigate a possible PHD-dependent regulation of Cdr2 protein stability, we
transfected HeLa cells with a V5-tagged Cdr2 expression vector. Transient
transfection assays were used, because no anti-Cdr2 antibodies were
commercially available at this time. After transfection, the cells were split and
incubated either under normoxic or hypoxic conditions, or treated with the PHD
inhibitors desferrioxamine (DFX) or DMOG. Whereas Cdr2 protein levels were
barely detectable by immunoblotting in normoxia, a strong increase was
observed in hypoxia or after DFX or DMOG treatment. Transfected HIF-1 and
ARNT served as positive and negative control, respectively (Fig. 23A). Similar
results were reproduced in MCF7 breast cancer cells (Fig. 23B). This data
suggest that Cdr2 protein levels are regulated in a PHD-dependent manner.
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Figure 23: Stabilization of Cdr2 protein in hypoxia and after PHD inhibition. Total cell
extracts of Hela (A) and MCF7 (B) cells, transfected with V5-Cdr2, V5-HIF-1 or V5-ARNT and
incubated under the indicated conditions, were analysed for V5-fusion, endogenous HIF-1 and
-actin protein levels by immunoblotting.
Proteasomal regulation of V5-Cdr2
The proteolytic regulation of Cdr2 is not known and we analysed whether
proteasomal pathways, as for HIF- subunits, are involved. Therefore, HeLa and
MCF7 cells were transiently transfected with V5-tagged Cdr2 and cultured in the
presence of the proteasomal inhibitor MG132 (5 M). As shown in Figure 24,
V5-Cdr2 protein stabilization was already observed after 30 minutes in HeLa
and 15 minutes in MCF7 cells (Fig. 24A and B), suggesting that Cdr2 protein
destruction is regulated by proteasomal pathways. Determination of endogenous
HIF-1 protein levels served as positive control.
Figure 24: Stabilization of Cdr2 after proteasomal inhibition. HeLa (A) and MCF7 (B) cells
were transiently transfected with V5-Cdr2 and treated with MG132 (5 M), DFX (100 M) or
DMOG (2 mM). Transfected V5-Cdr2, endogenous HIF-1 and -actin levels were determined
by immunoblotting.
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Cdr2 shows no transactivation activity
In 1991, Fathallah-Shaykh et al. suggested that Cdr2 might be involved in the
regulation of gene expression based on its predicted structure, which contains
leucine-zipper and zinc-finger motifs (Fathallah-Shaykh et al. 1991). Takanaga
et al. reported that PKN, a fatty acid-activated serine/threonine protein kinase, is
an interactor of Cdr2 (Takanaga et al. 1998). They fused Cdr2 to the Gal4 DNA-
binding domain (Gal4BD) and co-transfected C6 cells with Gal4BD-Cdr2 and the
reporter gene plasmid pG5CAT, which contains 5 Gal4 binding sites and a
minimal promoter linked to the chloramphenicol acetyltransferase (CAT) gene.
Surprisingly, determination of CAT activity showed transcriptional activation
when Cdr2 was fused to Gal4BD. Previously, Cdr2 was also reported to be a
cytoplasmic protein and no nuclear targeting sequence was identified. To
confirm or disprove Cdr2 transactivation activity, we cloned Gal4BD-Cdr2 and
transiently co-transfected HeLa cells together with the Gal4 firefly luciferase
reporter vector pGRE5xE1b and the renilla luciferase control vector pRL-SV40.
The C-terminal part of the oxygen-dependent degradation domain of HIF-1
(amino acid 526-603), cloned between the Gal4BD and the VP16 activation
domain (VP16AD), and pGRE5xE1b alone was used as positive and negative
control, respectively. Whereas the positive control was induced 3.5x fold after
PHD inhibition, no Cdr2 transactivation activity could be measured under
normoxic conditions or after DMOG treatment (Fig. 25).
Figure 25: Cdr2 possesses no transactivation activity. HeLa cells were transiently
transfected with Gal4BD-HIF-1-526-603-VP16AD or Gal4BD-Cdr2 expression vectors, Gal4
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response element-driven firefly luciferase reporter pGRE5xE1b as well as a renilla luciferase
control vector. After transfection, cells were cultivated under normoxic conditions in the presence
or absence of 2 mM DMOG. Firefly luciferase activities were determined and corrected for renilla
luciferase activity and normalized to the normoxic positive control which was arbitrarily defined
as 1. Results are mean values of relative luciferase activities ± SEM of 2 independent
experiments performed in triplicates.
Mapping the interaction site of Cdr2 and PHD1
The interaction of Cdr2 and PHD1 in yeast and in vitro as well as the PHD-
dependent stabilization of transfected Cdr2 suggested that Cdr2 could be
regulated by PHD1-dependent prolyl-4-hydroxylation. To narrow down the
interaction and/or hydroxylation sites of Cdr2, we cloned Cdr2 deletion
fragments by using restriction enzyme-mediated cloning and multiple amino acid
PCR deletions as depicted in Figure 26. Two proline clusters, amino acid 265-
314 and 410-454, were identified and also deleted.
Figure 26: Schematic representation of the predicted Cdr2 domain architecture and
cloned fragments thereof. The leucine cluster, the zinc finger domain and the two conserved
proline clusters (P) are indicated.
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To identify the interaction domain in Cdr2 with PHD1, a yeast two-hybrid assay
was carried out. Interaction with PHD1 was observed for full length Cdr2 (aa1-
454), proline cluster I (aa1-454265-314) and proline cluster II (aa1-409)
deletions as well as a fragment (aa1-208) (Fig. 27 and Table 29). No interaction
was determined with fragments lacking the first 215 amino acids. Interestingly,
the extended N-terminal fragment (aa1-409), including the leucine cluster as
well as the zinc finger domain, showed a much stronger interaction compared to
the fragment (aa1-208). Of note, the interacting Cdr2 fragment cloned in the
human testis, Matchmaker/Dualsystems human cDNA library screening (aa216-
454) could not be confirmed in this assay.
Figure 27: Interaction of PHD1 and Cdr2 fragments in yeast
Yeast reporter strain Mav203 expressing Gal4DB-PHD1 was transformed with the indicated
Gal4AD-Cdr2 constructs and subsequently assayed for histidine and uracil auxotrophy.
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Cdr2 constructs histidine auxotrophy growth uracil auxotrophy growth
hCdr2 1-454 25 mM 3-AT ++
hCdr2 1-454 265-314 25 mM 3-AT ++
hCdr2 1-409 25 mM 3-AT +
hCdr2 1-208 10 mM 3-AT -
hCdr2 216-454 No growth -
hCdr2 216-397 No growth -
hCdr2 216-454 265-314 No growth -
Control HIF-2ODD 25 mM 3-AT -
Table 29: Interaction of PHD1 and Cdr2 fragments in yeast. Yeast reporter strain Mav203
expressing Gal4DB-PHD1 was transformed with the indicated Gal4AD-Cdr2 constructs and
subsequently assayed for histidine and uracil auxotrophy.
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Generation of polyclonal anti-Cdr2 antibodies
To generate polyclonal anti-Cdr2 antibodies, rabbits were immunized with the
synthetic peptide PEYKALFKEIFSCIK derived from the conserved C-terminal
part of Cdr2 (aa420-434). Pre-immune, immune and affinity-purified immune
sera were obtained and used for detection of recombinant as well as transfected
Cdr2 by immunoblotting (Fig. 28). Pre-immune serum did not cross-react with
recombinant Cdr2 (Fig. 28A) and only detected nonspecific bands in total
lysates from HeLa cells (Fig. 28B). As demonstrated previously, transfected
Cdr2 protein levels were induced by hypoxia or after DMOG treatment (Fig.
28B).
Figure 28: Polyclonal anti-Cdr2 antibodies recognize recombinant as well as transfected
Cdr2. A, Recombinant Cdr2 (aa236-455) was detected by immune- and affinity-purified immune
serum but not by pre-immune serum. B, HeLa cells were transfected with V5-Cdr2 and cultivated
under normoxic or hypoxic conditions or treated with 2 mM DMOG. Subsequently, total cell
extracts were resolved by SDS-PAGE, blotted onto nitrocellulose membranes and incubated
with pre-immune or affinity-purified immune serum from rabbits immunized with Cdr2-derived
peptides.
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Unfortunately, although polyclonal anti-Cdr2 antibodies were able to detect
overexpressed Cdr2, no detection of endogenous Cdr2 was observed in several
cell lines (data not shown).
Generation of monoclonal anti-Cdr2 antibodies
Monoclonal antibodies were generated in cooperation with René Fischer (ETH
Zürich). Recombinant MBP-Cdr2 was expressed in E. coli, purified and used for
immunization of mice (Fig. 29). Therefore, MBP-Cdr2 was injected
subcutaneously into mice and isolated splenocytes were fused with myeloma
cells. Supernatants from the hybridoma cell lines were screened for the
presence of specific anti-Cdr2 antibodies by enzyme-linked immunosorbent
assay (ELISA). Hybridoma clone #33 was further tested by immunoblotting and
detected recombinant MBP-Cdr2 as well as overexpressed V5-Cdr2 (Fig. 30).
Figure 29: Bacterial expression and purification of recombinant MBP-hCdr2. Expression of
MBP-hCdr2 was induced in E. coli (TB1) with 0.2 mM isopropyl thiogalactoside (IPTG) for 4
hours at 37°C and affinity purified with an amylose-coated matrix (NEB). Indicated fractions were
resolved by SDS-PAGE and the gel coomassie stained.
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Figure 30: Hybridoma supernatant #33 contains specific anti-Cdr2 antibodies.
Recombinant MBP-hCdr2 (A) or cell extracts from transiently transfected HeLa cells (B) were
analyzed by immunoblotting with the indicated dilutions of the hybridoma supernatant #33.
Monoclonal antibodies specifically recognize hCdr2 but not mCdr2 and
hCdr3
Cdr2 and Cdr3 show a 44% homology in their protein sequences. We wanted to
exclude a recognizition of hCdr3 by monoclonal anti-Cdr2 antibodies and to
investigate if anti-Cdr2 #33 crossreacts with mCdr2. Therefore, V5-tagged
hCdr2, mCdr2 and hCdr3 were transcribed and translated in vitro (IVTT) and
immunoblotted. We showed that hybridoma supernatant #33 only recognizes
hCdr2 IVTT but not mCdr2 IVTT and hCdr3 IVTT (Fig. 31).
Figure 31: Monoclonal antibodies specifically recognize hCdr2
V5-tagged hCdr2, mCdr2 and hCdr3 were transcribed and translated in vitro and analyzed by
immunoblotting with the hybridoma supernatant #33 or with anti-V5 antibodies.
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No stabilization of endogenous Cdr2 in hypoxia and upon PHD inhibition
After generation of monoclonal anti-Cdr2 antibodies we investigated the
stabilization of endogenous Cdr2 in several cell lines. The ovarian carcinoma
cell line SKOV3 showed the highest expression for Cdr2. Cells were incubated
for indicated time durations in normoxia or hypoxia or treated with 1 mM DMOG,
respectively. In comparison to transient transfected V5-Cdr2, endogenous Cdr2
was very weakly stabilized after 4 up to 72 hours under hypoxia and DMOG
treatment (Fig. 32).
Figure 32: Endogenous Cdr2 is weakly stabilized under hypoxia and PHD inhibition.
SKOV3 cells were incubated for indicated time durations at 20% or 0.2 % oxygen or treated with
1 mM DMOG.
Unfortunately, we were not able to reproduce these data in SKOV3 cells (Fig.
33) and observed no stabilization in any other examined ovarian or breast
cancer cell line (data not shown). Further experiments such as preincubation of
SKOV3 in FCS-charcoal-stripped medium before treatment could not
reconstitute a hypoxic stabilization (data not shown).
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Figure 33: No stabilization of endogenous Cdr2 under hypoxia and PHD inhibition
SKOV3 cells were incubated at either 20% or 0.2% oxygen or in the presence of 1 mM DMOG
for the indicated time durations. Cell lysates were immunoblotted and analyzed with anti-Cdr2,
anti-HIF-1 and -actin antibodies.
Increased PHD1 protein levels do not decrease Cdr2 protein levels
Recently, several reports showed that PHD1 mRNA is inducible upon estrogen
treatment (Seth et al. 2002; Tian et al. 2006). In line with these results we
investigated Cdr2 protein in estradiol treated BT474 cells. Before treatment cells
were incubated for four days in FCS-charcoal-stripped medium (5%). Cells were
then incubated for 48 hours without or with 24 respectively 48 hours 20 ng/ml
17--estradiol. An increase of PHD1 protein was observed, whereas Cdr2
protein level stayed unchanged (Fig. 34).
Figure 34: Increased PHD1 protein levels upon estrogen treatment do not alter Cdr2
protein levels. BT474 cells were incubated with or without 17--estradiol for the indicated time
durations. Cell lysates were analyzed by immunoblotting with the indicated antibodies.
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Subcellular localization of Cdr2
Immunohistochemical analysis of cerebellar sections and ovarian tumors of PCD
patients as well as rat Purkinje cells with PCD antisera showed mainly
cytoplasmic staining (Corradi et al. 1997; Okano et al. 1999). To analyze the
subcellular localization of Cdr2, we cultured SKOV3 cells under normoxic or
hypoxic conditions or in the presence of DMOG and performed
immunofluoresence experiments (Fig. 35).
Figure 35: Cdr2 localizes to the nucleus in SKOV3 cells. Cells were grown on coverslips and
incubated for 16 hours at either 20% or 0.2% oxygen or in the presence of 1 mM DMOG. Cells
were fixed and indirect confocal immunofluorescence microscopy using anti-Cdr2 primary and
anti-mouse Alexa488-coupled secondary antibodies was performed. Nuclei were counterstained
with DAPI.
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Surprisingly, Cdr2 was predominantly found in the nucleus and not in the
cytoplasm. These data were confirmed in HeLa cells (data not shown).
However, no change in the localization of Cdr2 was observed in hypoxia or after
DMOG treatment compared to the normoxic control conditions.
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Discussion
Interaction of Cdr2 and PHD1 in yeast
Cdr2 but not Cdr3 interacts with PHD1 in yeast
Cdr2 mRNA is known to be ubiquitously expressed whereas the protein is under
physiological conditions limited to the brain (cerebellum / Purkinje neurons) and
the testis, both tissues with relatively low pO2. Whereas the anti-Yo antibody of
PCD patients is able to detect all three isoforms, Cdr1 (34 kDa), Cdr2 (52 kDa)
and Cdr3 (62 kDa) in normal brain and testis, only Cdr2 mRNA and protein was
found in ovary or breast tumors of these patients. These findings suggested a
major role of Cdr2 as tumor antigen in PCD (Corradi et al. 1997). Our results
showed no interaction of Cdr3 with PHD1 in yeast (data not shown) and in
contrast to Cdr2, Cdr3 showed no hypoxic stabilization when overexpressed in
HeLa cells (data not shown). These data suggest that PHD1 interacts
specifically with Cdr2. Importantly, our monoclonal antibodies derived from
hybridoma clone #33 were specific for Cdr2 and did not recognize IVTT-
produced Cdr3 (data not shown).
Expression pattern of Cdr2 protein
Cdr2 mRNA is ubiquitously expressed whereas the protein is under
physiological conditions limited to tissues with low oxygen partial
pressure
Determination of tissue pO2 levels is technically challenging. However, different
measurement techniques resulted in comparable values and indicated that there
are wide variations in tissue pO2 levels in all organs examined (Vanderkooi et al.
1991). Tissue pO2 values are in general considerable lower than those in mixed
venous blood. The cellular demand for oxygen varies among different tissues
largely due to variations in energy requirement. Whereas the lung represents the
organ with the highest pO2 of around 100 mm Hg the brain shows a wider
spectrum ranging from 1-3 mm Hg (pons) to 6-16 mm Hg (cortex) (Vanderkooi
et al. 1991). Different assumptions exist why the brain is considered as a tissue
with regions of low pO2 levels. Even the brain has a high heterogeneity, diverse
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tissues with different oxygen needs (ATP need), in general it has a high oxygen
consumption. In 2001, Stroka et al. showed by immunohistochemistry that HIF-
1 is present in normal mouse brain in the nucleus under normoxic conditions
(Stroka et al. 2001). They suggested that HIF-1 may be present in normal tissue
for a basal induction of genes that are necessary to provide the cellular energy
requirements. In addition to the brain, the testis is also considered as an organ
with low pO2 levels due to its anatomy and high oxygen consumption. Within the
testis blood vessels are found exclusively between the tubuli and oxygen
reaches the lumen of the tubuli seminiferi only by diffusion. The process of
spermatogenesis occurs along the pO2 gradient in the seminiferi tubuli. In
consideration of the high sperm production rate, spermatogonial self-renewal is
likely to consume high amounts of oxygen. Due to this two facts luminal pO2
levels are likely to be very low (Wenger and Katschinski 2005). Indeed, pO2
values as low as 2 mm Hg have been reported, which are among the lowest
values found in the body (Max 1992).
Our results demonstrate that Cdr2 is expressed ubiquitously with high mRNA
levels in the testis and the brain. Additionally, we showed that Cdr2 mRNA is not
regulated by oxygen, whereas the protein is stabilized under hypoxia in transient
transfections. These findings might explain the limited expression of Cdr2
protein in the brain and testis. In contrast to our expectations we could not
reproduce a stabilization of endogenous Cdr2 in hypoxia or upon PHD inhibition
in the tumor cell line SKOV3. The effect what we have seen with transfected
Cdr2 is still an enigma. Genetic modifications of the Cdr2 locus in SKOV3 cells
might represent one reason for loss of stability under hypoxia and PHD
inhibition. One further approach is the inducibility of PHD1 by estrogen which
was shown in BT474 cells. Cdr2 expression is thought to be limited to
gynecological tumors which are estrogen-dependent tissues. It might be that
Cdr2 protein in estrogen sensitive tissue undergoes no stabilization due to high
expression of PHD1. So far, it is not clear if Cdr2 is expressed in other tumors
which underlie no hormonal influence or estrogen influence, respectively and if
stabilization of Cdr2 can be observed in these tissues.
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Cdr2 protein expressed in tumor tissues functions as onconeural antigen
Low oxygen partial pressure is a characteristic of all solid tumors. It is now well
established that most tumors have lower median oxygen partial pressure than
their tissues of origin. Microelectrode oxygen measurements revealed that the
mean oxygen tension of normal tissue lies between 40 – 50 mm Hg, whereas
tumors reach values between 5 and 10 mm Hg or even lower (Vaupel et al.
1989). In addition, clinical studies show that in many cases invasive growth and
metastatic spread are associated with the degree of tumor hypoxia.
Explanations for tumor hypoxia are primitive and unstructured tumor
microcirculation and high oxygen consumption due to rapidly growing tumor
cells. Neoplastic vascularization occurs uncoordinatedly, resulting in functionally
poor vasculature incapable of meeting tumor demands for oxygen, thereby
giving rise to hypoxic areas within tumors. The cellular responses to hypoxia to
improve cell oxygenation and survival are angiogenesis, improved glycolytic flux
enhancing energy production and an upregulation of molecules related to cell
survival and apoptosis. HIF activation is seen throughout tumors and is likely to
explain the marked vascularity and high level of expression of glycolytic genes
(Semenza 2003). Usually, tumor hypoxia occurs at a distance farther than 100 –
200 m from blood vessels and cells which are not able to adapt to oxygen and
nutrient deprivation finally undergo cell death by apoptosis and / or necrosis
(Zhou et al. 2006). Figure 36 shows tumor hypoxia and its consequences on a
molecular level.
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Figure 36: Uncoordinated neoplastic vascularization in tumors resulting in functionally
poor vasculature incapable of meeting tumor demands of oxygen (Carmeliet and Jain
2000). Some tumor cells are due to the uncoordinated neoplastic vascularization located more
than 100 m (diffusion limit for oxygen) away from blood vessels (red-to-blue gradient indicates
progressive hypoxia). These cells become hypoxic and HIF stabilization leads to upregulation of
genes involved in angiogenesis (i.e. VEGF, Ang2, NOS and PDGF-B), to improved glycolytic flux
and upregulation of molecules related to cell survival and apoptosis.
Furthermore, hypoxia can also affect tumor growth positively by local adaptation.
Graeber et al. showed that hypoxia represents a physiological selective
pressure in tumor tissue. On one hand hypoxic conditions induce apoptosis in
tumor cells but on the other hand it induces genetic alterations, for example loss
of the p53 tumor-suppressor gene or overexpression of Bcl-2, an apoptosis-
inhibitor protein, and thereby decreases hypoxia-induced cell death. Additionally,
these hypoxic conditions select for cells with defects in apoptosis (Graeber et al.
1996). The consequence is often a more aggressive tumor phenotype in
combination with chemoresistance (Unruh et al. 2003). One example for local
hypoxic adaptation is increased anaerobic glycolysis which is facilitated by
increased expression of glucose transporters and glycolytic enzymes and
induced angiogenesis. Hypoxia seems to be able to induce pro- and anti-
apoptotic cellular mechanism and particularly the impact of HIF-1 is still not
elucidated (Zhou et al. 2006). Figure 37 summarizes HIF-1 dependent and HIF-
1 independent responses towards survival or cell death.
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Figure 37: Pro-survival and pro-apoptotic mechanisms as response to hypoxia in tumor
cells (Zhou et al. 2006) Abbreviations: AP-1: activator protein-1; bFGF: basic fibroblast growth
factor; BNIP3: Bcl-2/adenovirus E1B 19 kDa interacting protein 3; BNIP3L: Bcl-2 19 kDa
interacting protein like; Epo: erythropoietin; GLUT-1/-3/-4: glucose transporter-1/-3/-4; HK-1/-2:
hexokinase-1/-2; HO-1: heme oxygenase-1; hsp70: heat shock protein 70; IAPs: inhibitors of
apoptosis; IGF2: insulin-like growth factor; IGF-BP1/2/3: IGF-factor-binding protein 1/2/3; LDH A:
lactate dehydrogenase A; Mcl-1: myeloid cell factor-1; MDR1: multidrug resistance 1; NFκB: 
nuclear factor κB; NIX: Nip3-like protein X; NOXA: NADPH oxidase activator; PGK-1:
phosphoglycerate kinase 1; TGF-α/-β: transforming growth factor-α/-β; TSP-1: thrombospondin-
1; VEGF: vascular endothelial growth factor; VEGF-R: VEGF-receptor
Cdr2 is found mainly on the surface of ovarian and breast tumors. It is important
to mention that Cdr2 is not limited to PND connected tumors, but is found in
60% of ovarian and more than 25% of all breast cancer tumors. Interestingly,
Cdr2 expression in tumors does not always lead to PCD (Peterson et al. 1992).
It is unclear under which conditions the antigen is targeted by the immune
system. Additionally, studies with the antigen Hu showed that the antibody
production and antibody titer in patients was correlated with the onset of PND
(Dalmau et al. 1990). We showed that overexpressed Cdr2 is stabilized in HeLa
and MCF-7 cells in hypoxia and after PHD inhibition. Therefore, tumor hypoxia
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might be the trigger for Cdr2 protein stabilization in tumor tissues resulting from
reduced PHD1 hydroxylation activity.
In the proposed pathogenesis and mechanism of paraneoplastic cerebellar
degeneration it is thought that apoptotic tumor cells are internalized by tissue
dendritic cells. Apoptosis of tumor cells is assumed to be due to excessive
signaling in cell-cycle and DNA-repair pathways. Our findings that Cdr2 interacts
with PHD1 and the hypoxic stabilization of transfected Cdr2 protein suggest that
tumor cells might undergo apoptosis due to hypoxia and glucose deprivation.
Hypoxia might be one trigger for apoptosis of tumor cells and stabilization of
Cdr2 and thereby internalization of tumor cells via dendritic cells. It is still
unclear if Cdr2 is also directly involved in apoptosis of tumor cells. So far, it has
not been shown that expression of Cdr2 in tumor cells is involved in the
recognition of apoptotic tumor cells by tissue dendritic cells.
Hydroxylations sites of Cdr2
The LXXLAP PHD hydroxylation site in HIF- is highly conserved. Our database
search revealed no conserved LAP motif for Cdr2. Nevertheless, a recent
publication of Li et al. showed amino acid substitutions in a HIF-1 peptide
caused only minor changes in its hydroxylation. Alanine was the strictest
requirement for hydroxylation and no other amino acids was able to fully
substitute for it in case of PHD2, whereas in case of PHD1 and PHD3 it could
only be substituted by serine or isoleucine or valine and serine (Li et al. 2004).
These data were confirmed independently (Huang et al. 2002; Hirsilä et al.
2003). Cdr2 contains two conserved proline cluster in the C-terminal amino acid
sequence. We carried out multiple amino acid deletions to generate constructs
which contain either a single or no proline cluster. Cdr2 fragments including only
the N-terminal part of the zinc finger domain show a much weaker interaction
with PHD1 in yeast suggesting that the zinc finger is necessary for interaction.
No interaction was observed with the C-terminal part of Cdr2 including two
conserved proline cluster. In contrast, the C-terminal part 216-454 was found as
interactor in the yeast two-hybrid screening. These data suggest that Cdr2 binds
with its N-terminal part to PHD1 whereas the hydroxylation site is still unclear.
Furthermore, we expressed and purified these sequences in bacterial
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expression systems to analyze these recombinant proteins in hydroxylation
assays and by mass spectrometry.
Subcellular localization of Cdr2
In contrast to previous reports, we detected endogenous Cdr2 predominantly in
the nucleus of different cell lines rather than in the cytoplasm. This finding is
contradictive to previous immunohistochemical localization data of Cdr2 in the
cytoplasm (Corradi et al. 1997; Okano et al. 1999). Okano et al. suggested that
Cdr2 sequesters c-Myc in the cytoplasm and thereby regulates c-Myc
dependent transactivation of target genes. We investigated whether hypoxia
might trigger a change in the subcellular localization of Cdr2. But no change of
Cdr2 was observed when cells were incubated under hypoxic conditions or after
DMOG treatment. PHD1 was found exclusively in the nucleus when fused to
GFP (Metzen et al. 2003) whereas endogenous PHD1 was shown to be
localized in the cytoplasm and nucleus (Soilleux et al. 2005).
IB kinase- (IKK) is a hydroxylation target of PHD1
The transcription factor NFB is involved in promotion and progression of tumor
development and survival (Karin and Greten 2005). Several pro-inflammatory
cytokines and chemokines, such as TNF, IL-1 and IL-6 are target genes of the
IKK--dependent NFB-activation pathway and are known to be associated with
tumor development and progression. Two different pathways of distinct NFB-
activation, the classical and the alternative pathway, are distinguished. Both
pathways are involved in tumor development but the recent knowledge suggests
that the pro-carcinogenic function is mostly related to the classical pathway.
Figure 38 shows the classical activation pathway of NFB and its target genes
(Karin and Greten 2005). This pathway is triggered by infections, bacterial or
viral, as well by pro-inflammatory cytokines. First, the IKK complex is activated,
when pro-inflammatory cytokines, bacterial cell-wall components or viruses are
binding to the cellular receptor. The IKK complex consists of two catalytic
subunits, IKK- and IKK- and a regulatory subunit, IKK- (NEMO). The IKK
complex is able to phosphorylate NFB-bound IBs which leads to a
proteasomal degradation of IB and thereby a liberation of NFB dimers,
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composed of REL-A (p65) and p50. Now, the transcription factor is able to enter
the nucleus and to induce its target genes involved in inflammation, innate
immunity and cell survival.
Figure 38: Classical signaling pathway of NFB modified from (Karin and Greten 2005)
NFB dimers consisting of p50 and REL-A are bound in the cytoplasm to IB. Phosphorylation of
IB by IKK- leads to proteasomal degradation of IB and a liberation of the transcription factor
NFB, which enters the nucleus and induces its target genes. BCL-XL: B-cell lymphoma XL,
BFL1: a B cell-lymphoma-2-related protein, cIAPs: cellular inhibitors of apoptosis, COX2:
cyclooxygenase-2, iNOS: inducible nitric-oxide synthase, GADD45: growth arrest and DNA-
damage-inducible 45, SOD2: superoxide dismutase 2.
Even it was known that NFB is activated in hypoxia the underlying mechanism
was still unclear (Ryan et al. 2005). A recent report of Cummins et al. confirmed
previous studies and showed that the response of NFB in hypoxia and under
DMOG treatment is due to an inhibition of the PHDs, respectively mainly PHD1
(Cummins 2006). They identified a LXXLAP consensus motif in the IKK and
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IKK subunit of the IKK complex and found increased IKK protein levels under
hypoxia in HeLa cells. The mechanism was shown to be HIF-1-independent by
using siRNA against HIF-1, which did not alter hypoxia-induced IB
phosphorylation. Overexpressing of PHD1 decreased cytokine-stimulated NFB
reporter activity. Site-directed mutagenesis of IKK of putative IKK
hydroxylation site resulted in a loss of hypoxic inducibility. To summarize these
data the authors suggest that hypoxia increases NFB activity through PHD
inhibition and thereby inhibition of IKK hydroxylation. These results might
explain one further molecular mechanism how hypoxia contributes to tumor
development and progression (Cummins 2006). Furthermore these data show
that PHD1 regulates additional to HIF-1 another transcription factor, NFB.
Although we could not confirm a transactivation activity of Cdr2, Cdr2 might
represent an additional transcription factor regulated by PHD1.
Conclusion and Outlook
Taken together, we identified the onconeural antigen Cdr2 as an interactor of
the oxygen-sensing PHD1. We showed that Cdr2 protein is stabilized in hypoxia
and upon PHD inhibition when overexpressed in different cell lines. These
findings were letting us assume that the limited expression of Cdr2 protein to the
brain and to the testis, organs known as tissues with low oxygen partial
pressure, is due to a hypoxic stabilization of Cdr2 by inhibition of PHD1. The
generation of monoclonal antibodies enabled us to detect endogenous Cdr2 in
several breast and ovarian cancer cell lines. However, we could not reproduce
the stabilization of endogenous Cdr2 in hypoxia or upon PHD inhibition.
Furthermore, the induction of PHD1 under estrogen treatment showed no
change in endogenous Cdr2 protein level. The effect what we have seen with
transfected Cdr2 is still an enigma. Genetic modifications of the Cdr2 locus in
SKOV3 cells might represent one reason for loss of stability under hypoxia and
PHD inhibition. Therefore we started a selection of clones based on a limited
dilution. Nethertheless the investigation of Cdr2 interaction with PHD1 allow new
insights in the ectopic expression of Cdr2 in tumor tissue. Furthermore it
broadens the understanding of naturally occurring tumor immunity in
paraneoplastic cerebellar degeneration.
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